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Abstract 
Chronic	inflammatory	diseases	are	a	growing	global	health	problem.	Chronic	obstructive	pulmonary	
disease	 (COPD)	 represents	 a	 major	 cause	 of	 morbidity	 and	 mortality,	 and	 is	 currently	 the	 third	
leading	cause	of	death	worldwide.	COPD	 is	a	devastating	progressive	 lung	disease	characterized	by	
airflow	 limitation,	 chronic	 bronchitis	 and	 bronchiolitis,	 emphysema,	 and	 small	 airway	 remodeling.	
There	are	no	curative	options	for	COPD	to	date,	thus	there	is	a	desperate	need	for	novel	approaches	
and	 treatments.	To	 this	end,	 the	goal	of	 this	 thesis	work	was	 to	develop	and	evaluate	a	novel	 cell	
product	 composed	 of	mesenchymal	 stem/stromal	 cells	 (MSCs)	 genetically	modified	 to	 express	 the	
protease	 inhibitor	 alpha-1	 antitrypsin	 (AAT),	 thus	 combining	 the	 potent	 immunomodulatory	 and	
cytoprotective	properties	of	MSCs,	and	of	AAT.	A	major	focus	was	the	development	of	an	optimized	
expression	construct/vector	 system	 for	MSC	engineering.	Eight	versions	of	gamma-retroviral-based	
vectors	were	designed	and	tested	for	optimal	transgenic	expression	of	human	AAT	and	puromycin-N-
acetyltransferase	(pac)	for	antibiotic	selection.	The	constructs	differed	in	the	gene	promoter	used	for	
driving	 AAT	 expression,	 and	 in	 the	 relative	 position	 of	 the	 expression	 cassettes	 within	 the	 vector	
backbone.	 The	 vectors	 were	 then	 compared	 with	 regards	 to	 viral	 titers,	 transduction	 efficacy	 of	
primary	 human	MSCs,	 AAT	 expression	 in	 the	 supernatant	 of	 transduced	 cells,	 and	 cell	 yield	 after	
antibiotic	selection.	The	best	results	for	all	parameters	were	obtained	when	AAT	was	expressed	from	
the	human	eukaryotic	translation	elongation	factor	1	alpha	1	short	(EFS)	promoter,	and	the	pac	gene	
was	 linked	 via	 an	 internal	 ribosome	 entry	 site	 (IRES)	 sequence.	 This	 lead	 candidate	 expression	
cassette	was	then	transferred	to	a	 lentiviral	backbone	to	assess	 if	transduction	and	AAT	expression	
from	MSCs	could	be	further	increased	by	using	this	viral	system.	While	values	were	higher	with	the	
gamma-retroviral	vector	at	low	multiplicities	of	infection	(MOIs),	transduction	reached	a	plateau	and	
no	further	increase	was	possible	even	when	higher	MOIs	were	used.	Transduction	with	the	lentiviral	
construct,	 however,	 followed	 a	 clear	 dose-response,	 reaching	 transduction	 efficacies	 >80%	 at	 the	
highest	MOI	 tested.	 In	 vitro	 functionality	 of	 the	 protease	 inhibitor	 AAT	 expressed	 from	MSCs	was	
confirmed	 using	 a	 neutrophil	 elastase	 inhibition	 assay.	 A	 process	 for	 large	 scale	 transduction	 and	
expansion	 of	 gene-modified	 MSCs	 was	 subsequently	 developed.	 To	 evaluate	 the	 potential	
therapeutic	benefit	of	AAT-MSCs	in	vivo,	a	mouse	model	of	elastase-induced	emphysema	was	used.	
Treatment	 of	 the	mice	with	 AAT-MSCs	 resulted	 in	 significant	 improvement	 of	 pulmonary	 function	
parameters,	 while	 only	 a	 slight	 functional	 amelioration	 was	 observed	 after	 treatment	 with	 non-
modified	 MSCs.	 Histopathologic	 examination	 of	 AAT-MSC-treated	 mice	 revealed	 a	 significant	
decrease	of	airspace	enlargement,	indicating	regeneration	of	pulmonary	tissue.	Again,	the	effect	was	
smaller	 after	 treatment	 with	 non-modified	 MSCs,	 demonstrating	 a	 more	 than	 additive	 effect	 of	
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combining	AAT	and	MSCs.	In	conclusion,	the	present	study	provides	the	first	in	vivo	proof	of	concept	
for	the	treatment	of	emphysematous	COPD	using	engineered	AAT-MSCs.	
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Zusammenfassung 
Chronisch	 entzündliche	 Erkrankungen	 sind	 heutzutage	 ein	 globales,	 im	 Steigen	 begriffenes	
Gesundheitsproblem.	Ein	wichtiges	Beispiel	 ist	die	chronisch	obstruktive	Lungenerkrankung	(COPD),	
eine	 verheerende,	 fortschreitende	 Erkrankung	 der	 Lunge	 mit	 hoher	 Morbidität	 und	 Mortalität,	
gegenwärtig	 die	 dritthäufigste	 Todesursache	 weltweit.	 Symptome	 der	 COPD	 sind	 Atemnot,	 eine	
chronische	Entzündung	der	Bronchien	und	Bronchiolen,	die	Entwicklung	eines	Emphysems	und	ein	
Umbau	 der	 engen	 Atemwege.	 Da	 bislang	 eine	 Heilung	 der	 COPD	 nicht	 möglich	 ist,	 besteht	 ein	
dringender	 Bedarf	 an	 innovativen	 Therapieansätzen.	Wir	 entwickelten	 ein	 neuartiges	 Zellprodukt,	
basierend	 auf	 mesenchymalen	 Stamm-/Stromazellen	 (MSCs),	 die	 genetisch	 modifiziert	 wurden,	
sodass	 sie	 den	 Protease-Inhibitor	 Alpha-1	 Antitrypsin	 (AAT)	 exprimieren.	 Diese	 Kombination	
ermöglicht	 es,	 die	 immunmodulatorischen	 und	 zytoprotektiven	 Eigenschaften	 der	MSCs	mit	 jenen	
von	AAT	 in	 einem	Produkt	 zu	 vereinen.	 Dabei	wurde	 in	 der	 vorliegenden	Arbeit	 ein	 Fokus	 auf	 die	
Entwicklung	 eines	 optimierten	 Expressionskonstruktes	 gelegt.	 Es	 wurden	 acht	 gamma-retrovirale	
Vektoren	 für	 die	 Expression	 von	 AAT	 und	 Puromycin-N-Acetyltransferase	 (pac),	 das	 eine	
Antibiotikaselektion	 genmodifizierter	 Zellen	 erlaubt,	 konzipiert	 und	 kloniert.	 Diese	 Konstrukte	
unterscheiden	sich	sowohl	im	Promoter,	der	für	die	AAT-Expression	verwendet	wird,	als	auch	in	der	
relativen	Anordnung	der	Expressionskassetten	im	Plasmid.	Die	Auswahl	des	besten	Konstrukts	wurde	
anhand	 eines	 Vergleichs	 der	 Vektoren	 hinsichtlich	 der	 erzielten	 viralen	 Titer,	 der	
Transduktionseffizienz	 von	 primären	 humanen	MSCs,	 des	 AAT-Gehalts	 im	 Zellkulturüberstand	 von	
transduzierten	 MSCs	 sowie	 der	 Zellausbeute	 nach	 Antibiotikaselektion	 durchgeführt.	 Die	 jeweils	
besten	 Ergebnisse	 wurden	 erzielt,	 wenn	 AAT	 von	 der	 kurzen	 Form	 des	 Promoters	 des	 humanen	
eukaryotischen	 Translationselongationsfaktors	 1	 alpha	 1	 (EFS)	 exprimiert	wurde,	 und	 das	 pac	 Gen	
durch	 eine	 interne	 ribosomale	 Eintrittsstelle-	 (IRES)-Sequenz	 verknüpft	 war.	 Diese	 favorisierte	
Expressionskassette	 wurde	 in	 ein	 lentivirales	 Plasmid	 transferiert,	 um	 zu	 untersuchen,	 ob	
Transduktion	 und	 AAT-Expression	 in	 einem	 solchen	 System	 weiter	 verbessert	 werden	 können.	 Es	
zeigte	sich,	dass	mittels	des	gamma-retroviralen	Vektors	größere	Transduktionseffizienzen	und	AAT-
Mengen	 bei	 niedriger	 Multiplizität	 der	 Infektion	 (MOI)	 erzielt	 werden	 konnten,	 aber	 bei	 höheren	
MOIs	keine	zusätzliche	Verbesserung	zu	erreichen	war.	Im	Gegensatz	dazu	folgten	Transduktion	und	
AAT-Expression	mittels	des	lentiviralen	Vektors	einer	eindeutigen	Dosis-Wirkung,	die	bei	hohen	MOIs	
in	Transduktionseffizienzen	von	>80%	resultierte.	Ein	Neutrophile	Elastase	Inhibitionstest	bestätigte	
die	in	vitro	Funktionalität	von	MSC-sezerniertem	AAT	als	Proteaseinhibitor,	bevor	Transduktions-	und	
Expansionsprozesse	 zur	 Herstellung	 von	 AAT-MSCs	 im	 Großformat	 etabliert	 wurden.	 Um	 die	
therapeutische	 Wirkung	 von	 AAT-MSCs	 in	 vivo	 zu	 untersuchen,	 wurde	 ein	 Mausmodell	 eines	
Elastase-induzierten	Emphysems	durchgeführt.	Es	zeigte	sich,	dass	die	Behandlung	von	Mäusen	mit	
AAT-MSCs	zu	einer	signifikanten	Verbesserung	der	Lungenfunktion	der	Tiere	führte,	während	nicht-
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modifizierte	MSCs	nur	eine	geringfügige	Wiederherstellung	der	pulmonalen	Funktion	bewirkten.	Die	
histopathologische	Analyse	ergab,	dass	die	Überblähung	der	 Lunge	durch	die	Applikation	von	AAT-
MSCs	 signifikant	 vermindert	 werden	 konnte,	 was	 auf	 eine	 Regeneration	 des	 Lungengewebes	
hindeutet.	 Auch	 in	 dieser	 Auswertung	 fiel	 der	 durch	 die	 Behandlung	mit	 nicht-modifizierten	MSCs	
erzielte	 Effekt	 geringer	 aus,	 was	 eine	 additive	 Wirkung	 von	 AAT	 und	 MSCs	 nahelegt.	
Zusammenfassend	kann	festgestellt	werden,	dass	die	vorliegende	Arbeit	einen	ersten	Nachweis	des	
Wirkkonzepts	 von	 AAT-MSCs	 für	 die	 Behandlung	 von	 entzündlichen	 Lungenerkrankungen	 wie	
emphysematöser	COPD	erbringen	konnte.	
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1. Introduction 
1.1. Chronic obstructive pulmonary disease 
1.1.1. Epidemiology and economics 
Chronic	 inflammatory	 diseases	 are	 a	 growing	 health	 problem	 worldwide,	 imposing	 an	 increasing	
burden	on	 individuals,	 populations,	 and	economies	 1.	Among	 them,	 chronic	obstructive	pulmonary	
disease	(COPD)	must	be	given	a	central	role.	 It	 is	a	heterogeneous,	common,	and	complex	disorder	
that	is	at	present	the	third	leading	cause	of	mortality	globally,	being	responsible	for	more	than	three	
million	 deaths	 worldwide	 (equal	 to	 6%	 of	 all	 deaths)	 in	 2012	 2.	 Since	 mild	 disease	 often	 goes	
unrecognized	 and	 thus	 undiagnosed,	 it	 is	 difficult	 to	 obtain	 prevalence	 data	 for	 COPD	 3.	 It	 is,	
however,	 estimated	 that	 in	 2013	 COPD	 affected	 329	 million	 people	 or	 nearly	 5%	 of	 the	 global	
population	 4,5.	 COPD	 is	 also	 associated	 with	 a	 substantial	 economic	 burden.	 As	 of	 2010,	 COPD	 is	
believed	to	result	in	global	economic	costs	of	$2.1	trillion,	where	$1.9	trillion	are	direct	costs	such	as	
medical	care,	and	$0.2	trillion	are	indirect	costs	such	as	missed	work	6.	In	the	European	Union,	COPD	
accounts	 for	 56%	 of	 all	 costs	 related	 to	 respiratory	 diseases,	 amounting	 to	 €38.6	 billion,	 where	
exacerbations	account	for	the	majority	of	the	total	health	costs	related	to	COPD	7.		
1.1.2. Pathophysiology 
COPD	is	a	progressive	obstructive	lung	disease	that	is	characterized	by	airflow	limitation,	an	excessive	
chronic	 inflammatory	 response	 to	 noxious	 particles	 in	 the	 large	 and	 small	 airways	 of	 the	 lungs	
(bronchitis	and	bronchiolitis,	respectively),	with	fibrosis	and	airway	remodeling,	alveolar	destruction	
with	airspace	enlargement	(emphysema),	and	mucus	hypersecretion	3,8,9.	COPD	is	pathologically	and	
histologically	heterogeneous,	and	the	symptoms	vary	in	proportion	between	affected	individuals	10.	
Furthermore,	 the	 clinical	 picture	 can	 often	 be	 accompanied	 by	 cardiovascular	 disease,	 fatigue,	
depression,	 musculoskeletal	 dysfunction,	 weight	 loss,	 and	 osteoporosis	 3,11.	 The	 severity	 of	 the	
disease	 is	 currently	 categorized	 based	 on	 GOLD	 (Global	 initiative	 for	 chronic	 Obstructive	 Lung	
Disease)	criteria	on	a	0–4	scale,	depending	on	symptoms	and	the	decline	in	lung	function	8.	Patients	
suffering	from	advanced	disease	(GOLD	score	2	and	higher)	progressively	experience	more	frequent	
and	severe	acute	exacerbations	as	 their	 condition	continues	 to	deteriorate	 12.	These	exacerbations	
are	most	often	the	result	of	viral	or	bacterial	chest	infections	or	environmental	pollutants	8.		
Classically,	 COPD	 is	 diagnosed	 by	 spirometry,	with	 the	 clinical	 criteria	 defining	 COPD	 comprising	 a	
forced	expiratory	volume	after	one	second	(FEV1)	value	of	<80%	predicted,	and	a	post-bronchodilator	
FEV1:FVC	(forced	vital	capacity)	ratio	<0.70	13.		
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1.1.3. Risk factors for COPD development 
The	 most	 important	 risk	 factor	 for	 the	 development	 of	 COPD	 is	 tobacco	 smoking,	 probably	
accounting	for	80–95%	of	all	COPD	cases	in	industrialized	countries	10,14,15;	however,	only	15–25%	of	
smokers	 develop	 COPD	 16–18.	 Other	 environmental	 factors	 such	 as	 increasing	 air	 pollution,	 whose	
connection	 to	 lung	 disease	 was	 established	 during	 the	 London	 smog	 years	 of	 the	 1950s	 19,	
occupational	exposure	to	fumes	and	particulates	20,	as	well	as	the	inhalation	of	domestic	and	cooking	
fumes,	have	also	been	linked	to	an	increased	risk	of	COPD	development	21,22.	These	risk	factors	can	
lead	to	an	accelerated	progression	of	the	disease	in	combination	with	cigarette	smoking.		
It	 is	 commonly	 accepted	 that	 the	 chronic	 inflammation	 seen	 in	 the	 respiratory	 tract	 of	 patients	
suffering	from	COPD	results	from	an	excessive	immune	response	to	chronic	irritants	such	as	tobacco	
smoke.	 The	 reasons	 for	 this	 inflammation	 are	 not	 yet	 fully	 understood,	 but	 could	 be	 in	 part	
genetically	determined,	 since	 there	clearly	are	COPD	patients	who	are	non-smokers,	and	 there	are	
also	 many	 smokers	 who	 never	 develop	 COPD,	 despite	 having	 chronic	 lung	 inflammation	 that	
continues	 for	many	years	even	after	smoking	cessation	7,15.	Moreover,	COPD	 is	known	to	cluster	 in	
families,	 strongly	 hinting	 at	 the	 involvement	 of	 genetic	 factors	 11.	 Indeed,	 accumulating	 evidence	
suggests	that	there	might	be	a	genetic	predisposition	to	COPD	23–27.	One	candidate	gene	is	SERPINA1,	
the	gene	encoding	for	the	protein	alpha-1	Antitrypsin	(AAT,	for	more	details	please	see	chapter	1.4).	
The	potential	correlation	of	AAT	deficiency	and	COPD	was	first	suggested	by	Lomas	and	colleagues	in	
2006	 28,	 their	 theory	 has	 found	 support	 in	 several	 studies	 during	 the	 last	 decade,	 and	 it	 is	 now	
generally	accepted	that	carrier	status	of	AAT	deficiency	alleles	 is	a	strong	genetic	 factor	associated	
with	the	development	of	COPD	12,29–33.		
1.1.4. Pathogenesis 
The	pathogenesis	of	COPD	is	hypothesized	to	result	from	three	major	pathways:	(1)	dysregulation	of	
tissue	homeostasis	within	 the	 lung,	 (2)	oxidative	 stress,	and	 (3)	protease-antiprotease	 imbalance	 3.	
However,	 the	 interplay	of	 these	pathways	and	the	molecular	mechanisms	 leading	to	COPD	are	still	
incompletely	understood	11.		
1.1.4.1. Inflammatory cells and mediators 
A	plethora	of	cell	types	are	involved	in	the	pathogenesis	of	COPD,	with	neutrophilic	granulocytes	and	
alveolar	macrophages	thought	to	represent	very	important	cell	types	in	the	disease.	In	comparison	to	
normal	smokers,	patients	with	COPD	have	5-	to	10-fold	elevated	macrophage	levels	in	their	airways,	
lung	 parenchyma,	 bronchoalveolar	 lavage	 fluid	 (BALF)	 and	 sputum	 34,35,	 and	macrophage	 numbers	
strongly	correlate	with	disease	severity	36.	Macrophages	are	potent	immune	effector	cells,	and	upon	
contact	with	cigarette	smoke	or	other	noxious	substances	they	can	secrete	inflammatory	mediators	
such	 as	 tumor	 necrosis	 factor-alpha	 (TNF-alpha),	 monocyte	 chemoattractant	 protein-1	 (MCP-1),	
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reactive	oxygen	species	(ROS),	chemotactic	factors	for	neutrophilic	granulocytes	such	as	interleukin	8	
(IL-8),	and	a	number	of	elastolytic	enzymes	 like	matrix	metalloproteinases	or	cathepsins,	which	are	
involved	in	the	destruction	of	the	lung	tissue	leading	to	emphysema	14.	Patients	suffering	from	COPD	
also	have	elevated	 levels	of	neutrophils	which	are	 linked	to	the	severity	of	the	disease	34,	and	with	
deterioration	of	lung	function	37.	Neutrophils	are	powerful	immune	cells	that	can	secrete	a	variety	of	
inflammatory	mediators	such	as	tissue	proteases	like	neutrophil	elastase,	proteinase-3	and	cathepsin	
G,	all	of	which	can	lead	to	destruction	of	the	lung	parenchyma,	and	ROS	or	lipid	mediators	38,39.	Cells	
of	the	adaptive	immune	system	are	also	associated	with	COPD	inflammation,	with	CD8+	T	cells	and	T	
helper	(Th)	17	cells	thought	to	be	the	most	clinically	important	40,41.		
1.1.4.2. Oxidative stress 
A	second	important	aspect	in	the	pathogenesis	of	COPD	is	oxidative	stress,	a	very	important	factor	to	
consider	with	 regards	 to	 the	massive	 oxidant	 burden	 seen	 in	 smokers.	 Cigarette	 smoke	 comprises	
over	4700	chemical	compounds	and	more	than	1015	free	radicals	and	oxidants,	which	can	give	rise	to	
damaging	levels	of	ROS	produced	by	inflammatory	and	epithelial	cells	42.	Generation	of	ROS	further	
exacerbates	 inflammatory	 processes,	 leads	 to	 DNA	 damage,	 lipid	 peroxidation,	 and	 protein	
denaturation	43.	An	interesting	aspect	that	again	underscores	the	potential	importance	of	AAT	in	the	
pathogenesis	of	COPD,	especially	in	patients	who	smoke,	is	that	cigarette	smoke	has	been	shown	to	
result	in	oxidation	of	the	critical	methionine	at	position	358	of	AAT	44.	This	modification	renders	the	
protein	non-functional	as	an	inhibitor	of	neutrophil	elastase,	thereby	contributing	to	the	proteinase-
antiproteinase	imbalance	thought	to	play	a	role	in	the	development	of	emphysema	44–46.		
1.1.4.3. Proteinases in COPD 
As	detailed	above,	a	variety	of	proteinases	are	secreted	from	immune	cells	such	as	neutrophils	and	
macrophages	as	part	of	the	excessive	inflammatory	response	in	COPD.	Due	to	an	imbalance	between	
proteinases	and	endogenous	 inhibitors,	which	normally	have	a	protective	effect	on	the	 lung	tissue,	
extracellular	 matrix	 (specifically	 elastin)	 in	 the	 lung	 parenchyma	 is	 destroyed	 by	 action	 of	 the	
proteinases	resulting	in	airspace	enlargement	and	emphysema	47.	The	major	proteinases	involved	in	
COPD	are	neutrophil	elastase,	proteinase-3	and	various	matrix	metalloproteinases	48,49.	With	regards	
to	 the	 present	 work,	 it	 is	 important	 to	 point	 out	 that	 AAT	 acts	 as	 a	 major	 endogenous	 serine	
proteinase	 inhibitor	 and	 thus	 plays	 an	 important	 role	 in	 counterbalancing	 the	 excessive	 release	of	
proteinases.	 As	 described	 above,	 patients	 suffering	 from	 AAT	 deficiency	 are	 at	 increased	 risk	 of	
developing	emphysema	and	COPD	28,31,50.	AAT	may	also	have	additional	modes	of	action	relevant	for	
emphysema	and	COPD	apart	 from	 its	 function	as	protease	 inhibitor,	since	mutations	 in	AAT	clearly	
are	associated	with	these	diseases,	while	mutations	in	neutrophil	elastase	are	not	3.		
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1.1.5. Treatment 
To	 date,	 there	 is	 no	 cure	 for	 COPD	 13.	 However,	 the	 major	 cause	 of	 the	 disease	 and	 means	 of	
prevention	are	well	recognized.	COPD	is	thought	to	be	largely	preventable,	or	at	least	its	progression	
can	be	decelerated,	by	smoking	cessation	51,52.	Due	to	the	addictive	nature	of	 tobacco,	attempts	 in	
quitting	over	five	years	are	successful	in	only	37%	of	cases	53.	Additional	preventive	measures	include	
improving	 air	 quality	 51,	 as	 well	 as	 influenza	 and	 pneumococcus	 vaccinations	 for	 patients	 already	
suffering	from	COPD	and	experiencing	exacerbations	54,55.		
Once	patients	are	diagnosed	with	COPD,	the	focus	of	therapy	is	on	managing	the	disease	and	treating	
the	 symptoms,	 preventing	 and	 treating	 acute	 exacerbations,	 as	 well	 as	 controlling	 associated	
illnesses	56.	The	only	therapeutic	approaches	that	have	been	described	to	reduce	COPD	mortality	are	
supplemental	oxygen	and	smoking	cessation,	of	which	 the	 latter	can	decrease	 the	 risk	of	death	by	
18%	57,58.	Other	current	standard	pharmacologic	medications	are	primarily	used	to	reduce	symptoms	
and	 improve	 lung	 function;	 however,	 to	 date	 there	 are	 no	 drugs	 found	 that	 can	 significantly	 limit	
disease	 progression	 9.	 Drugs	 that	 can	 provide	 a	measure	 of	 help	 include	 inhaled	 short-acting	 and	
long-acting	 bronchodilators.	 They	 are	 the	 most	 commonly	 used	 and	 usually	 yield	 a	 small	 overall	
benefit	for	patients	by	helping	to	alleviate	shortness	of	breath,	resulting	in	an	improvement	in	quality	
of	life	59,60.	Inhaled	corticosteroids	are	typically	added	to	the	bronchodilators	57,	which	can	work	fairly	
well	in	controlling	acute	exacerbations,	especially	in	patients	with	either	moderate	or	severe	COPD	61.	
Additional	 treatment	 options	 include	 antibiotics,	which	 are	mainly	 used	 in	 patients	 suffering	 from	
two	or	more	acute	exacerbations	per	 year	 62,63.	 The	 last	 treatment	option	 for	patients	with	 severe	
COPD	 is	surgery.	This	can	be	either	 lung	volume	reduction	surgery	to	remove	the	parts	of	 the	 lung	
that	 are	 destroyed	 by	 emphysema	 and	 thus	 allow	 the	 remaining	 parts	 of	 the	 lung	 to	 work	more	
effectively,	or	–	 in	very	 severe	cases,	and	primarily	 in	younger	 subjects	–	 lung	 transplantation	 64,65.	
However,	 despite	 improved	 survival	 rates	 after	 lung	 transplantation,	 this	 is	 unfortunately	 not	 an	
option	for	most	patients	due	to	the	increasing	demand	and	the	scarcity	of	donor	organs	65,66.		
During	 the	 last	 decade,	 new	 therapeutic	 strategies	 such	 as	 TNF-alpha	 antagonism	 67–69	 or	 IL-8	
antagonism	70	have	been	 tested	 in	clinical	 trials;	however,	despite	TNF-alpha	and	 IL-8	clearly	being	
involved	in	the	pathogenesis	of	COPD,	none	of	the	studies	showed	subjective	or	objective	long-term	
improvements.	Moreover,	the	blockage	of	single	key	cytokines	raises	questions	regarding	long-term	
safety,	i.e.	a	possibly	increased	likelihood	of	developing	infections	or	malignancies	9.	Thus,	there	is	a	
compelling	need	for	the	development	of	novel,	improved	therapeutic	strategies	for	the	treatment	of	
inflammatory	 lung	 diseases	 such	 as	 COPD	 that	 aim	 at	 persistently	 controlling	 the	 underlying	
inflammatory	processes,	while	at	the	same	time	leading	to	regeneration	of	the	damaged	lung	tissue.	
This	thesis	presents	an	innovative	cell	therapy-based	approach	to	accomplish	this	task.	
Introduction   
	
5
1.2. Cell therapy and mesenchymal stem/stromal cells  
Since	the	first	successful	hematopoietic	stem	cell	(HSC)	transplantation	reported	in	1959	71,	there	has	
been	 a	 continuing	 expansion	 in	 the	 number	 of	 clinical	 trials	 investigating	 the	 application	 of	 stem	
cells	72.	In	addition	to	HSCs,	embryonic	stem	cells	(ESCs)	73,74,	induced	pluripotent	stem	cells	(iPSCs)	75,	
limbal	stem	cells	76,	neural	stem	cells	77,78,	and	endothelial	stem	and	progenitor	cells	79,80	are	currently	
being	 tested	 in	 clinical	 trials	 for	 the	 treatment	 of	 a	 variety	 of	 diseases	 including	 macular	
degeneration,	corneal	destruction,	 repair	of	 the	central	nervous	system,	and	critical	 limb	 ischemia.	
The	clinical	use	of	ESCs	and	iPSCs	has	been	impeded	by	ethical	issues,	the	risk	of	genomic	instability,	
teratoma	formation	as	well	as	allogeneic	rejection	problems	81,82.		
In	addition	to	HSCs,	mesenchymal	stem/stromal	cells	(MSCs)	are	currently	the	most	favored	cell	type	
under	 investigation,	 with	 as	 many	 as	 520	 registered	 clinical	 trials	 (studies	 with	 unknown	 status	
excluded)	listed	in	the	NIH	clinical	trial	database	on	June	15,	2016	83.	Due	to	their	broad	repertoire	of	
beneficial	 features	 including	 immunomodulation,	 growth	 factor	 production,	 anti-fibrosis	 and	 anti-
apoptosis,	 angiogenesis,	 and	 neuroprotection,	 MSCs	 are	 under	 clinical	 trial	 for	 the	 treatment	 of	
diverse	diseases,	and	the	results	to	date	have	been	highly	encouraging	in	the	potential	treatment	of	
Graft	 versus	 Host	 Disease	 (GvHD)	 84,85,	 type	 1	 diabetes	 86,	 transplant	 rejection	 87,88,	 myocardial	
ischemia	and	infarction	89,90,	and	Crohn’s	disease	91,92.	MSCs	are	also	being	investigated	for	therapy	of	
lung	 diseases	 such	 as	 acute	 respiratory	 distress	 syndrome	 (ARDS)	 93,	 and	 COPD	 94,	 thus	 far	
demonstrating	an	excellent	safety	profile.	These	studies	are	only	 in	 the	early	phases	of	 testing	and	
thus	 not	 yet	 empowered	 to	 assess	 efficacy	 94.	 However,	 positive	 outcomes	 indicative	 of	 potential	
efficacy	have	been	seen,	as	for	instance	a	significant	reduction	of	C-reactive	protein	(CRP)	levels	in	a	
subgroup	of	patients	who	had	elevated	levels	at	baseline	in	a	clinical	trial	of	MSCs	in	COPD	94.	
The	 following	 section	 sets	 out	 to	 describe	 the	 biology	 of	 MSCs	 in	 greater	 detail	 and	 to	 highlight	
features	specifically	important	to	the	treatment	of	inflammatory	lung	diseases	such	as	COPD.		
1.2.1. General MSC biology 
MSCs	 are	 multipotent	 progenitor	 cells	 of	 non-hematopoietic	 origin	 that	 were	 first	 described	 by	
Friedenstein	 and	 colleagues	 in	 the	 late	 1960s	 as	 the	 “colony-forming	 unit	 fibroblast”	 95.	 They	
described	 adult,	 plastic-adherent,	 spindle-shaped,	 fibroblast-like	 cells	 which	were	 defined	 by	 their	
capacity	to	form	new	bone	when	transplanted	to	an	ectopic	site	96,97.	These	cells	were	later	renamed	
“mesenchymal	stem	cells”	and	their	differentiation	potential	expanded	to	“tri-lineage”	mesenchymal	
tissues;	 bone,	 cartilage,	 and	 fat	 98.	 However,	 their	 level	 of	 “stemness”	 is	 still	 a	 matter	 of	 debate	
among	scientists	as	in	vivo	confirmation	of	their	stem	cell	characteristics	has	not	been	established	99.	
The	International	Society	for	Cellular	Therapy	(ISCT)	published	a	statement	paper	in	2005	addressing	
this	 inconsistency	 between	 nomenclature	 and	 biologic	 characteristics,	 suggesting	 that	 the	 term	
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“stem	 cell”	 should	 be	 only	 used	 when	 specified	 stem	 cell	 criteria	 have	 been	 confirmed,	 while	 all	
other	cells	should	be	named	“multipotent	mesenchymal	stromal	cells”	100.	It	was	suggested	that	the	
commonly	used	acronym	“MSC”	should	be	employed	for	both	cell	populations,	as	subsequently	done	
in	the	present	work.	It	is	important	to	note	that	the	various	clinical	values	of	MSCs	described	to	date	
do	seem	to	be	largely	independent	of	potential	stem	cell	properties	99.		
One	major	 advantage	MSCs	have	 regarding	 their	 clinical	 utilization	with	 respect	 to	other	 stem	cell	
types	is	their	ease	of	accessibility	for	 isolation:	MSCs	have	successfully	been	isolated	and	expanded	
from	 various	 tissues	 including	 bone	 marrow,	 umbilical	 cord,	 adipose	 tissue,	 dental	 pulp,	 and	
placenta	101,102.	It	is	thought	that	most	organs	have	endogenous	populations	of	MSCs,	and	that	MSCs	
may	have	a	perivascular	origin	103,104.	 In	the	bone	marrow,	MSCs	can	be	found	 in	the	so-called	HSC	
niche,	 where	 they	 support	 the	 survival,	 self-renewal,	 migration,	 and	 differentiation	 of	 HSCs	 and	
precursor	cells	105.	In	lung	tissue,	MSCs	are	predominantly	localized	to	the	perivascular	region	106,107.	
Since	 there	 is	 no	 distinct	 surface	 marker	 defining	 MSCs,	 and	 MSCs	 are	 represented	 by	 a	 fairly	
heterogeneous	population	of	cells,	 the	 ISCT	 issued	another	position	paper	 in	2006	proposing	 three	
minimal	criteria	defining	MSCs	to	avoid	ambiguities	and	inconsistencies	in	the	field	108.	A	summary	of	
the	benchmark	values	is	shown	in	Table	1.		
Table	1:	The	minimal	criteria	defining	MSCs	according	to	ISCT.	
1	 Adherence	to	plastic	in	standard	culture	conditions		
2	 Phenotype	 Positive	(≥95%+)	 Negative	(≤2%+)	
		
	
CD105	 CD45	
		
	
CD73	 CD34	
		
	
CD90	 CD14	or	CD11b	
		
	  
CD79a	or	CD19	
		 		 		 HLA-DR	
3	 In	vitro	differentiation	into	osteoblasts,	adipocytes,	and	chondroblasts	
	
1.2.2. Mode of action of MSCs 
In	early	MSC	research	it	was	thought	that	the	beneficial	effect	of	MSCs	is	mainly	derived	from	their	
supportive	 action	 on	 HSCs	 109,	 their	 co-localization	 and	 engraftment	 at	 the	 site	 of	 injury,	 and	
replacement	of	damaged	tissue	110.	However,	the	field	has	since	undergone	a	paradigm	shift.	Today	
more	emphasis	has	been	placed	on	 the	 trophic	and	 immunomodulatory	capabilities	of	MSCs,	 their	
secretion	of	a	plethora	of	 cytokines,	growth	 factors,	and	of	extracellular	vesicles	 99,111–114.	 It	 is	now	
thought	 that	 the	 cells	 may	 only	 briefly	 interact	 with	 injured	 tissues,	 but	 in	 this	 time	 they	 act	 on	
inflammatory	 and	 damaged	 cells	 to	 dampen	 inflammation,	 limit	 tissue	 destruction,	 and	 enhance	
repair	109,	a	mechanism	that	has	been	referred	to	as	“hit-and-run”	by	some	researchers.	Interestingly,	
recent	data	show	that	even	though	MSCs	do	not	persist	in	vivo,	the	beneficial	effects	they	exert	can	
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remain	detectable	long	after	the	cells	have	disappeared	115,116.	Support	of	this	hypothesis	is	found	in	a	
recent	work	by	Dos	Santos	and	colleagues,	who	described	that	after	application	of	MSCs	in	a	mouse	
model	of	sepsis,	13%	of	the	mouse	genome	was	transcriptionally	reprogrammed	117.	They	observed	a	
change	in	transcriptional	activity	of	genes	involved	in	mitochondrial-related	functional	derangement,	
innate	 immune	 pro-inflammatory	 responses,	 and	 vascular	 integrity,	 leading	 to	 significant	 MSC-
induced	amelioration	of	sepsis	117.		
1.2.3. MSCs and tissue repair by paracrine signaling 
Due	 to	 their	 wide	 tissue	 distribution,	 and	 their	 multipotent	 differentiation	 capabilities,	 MSCs	 are	
thought	to	play	important	roles	in	the	repair	of	damaged	tissues	118.	During	tissue	injury,	such	as	the	
emphysema	present	 in	COPD,	 immune	cells	are	recruited	to	the	site	of	damage	by	factors	secreted	
from	 apoptotic	 and	 necrotic	 cells,	 injured	 microvasculature,	 and	 stroma,	 so-called	 damage-
associated	 molecular	 patterns	 (DAMPs)	 119–121.	 These	 inflammatory	 cells	 in	 turn	 produce	 pro-
inflammatory	 cytokines	 such	 as	 interleukin	 1-beta	 (IL-1beta),	 interferon	 gamma	 (IFN-gamma),	 and	
TNF-alpha,	 chemokines,	 and	 free	 radicals,	which	 conversely	 induce	 the	 secretion	of	growth	 factors	
from	MSCs,	 including	 interleukin	 6	 (IL-6),	 epidermal	 growth	 factor	 (EGF),	 fibroblast	 growth	 factor	
(FGF),	platelet-derived	growth	factor	(PDGF),	vascular	endothelial	growth	factor	(VEGF),	hepatocyte	
growth	 factor	 (HGF),	 keratinocyte	 growth	 factor	 (KGF),	 insulin-like	 growth	 factor-1	 (IGF-1),	
antiopoietin-1	(ANGPT1),	stromal	cell	derived	factor-1	(SDF-1),	and	transforming	growth	factor-beta	
(TGF-beta)	 122–125.	These	molecules	orchestrate	a	molecular	program	that	 leads	 to	a	 support	of	 the	
development	of	myofibroblasts,	endothelial	cells	as	well	as	tissue	progenitor	cells,	resulting	in	tissue	
regeneration	 and	 repair,	 amelioration	 of	 tissue	 integrity	 and	 support	 of	 angiogenesis	 126–132.	 A	
paracrine	factor	which	seems	to	be	specifically	 important	in	regard	to	lung	injury	is	HGF,	which	has	
been	shown	to	not	only	restore	integrity	and	permeability	of	endothelial	cells,	but	to	also	ameliorate	
lung	injury	in	models	of	both	emphysema	and	pulmonary	fibrosis	133–135.	Another	cytokine	crucial	for	
MSC-induced	 tissue	 regeneration	 is	 IL-6,	 which	 has	 been	 recently	 described	 to	 support	 the	
regeneration	of	airway	ciliated	cells	from	basal	stem	cells	in	vivo	136.		
Apart	from	classical	growth	factors	and	cytokines,	MSCs	also	secrete	other	types	of	molecules	such	
as	 the	 anti-microbial	 peptide	 LL37	 137	 and	 Lipoxin	 A4,	 a	 lipid	 mediator	 which	 has	 recently	 been	
described	 to	 lead	 to	 significant	 amelioration	 of	 acute	 lung	 injury	 138.	 These	 molecules	 could	 be	
especially	important	in	light	of	the	treatment	of	COPD	patients	suffering	from	acute	exacerbations	of	
disease	due	to	bacterial	and	viral	infections.	
1.2.4. Immunomodulatory properties of MSCs 
MSCs	possess	highly	effective	immunoregulatory	properties,	affecting	both	the	innate	and	adaptive	
immune	system	111.	 It	 is	 important	 to	note	 that	 there	 is	a	plasticity	of	MSCs	 in	 immunomodulation	
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that	 is	 dependent	 on	 the	 microenvironment	 139,140.	 In	 the	 context	 of	 inflammation,	 MSCs	 are	
predominantly	 instructing	 anti-inflammatory	 functions,	while	 in	 an	 anti-inflammatory	 environment	
they	 support	 pro-inflammatory	 actions	 of	 immune	 cells,	 providing	 a	 mechanism	 to	 maintain	 a	
balanced	immune	response	141.		
In	 co-culture	 experiments	 MSCs	 have	 been	 shown	 to	 have	 the	 ability	 to	 modulate	 a	 variety	 of	
immune	 cells,	 including	 T	 cells,	 B	 cells,	 neutrophils,	 macrophages,	 natural	 killer	 (NK)	 cells,	 and	
dendritic	 cells	 (DCs)	 142,143.	 These	 effects	 are	 thought	 to	 be	 primarily	 mediated	 via	 a	 number	 of	
soluble	 factors	 secreted	 by	 MSCs	 including:	 indoleamine	 2,3-dioxygenase	 (IDO),	 prostaglandin	 E2	
(PGE2),	 interleukin	 10	 (IL-10),	 IL-1	 receptor	 antagonist	 (IL-1ra),	 TGF-beta,	 HLA-G5,	 and	 TNF-alpha-
stimulated	 gene	 6	 (TSG-6)	 141.	 These	 paracrine	 factors	 can	 influence	 immune	 processes	 as	
demonstrated	by	the	example	of	IL-1ra	secreted	by	MSCs,	shown	to	mediate	both	anti-inflammatory	
and	anti-fibrotic	processes	 in	a	mouse	model	of	bleomycin-induced	 lung	 fibrosis	 144.	However,	 cell-
cell	contact	leading	to	FAS/FAS	ligand	or	the	programmed	cell	death	protein-1	(PD-1)/	programmed	
death-ligand	1	(PD-L1)	pathway	activation	has	also	been	linked	to	immunomodulation	by	MSCs	145,146.		
MSCs	can	directly	inhibit	T	cell	function	in	an	inflammatory	milieu,	rendering	T	cells	anergic,	or	they	
can	 help	 induce	 a	 shift	 towards	 a	 regulatory	 T	 cell	 phenotype,	 even	 in	 the	 case	 of	 Th17	 effector	
cells	147–150.	Interestingly,	these	effects	of	MSCs	on	T	cell	biology	have	also	been	described	in	models	
of	allergic	airway	 inflammation	and	acute	 lung	 injury	 151,152.	Direct	 cell-cell	 contact	 via	 the	FAS/FAS	
ligand	death	pathway	 is	 thought	 to	play	 a	 role	 in	 the	 induction	of	 apoptosis	of	 T	 cells	 by	MSCs	as	
described	 in	 mouse	 models	 of	 systemic	 sclerosis	 and	 experimental	 colitis	 153.	 Furthermore,	 MSCs	
have	been	shown	to	suppress	B	cell	proliferation	and	differentiation	towards	plasma	cells	154,155,	and	
to	induce	the	development	of	IL-10-secreting	regulatory	B	cells	156.		
In	 addition,	 MSCs	 have	 the	 ability	 to	 regulate	 T	 and	 B	 cells	 through	 their	 effects	 on	 antigen-
presenting	 cells,	 such	 as	 DCs	 or	 monocytes,	 both	 of	 which	 adopt	 a	 suppressive,	 IL-10-producing	
phenotype	in	the	presence	of	MSCs	157–159.		
As	detailed	above,	macrophages	and	neutrophils,	cells	of	the	innate	immune	system,	are	thought	to	
represent	major	 effector	 immune	 cell	 types	 involved	 in	 the	 pathogenesis	 of	 COPD.	MSCs	 can	 also	
regulate	macrophage	and	neutrophil	biology	142,143.	Upon	exposure	to	MSCs,	macrophages	undergo	a	
phenotypic	 switch	 from	 classically	 activated	 pro-inflammatory	 macrophages	 (M1),	 to	 alternatively	
activated	 anti-inflammatory	macrophages	 (M2),	 in	 response	 to	 PGE2	 and	 TSG-6	 secreted	 by	MSCs	
under	 inflammatory	 conditions	 160,161.	 Accordingly,	 MSCs	 have	 been	 described	 to	 alleviate	
emphysema	 and	 airway	 inflammation	 in	 a	 rat	 model	 through	 their	 interaction	 with	 alveolar	
macrophages	 162.	 It	 has	 furthermore	 been	 shown	 that	 MSCs	 effectively	 decrease	 neutrophil	
infiltration	 in	 mouse	 models	 of	 experimental	 emphysema	 and	 obliterative	 bronchiolitis	 163,164	 and	
inhibit	neutrophil-mediated	tissue	damage	in	a	murine	model	of	vasculitis	165.		
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A	 newly	 discovered	mechanism	 of	 cell	 communication	 is	 based	 on	 their	 secretion	 of	 extracellular	
vesicles	 or	 exosomes	 which	 contain	 proteins,	 RNAs,	 lipids,	 and	 other	 bioactive	 factors	 166.	
Microvesicles	derived	from	human	MSCs	have	been	reported	to	exert	positive	effects	on	pulmonary	
edema	and	decreased	neutrophil	infiltration	when	applied	intratracheally	to	mice	in	a	model	of	acute	
lung	injury	167.		
Taken	together,	MSCs	exert	a	plethora	of	 immunomodulatory	and	regenerative	functions	that	have	
been	shown	to	be	beneficial	in	a	variety	of	inflammatory	diseases.		
1.2.5. Advantages of MSCs for clinical use 
Apart	 from	 their	 outstanding	 immunomodulatory	 and	 tissue-protective	 functions,	 MSCs	 have	
additional	characteristics	that	make	them	very	attractive	candidate	cells	for	clinical	use.	As	described	
above,	one	is	their	ease	of	access.	They	can	be	isolated	from	a	variety	of	different	tissues,	some	of	
which	 otherwise	would	 even	 be	 subject	 to	 discard,	 such	 as	 adipose	 tissue	 or	 placenta.	Moreover,	
they	can	readily	be	expanded	using	basic	standard	cell	culture	methods,	which	to	date	is	not	possible	
to	that	extent	 for	many	other	cell	 types	such	as	e.g.	HSCs	168.	Furthermore,	 in	comparison	to	ESCs,	
there	are	no	ethical	issues	associated	with	the	clinical	use	of	MSCs,	and	as	opposed	to	iPSCs,	MSCs	do	
not	entail	the	risk	of	teratoma	formation	due	to	the	fact	that	they	are	not	pluripotent	169.	Owing	to	
their	 limited	 lifespan	and	other	 intrinsic	 factors,	also	 the	overall	 risk	of	 tumorigenicity	seems	to	be	
negligible	 170.	 Another	 advantage	MSCs	have	 in	 contrast	 to	 other	 cell	 types	 is	 the	 fact	 that	 due	 to	
their	 immunomodulatory	 properties,	 they	 are	 immune-evasive	 and	 can	 be	 administered	 in	 an	
allogeneic	 setting	 99.	 In	 fact,	 most	 patients	 in	 clinical	 trials	 receive	 allogeneic	 MSCs	 171,	 and	 their	
application	 seems	 to	 be	 feasible	 and	 safe	 so	 far	 115,172.	 One	 major	 advantage	 MSCs	 have	 in	
comparison	to	other	therapies,	such	as	small	molecules	or	biologics,	 is	 that	based	on	their	 intrinsic	
ability	 to	home	to	sites	of	 injury	and	 inflammation,	 they	exert	 their	effects	 locally,	 thus	minimizing	
the	toxicity	oftentimes	seen	with	the	first-mentioned	substances	173.	Moreover,	while	many	non-cell-
based	medications	have	to	be	applied	many	times	to	yield	a	 therapeutic	benefit	due	to	their	short	
half-life,	 it	 is	 thought	that	even	a	single	application	of	MSCs	 is	beneficial	due	to	their	“hit-and-run”	
mode	 of	 action	 115,116,174,175.	 All	 these	 features	 taken	 together	make	MSCs	 an	 extremely	 attractive	
candidate	cell	for	clinical	applications.		
MSCs	 seem	 ideally	 suited	 as	 therapy	 vehicles	 for	 the	 treatment	 of	 COPD	 due	 to	 their	 potent	
immunomodulatory	 and	 regenerative	 properties	 combined	with	 their	 ease	 of	 clinical	 applicability.	
Recently,	 gene	modification	 has	 emerged	 as	 a	 potent	 tool	 to	modulate	 cell	 therapy	 products.	 The	
goal	of	this	thesis	is	focused	at	exploring	the	potential	of	genetically	modified	MSCs	as	an	optimized	
cell	product	for	the	treatment	of	COPD.	
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1.3. Cell-based gene therapy 
Cell-based	gene	therapy	is	described	as	the	introduction	of	genetic	material	into	cells,	and	the	use	of	
these	 gene-modified	 cells	 with	 their	 new	 or	 enhanced	 therapeutic	 properties	 for	 the	 prevention,	
alleviation,	 or	 cure	 of	 a	 disease.	 The	 most	 common	 strategy	 employed	 for	 the	 introduction	 of	
transgenes	 into	 cells	 makes	 use	 of	 integrating	 viral	 vectors	 such	 as	 gamma-retroviral	 or	 lentiviral	
vectors	 176,177.	 Since	 its	 infancy	 in	 the	 1970s,	 when	 the	 first	 clinical	 trials	 using	 gene	 therapy	
approaches	were	performed	 178–181,	 gene	 therapy	has	undergone	great	ups	and	downs,	but	 in	May	
2016	 the	 first	 ex	 vivo	 stem	 cell	 gene	 therapy	 product	 received	 marketing	 authorization	 by	 the	
European	 Commission	 182.	 However,	 as	 straight	 forward	 as	 this	 approach	 sounds,	 the	 obstacles	 of	
putting	it	into	practice	are	extremely	challenging.	New	genetic	information	must	be	introduced	into	
the	 target	 cells	 past	 complicated	 cellular	 barriers;	 the	 transgene	 has	 to	 be	 expressed	 at	 sufficient	
levels	 to	 yield	 a	 therapeutic	 benefit	 without	 disrupting	 important	 regulatory	 mechanisms;	 the	
genetically	modified	 cells	must	 then	 be	 produced	 in	 sufficient	 amounts;	 and	when	 applied	 to	 the	
patient,	 the	 cells	 must	 evade	 the	 patient’s	 immunological	 surveillance	 long	 enough	 to	 be	 able	 to	
exert	their	therapeutic	effects	177.	Thus	it	is	not	surprising	that	only	a	limited	number	of	clinical	gene	
therapy	trials	performed	during	the	last	two	decades	were	able	to	demonstrate	clear	benefits	for	the	
patients	 183,184.	 In	 some,	 the	 patients	 even	 experienced	 severe	 adverse	 events	 such	 as	 the	
development	of	leukemia	due	to	vector	integration	near	oncogenes	during	their	long-term	follow-up	
185–187,	which	led	to	increased	skepticism	towards	this	therapeutic	approach	177.	More	recently	there	
has	been	a	shift	in	attitudes	towards	gene	therapy,	due	in	large	part	to	several	recent	pivotal	studies	
reporting	remarkable	efficacy	and	also	safety	of	gene	therapy	approaches,	enabling	the	treatment	of	
life-threatening	 diseases	 like	 primary	 immunodeficiencies	 184,188,189,	 Wiskott-Aldrich	 syndrome	 190,	
thalassemia	 191,	 and	neurodegenerative	 storage	diseases	 192,193.	 These	have	been	made	possible	by	
the	 development	 of	 viral	 vectors	with	 improved	 safety	 and	 efficacy,	 such	 as	 self-inactivating	 (SIN)	
vectors	and	split-genome	conditional	packaging	systems	194,195.	To	date,	most	of	the	stem	cell-based	
clinical	gene	therapy	trials,	including	those	mentioned	above,	have	made	use	of	HSCs.		
MSCs	have	only	very	recently	appeared	on	the	gene-therapy	field.	However,	gene-modified	MSCs,	for	
example	armed	with	a	suicide	gene,	are	currently	 in	a	 first-in-human	phase	 I/II	 study	 for	advanced	
gastrointestinal	 tumors	 196	 and	 have	 demonstrated	 an	 excellent	 safety	 profile	 so	 far	 (C.	 Günther,	
personal	 communication).	 Of	 course,	 suicide	 genes	 represent	 only	 one	 approach	 for	 genetically	
modifying	 MSCs	 with	 to	 give	 them	 additional	 features.	 The	 potential	 importance	 of	 AAT	 for	
inflammatory	lung	diseases,	especially	emphysematous	COPD,	has	been	laid	out	above.	Thus,	out	of	
the	 plethora	 of	 potentially	 beneficial	 genes	 that	 could	 be	 used	 to	 equip	 MSCs	 for	 the	 enhanced	
treatment	of	inflammatory	diseases,	we	chose	AAT	based	on	its	variety	of	functions	described	in	the	
following	section.	
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1.4. Alpha-1 antitrypsin 
1.4.1. The discovery of AAT 
The	ability	of	human	plasma	to	inhibit	proteases	was	first	described	in	1894	197.	It	was	not	until	1955	
that	Schultze	and	colleagues	discovered	the	protein	responsible	for	this	anti-protease	activity.	They	
gave	 it	 the	name	“alpha-1	antitrypsin”	since	 it	moved	within	the	alpha-1	globulin	fraction	 in	serum	
protein	electrophoresis,	and	had	the	ability	to	 inhibit	trypsin	198.	 In	the	1960s	it	was	found	that	the	
absence	of	the	AAT	band	from	the	alpha-1	globulin	fraction	was	linked	to	an	inherited	deficiency	and	
associated	with	severe	and	early-onset	lung	emphysema	199,200,	suggesting	the	general	importance	of	
this	 protein	 for	 human	 health	 and	 disease.	 At	 the	 same	 time	 it	 was	 described	 that	 intratracheal	
instillation	 of	 papain,	 a	 protease	 present	 in	 the	 fruit	 papaya,	 caused	 emphysema	 in	 rats	 201.	 Both	
studies	taken	together	supported	the	hypothesis	of	a	proteolytic	pathogenetic	mechanism	resulting	
from	the	lack	of	sufficient	inhibition	of	proteases	by	AAT,	leading	to	a	breakdown	of	lung	tissue	and	
the	destruction	of	alveolar	integrity	in	the	development	of	emphysema	in	AAT-deficient	patients	202.	
These	publications	provided	the	basis	 for	subsequent	studies	that	 identified	elastase	released	from	
neutrophilic	granulocytes	as	a	major	cause	of	emphysema	in	AAT-deficient	patients,	and	a	target	of	
AAT	 action	 203–206.	 At	 the	 same	 time,	 a	 close	 link	 between	 smoking	 and	 the	 development	 of	
emphysema	 was	 identified	 207,208.	 In	 further	 studies,	 a	 protease-antiprotease	 imbalance	 was	
hypothesized	 as	 the	 cause	of	 emphysema	not	 only	 for	 patients	 suffering	 from	AAT	deficiency,	 but	
also	by	extension,	for	COPD	patients	45,209,210.	Supported	by	the	work	of	Gadek	and	colleagues	211,	the	
US	Food	and	Drug	Administration	approved	 the	marketing	of	AAT	purified	 from	human	plasma	 for	
replacement	therapy	in	patients	with	severe	AAT	deficiency	and	emphysema	in	1987	212,213.	Since	that	
time,	major	progress	has	been	made	regarding	the	mechanism	and	epidemiology	of	the	disease	214,215	
as	well	as	in	the	understanding	of	novel	characteristics	of	AAT	202,216–218.		
1.4.2. AAT deficiency 
AAT	deficiency	is	a	genetic	disorder	marked	by	production	of	defective	AAT	protein,	decreased	serum	
AAT	 concentrations,	 and	 accumulation	 of	 misfolded	 protein	 in	 the	 endoplasmic	 reticulum	 (ER)	 of	
hepatocytes	219.	The	most	severe	variant,	the	so-called	Z-phenotype,	affects	approximately	1	in	2000	
North	 European	 Caucasians	 220.	 Clinically,	 this	 archetypal	 conformational	 serpinopathy	 is	
characterized	 by	 early-onset	 panlobular	 basal	 lung	 emphysema	 due	 to	 uninhibited	 breakdown	 of	
lung	 tissue	 by	 proteases	 200,221.	 As	 such,	 AAT	 deficiency	 is	 the	 only	 known	 genetic	 cause	 of	
emphysema	 3	 and	 the	 only	 recognized	 genetic	 factor	 that	 increases	 the	 predisposition	 to	 develop	
COPD	222,223.	 In	addition	to	 lung	disease,	patients	carrying	the	severe	Z	deficiency	allele	often	suffer	
from	neonatal	hepatitis,	cirrhosis,	and	hepatocellular	carcinoma	224,225.	Furthermore,	AAT	deficiency	
has	 been	 linked	 to	 several	 inflammatory	 diseases	 such	 as	 panniculitis,	 vasculitis	 (in	 particular	
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Wegener’s	 granulomatosis),	 bronchiectasis,	 and	 ulcerative	 colitis,	 suggesting	 that	 neutrophil	
proteases	 are	 also	 involved	 in	 the	 pathogenesis	 of	 these	 diseases	 226,	 and	 demonstrating	 the	
importance	of	AAT	in	maintaining	tissue	homeostasis	and	controlling	inflammation.		
1.4.3. Biochemical characteristics of AAT 
AAT,	also	termed	alpha-1	proteinase	inhibitor	(A1PI),	 is	a	52kDa,	water-soluble	and	tissue-diffusible	
394-amino	acid	circulating	glycoprotein	encoded	by	the	SERPINA1	gene	227–229.	AAT	is	the	prototypic	
member	 of	 the	 serine	 protease	 inhibitor	 (SERPIN)	 superfamily	 230.	 Serpins	 are	 protease	 inhibitors	
found	in	all	kingdoms	of	life	that	play	important	roles	in	a	variety	of	biological	processes	including	the	
control	of	 inflammation	or	coagulation	 231,232.	Despite	 its	name,	 the	major	 target	of	 this	 inhibitor	 is	
the	serine	protease	elastase	released	from	neutrophils	during	inflammation,	and	AAT	binds	to	it	with	
one	of	the	highest	association	rate	constants	observed	in	biology	233.	In	addition,	AAT	can	also	block	
proteinase	 3,	myeloperoxidase,	 and	 cathepsin	 G	 secreted	 by	 neutrophils,	 the	 coagulation	 cascade	
proteinases	 plasmin,	 thrombin,	 urokinase,	 and	 factor	 Xa,	 the	 kallikreins	 7	 and	 14,	 cell-surface	
proteases	such	as	matriptase,	and	the	cysteine	proteinase	caspase-3	234–237,	thus	accounting	for	more	
than	90%	of	the	antiproteinase	activity	in	human	plasma	229.		
More	than	80%	of	AAT	is	produced	and	secreted	by	hepatocytes;	however,	pulmonary	alveolar	cells,	
monocytes,	macrophages,	neutrophils,	endothelial	cells,	intestinal	paneth	cells,	pancreatic	islet	cells	
and	some	types	of	cancer	cells	can	produce	small	amounts	of	the	protein,	mainly	in	a	tissue-specific	
context	 during	 inflammatory	 reactions	 216,238–242.	 Bone	 marrow-derived	 MSCs	 do	 not	 appear	 to	
express	 AAT	 243.	 Humans	 produce	 large	 amounts	 (i.e.	 34mg	 AAT/kg/day)	 resulting	 in	 plasma	
concentrations	as	high	as	0.9–1.75g/L	216,	and	the	protein	is	cleared	with	a	half-life	of	3–5	days	244,245.	
From	the	plasma,	80%	of	AAT	diffuse	to	interstitial	tissues,	while	the	rest	reaches	body	fluids	such	as	
saliva,	tears,	milk,	semen,	urine,	bile,	and	cerebrospinal	fluid	246–250.	The	distribution	of	the	protein	is	
not	uniform,	since	e.g.	in	the	epithelial	lining	fluid	of	the	lower	respiratory	tract,	the	concentration	of	
AAT	is	believed	to	be	only	10%	of	that	seen	in	plasma	levels	251,	suggesting	that	even	small	amounts	
of	AAT	may	have	strong	local	effects.		
1.4.4. Mechanism of proteinase inhibition 
The	irreversible	suicide	substrate-like	inhibitory	mechanism	that	AAT	is	well-known	for	is	linked	to	its	
tertiary	structure,	which	is	highly	similar	among	all	serpins.	It	consists	of	three	beta	sheets	(named	A,	
B,	and	C),	9	alpha	helices	 (A–I),	and	an	exposed	9-amino	acid	C-terminal	 reactive	center	 loop	(RCL,	
Figure	1A)	252.	Contained	within	this	RCL	is	the	protease	recognition	site	centered	at	residues	Met358	–	
Ser359	253,254,	which	is	presented	to	the	protease	like	a	“bait”.	Cleavage	of	the	targeted	peptide	bond	
at	this	recognition	site	by	e.g.	elastase	leads	to	an	irreversible	binding	of	the	protease	to	the	serpin	
(Figure	 1B)	 and	 initiates	 a	 dramatic	 conformational	 change	 for	 both	 AAT	 as	 well	 as	 the	 protease	
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(Figure	 1C).	 During	 this	 so-called	 stressed	 to	 relaxed	 transition,	 the	 covalently	 bound	 protease	 is	
transferred	 from	 one	 pole	 of	 the	 AAT	 protein	 to	 the	 other	 by	 the	 RCL.	 This	 mousetrap-like	
mechanism	is	a	suicide	interaction	for	both	parties	involved	and	results	in	an	energetically	favorable	
conformation	 of	 the	 serpin	 and	 complete	 distortion	 of	 the	 structure	 of	 the	 protease,	 thereby	
inactivating	 it	 and	at	 the	 same	 time	 inducing	 clearing	pathways	 to	degrade	 the	 inactivated	 serpin-
protease-complex	216,255,256.		
	
Figure	 1:	 Proteases	 are	 inhibited	 by	 AAT	 by	 a	 suicide	 substrate-like	 mechanism.	 A:	 Tertiary	
structure	of	AAT.	Indicated	are	the	RCL	(red)	with	the	reactive	site	centered	at	Met358	–	Ser359	(green	
and	yellow	balls,	respectively).	B:	AAT-protease	docking	complex.	The	protease	binds	to	Ser359	in	an	
attempt	 to	 cleave	 the	 reactive	 site	bond	between	Met358	 –	 Ser359.	C:	 Final	AAT-protease	 complex.	
After	 cleaving	 the	 reactive	 site	 bond,	 the	 protease	 remains	 stably	 bound	 to	 Ser359,	 while	 AAT	
undergoes	a	conformational	change,	leading	to	structural	distortion	and	inactivation	of	the	protease.	
Figure	 modified	 from	 PeproTechFocus.	 Serpins,	 Serpinopathies,	 and	 Conformational	 Diseases	
(n.d.)252.		
1.4.5. Anti-inflammatory and immunomodulatory properties of AAT 
Solely	 considering	 the	 name	 of	 the	 protein,	 one	 is	 tempted	 to	 assume	 that	 the	 anti-inflammatory	
activity	of	AAT	is	purely	biochemical	and	related	to	the	inhibition	of	proteases	during	inflammatory	
processes.	 However,	 during	 the	 last	 decade	 it	 has	 been	 recognized	 that	 AAT	 not	 only	 is	 a	 potent	
protease	inhibitor	protecting	tissues	from	the	damaging	effect	of	enzymes	excessively	released	from	
inflammatory	cells,	but	also	has	powerful	immunomodulatory	and	tissue-protective	properties,	some	
of	 which	 are	 most	 likely	 independent	 of	 its	 function	 as	 a	 protease	 inhibitor	 216,257.	 However,	 the	
mechanisms	underlying	these	favorable	functions	of	AAT	are	still	a	field	of	intense	research	242.	The	
following	section	provides	an	overview	of	the	current	state	of	our	knowledge.		
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1.4.5.1. AAT as acute phase protein – anti-inflammatory effects 
AAT	 is	 a	 hepatic	 acute	 phase	 protein	 with	 an	 inflammation-,	 cortisol-	 and	 hypoxia-inducible	 gene	
promoter	258.	Upon	induction,	 its	concentration	can	increase	more	than	4-fold	in	plasma,	and	up	to	
11-fold	 in	 tissues	 such	 as	 the	 lung,	 pancreas	 or	 intestine	 due	 to	 it	 being	 locally	 synthesized	 by	
inflammatory	cells	as	a	protective	response	to	infection	and	inflammation	251,259–263.	AAT	levels	in	the	
circulation	 also	 rise	 during	 pregnancy,	 a	 state	 in	 which	 the	 induction	 of	 tolerance	 is	 especially	
important	264.		
Many	of	the	anti-inflammatory	functions	of	AAT	are	related	to	its	ability	to	 inhibit	proteases.	 It	has	
e.g.	 been	 described	 that	 serine	 proteases	 activate	 IL-1	 precursor	 proteins	 exposed	 from	 necrotic	
cells,	 which	 is	 diminished	 in	 the	 presence	 of	 increased	 levels	 of	 AAT	 265.	 This	 mechanism	 is	 of	
particular	 importance	 for	 the	 present	work,	 since	 it	 is	 commonly	 accepted	 that	 IL-1	 is	 one	 of	 the	
major	 pro-inflammatory	 cytokines	 involved	 in	 the	 pathogenesis	 of	 smoke-induced	 COPD	 266.	 It	 has	
also	been	suggested	that	the	anti-inflammatory	potential	of	AAT	 is	mediated	by	the	 inactivation	of	
serine	proteases	which	signal	via	a	group	of	membrane	protein	receptors	named	protease-activated	
receptors	 (PARs),	 such	 as	 for	 example	 trypsin	 or	 neutrophil	 elastase	 216.	 PARs	 are	 described	 to	 be	
essential	for	various	inflammatory	processes	including	the	release	of	MCP-1,	IL-1,	IL-6,	and	TNF-alpha	
from	inflammatory	cells,	 increased	neutrophil	migration,	and	the	maturation	of	DCs	267–271.	Many	of	
these	processes	play	crucial	roles	in	the	excessive	inflammation	present	in	COPD	266.	Surprisingly,	AAT	
also	targets	some	proteins	that	are	not	serine	proteases,	such	as	a	disintegrin	and	metalloproteinase	
with	 thrombospondin	 motifs	 4	 (ADAMTS-4),	 a	 protein	 involved	 in	 rheumatoid	 arthritis,	 or	 matrix	
metallopeptidase-9	(MMP-9),	which	is	related	to	COPD	272–274.		
Furthermore,	AAT	has	been	described	to	have	anti-inflammatory	functions	that	are	 independent	of	
protease	 inhibition.	 The	 binding	 of	 IL-8,	 the	major	 neutrophil	 chemoattractant,	 seems	 to	 function	
without	utilizing	the	protease	binding	site	of	AAT,	and	leads	to	disrupted	migration	of	neutrophils	275.	
As	described	earlier,	neutrophils	are	crucially	involved	in	the	pathogenesis	of	COPD	8,39.	Accordingly,	
the	lack	of	AAT	in	the	lungs	of	patients	suffering	from	AAT	deficiency	results	in	excessive	mobilization	
of	neutrophils	into	the	pulmonary	parenchyma	216.	Moreover,	it	has	been	shown	that	AAT	binds	heat	
shock	 proteins	 like	 heat	 shock	 protein	 90kDa	 beta	 member	 1	 (HSP90B1)	 and	 heat	 shock	 protein	
70kDa	 (HSP70),	 indicating	 that	 it	 also	 plays	 a	 role	 in	 diminishing	 immune	 responses	 to	 DAMP	
molecules	276,277.	AAT	has	also	been	described	to	bind	both	receptors	of	TNF-alpha,	although	at	a	low	
affinity,	indicating	that	this	anti-inflammatory	mechanism	is	important	mainly	during	phases	in	which	
AAT	is	present	at	high	levels,	such	as	acute	phase	reactions	258,278.		
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1.4.5.2. Effects on innate immunity 
It	 is	 thought	 that	AAT	has	 the	ability	 to	shift	 local,	as	well	as	systemic	cytokine	environments	 from	
pro-	to	anti-inflammatory	257.	This	is	thought	to	be	mediated	by	effects	on	cells	of	the	innate	immune	
system	such	as	monocytes/macrophages	and	neutrophils	–	cell	types	significantly	associated	with	the	
pathogenesis	of	COPD	266.	 It	has	been	shown	 in	numerous	studies	 that	AAT	has	a	potent	 inhibitory	
effect	 on	 the	 production	 of	 pro-inflammatory	 cytokines	 such	 as	 IL-1beta,	 TNF-alpha,	 and	 IL-8	 by	
either	monocytes	or	PBMCs,	while	at	 the	 same	 time	promoting	 the	 secretion	of	anti-inflammatory	
molecules	like	IL-10	and	IL-1ra	279–286.	The	second	cell	type	strongly	influenced	by	AAT	is	neutrophilic	
granulocytes.	Several	groups	have	described	a	suppressive	effect	of	AAT	on	neutrophil	activation	and	
chemotaxis	284,287–289.	The	mechanism	underlying	the	latter	effect	was	associated	with	binding	by	AAT	
to	a	major	chemoattractant	 for	neutrophils,	 the	cytokine	 IL-8	 275.	The	same	group	recently	showed	
that	 AAT	 regulates	 TNF-alpha-induced	 degranulation	 of	 neutrophils,	 and	 thus	 the	 release	 of	
elastase	278.		
AAT	also	exerts	tolerance-inducing	effects	on	DCs	and	macrophages.	Recently,	it	was	reported	that	in	
the	 presence	 of	 AAT,	 the	 expression	 of	 CD40,	 CD84	 and	major	 histocompatibility	 complex	 (MHC)	
class	 II	 in	 stimulated	 DCs	 is	 reduced.	 At	 the	 same	 time,	 IL-10	 production	 is	 increased	 and	 the	
expansion	 of	 regulatory	 T	 lymphocytes	 (Tregs)	 promoted	 290.	 An	 interesting	 finding	 is	 that	 the	
inflammation-driven	migratory	capacity	of	the	DCs	was	not	blunted	by	AAT,	allowing	them	to	reach	
the	draining	lymph	nodes	and	exert	their	tolerogenic	function	there	290.		
NK	cells	are	crucial	for	the	response	against	viral	infection	and	tumor	development	and	have	recently	
been	described	to	exert	functions	attributable	to	both	the	innate	and	adaptive	immunity	291.	It	might	
be	assumed	that	just	like	with	the	many	cell	types	described	above,	AAT	would	also	interfere	with	NK	
cell	function,	resulting	in	an	increase	in	viral	infections	or	elevated	tumor	incidence.	This	would	be	a	
major	 problem,	 especially	 for	 COPD	 patients	 suffering	 from	 acute	 exacerbations	 292.	 However,	
although	DC-derived	IL-15-related	NK	cell	responses	are	reduced	in	the	presence	of	AAT	293,	patients	
suffering	from	AAT-deficiency	are	at	 increased	risk	of	developing	various	types	of	cancer	compared	
to	individuals	with	normal	AAT	levels	294–296.	Moreover,	AAT	has	been	described	to	mediate	anti-viral	
and	anti-tumor	effects	 297–300.	The	hypothesized	underlying	mechanism	 is	 that	 the	effect	of	AAT	on	
NK	 cells	 is	 immune	 permissive	 in	 the	 case	 of	 infected	 or	 transformed	 cells,	 but	 suppressive	 if	 the	
target	cells	are	healthy	and	the	immune	signal	predominantly	antigen	presenting	cell-mediated	258.		
1.4.5.3. Effects on adaptive immunity 
Numerous	studies	have	confirmed	the	hypothesis	that	AAT	has	no	direct	effects	on	T	cells	in	vitro,	as	
indicated	by	persisting	levels	of	 interleukin	2	(IL-2)	and	related	responses	in	the	presence	of	AAT	in	
cell	culture	experiments	301,302;	however,	a	growing	body	of	knowledge	indicates	that	AAT	treatment	
influences	T	cells	in	an	indirect	manner,	leading	to	a	reduction	in	T	cell	infiltrates,	alteration	of	the	T	
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cell	 receptor	 repertoire	 and	 expansion	 of	 Tregs	 in	 models	 of	 autoimmunity	 or	
allotransplantation	285,286,290,303–306.	 It	 is	 suspected	 that	 all	 these	 effects	 on	 the	 adaptive	 immune	
system	result	from	a	shift	of	the	cytokine	environment	from	pro-	to	anti-inflammatory	and	from	the	
induction	of	 tolerogenic,	 IL-10-secreting	DCs	 257,290.	Another	effect	AAT	appears	 to	exert	on	cells	of	
the	adaptive	immune	system	is	a	suppression	of	the	activation	and	proliferation	of	B	lymphocytes,	as	
recently	 shown	 in	 a	 model	 of	 allogeneic	 skin	 transplantation	 307.	 Surprisingly,	 antigen-specific	
antibody	 production	 remained	 intact	 in	 the	 presence	 of	 high	 AAT	 levels;	 however,	 an	 isotype	
switching	towards	an	 IgM-high/IgG-low	phenotype	was	observed.	Furthermore,	an	 IL-10-expressing	
regulatory	subpopulation	of	B	cells	considered	to	be	highly	important	in	alloantigen	tolerance	seems	
to	be	expanded	by	treatment	with	AAT,	and	this	cell	population	was	shown	to	be	required	for	AAT-
induced	Treg	expansion	307,308.		
1.4.6. Anti-apoptotic and regenerative effects 
Of	special	importance	for	the	present	work	is	the	observation	that	AAT	has	significant	anti-apoptotic	
and	 cytoprotective	 effects	 in	 addition	 to	 its	 anti-inflammatory	 potential.	 Petrache	 and	 colleagues	
showed	 that	 AAT	 is	 able	 to	 inhibit	 pulmonary	 alveolar	 cell	 apoptosis	 by	 suppression	 of	 caspase-3	
activation	 and	 oxidative	 stress,	 and	 attenuate	 emphysema	 development	 in	 animal	 models	 of	
apoptosis-dependent	 emphysema	 lacking	 neutrophilic	 inflammation	 237,309.	 Furthermore,	 two	
separate	clinical	 trials	of	 i.v.	AAT	augmentation	 therapy	 for	genetic	AAT-deficient	 lung	emphysema	
confirmed	this	cytoprotective	potential	in	the	human	setting	as	seen	by	a	significant	reduction	of	the	
decline	in	lung	density	and	an	arrest	of	emphysema	development	310.	Moreover,	 it	has	been	shown	
that	AAT	exerts	anti-apoptotic	functions	on	endothelial	cells	and	vascular	smooth	muscle	cells311–313,	
while	 also	 inducing	 the	 production	 and	 preventing	 the	 elastase-dependent	 degradation	 of	 VEGF,	
thereby	contributing	to	tissue	neovascularization	and	regeneration	314,315.	
1.4.7. Anti-microbial functions 
In	addition	to	its	 immunomodulatory	and	regenerative	properties,	AAT	has	been	described	to	exert	
anti-bacterial	 and	 anti-viral	 functions.	 Shapiro	 and	 colleagues	 initially	 found	 that	 while	 in	 vitro	
infection	of	human	whole	blood	with	the	human	immunodeficiency	virus	(HIV)	does	not	occur,	whole	
blood	 from	AAT-deficient	patients	 is	 readily	 infected	 316.	 Later,	 the	 same	group	described	 that	HIV	
infection	 is	 linked	 to	 reduced	 serum	AAT	 levels	 317	 and	 that	patients	 suffering	 from	AAT	deficiency	
might	be	at	higher	risk	for	acquiring	HIV	infection	299.	Furthermore,	aerosolized	AAT	has	been	shown	
to	 be	 able	 to	 suppress	 Pseudomonas	 aeruginosa	 proliferation	 in	 a	 rat	 model	 of	 chronic	 lung	
infection318	 and	 in	 patients	 suffering	 from	 cystic	 fibrosis	 319.	 Another	 anti-bacterial	 property	
associated	with	AAT	is	its	binding	to	the	secreted	enteropathogenic	Escherichia	coli	proteins	B	and	D	
(EspB,	 EspD),	 thereby	 potently	 inhibiting	 hemolysis	 of	 red	 blood	 cells	 320.	 These	 anti-microbial	
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properties	could	be	especially	important	with	regards	to	the	treatment	of	acute	exacerbations,	since	
these	oftentimes	 life-threatening	complications	 in	patients	with	severe	COPD	are	mostly	caused	by	
bacterial	or	viral	infections	292.		
1.4.8. Summary 
Taken	 together,	 AAT	 is	 not	 a	 prototypic	 anti-inflammatory	 molecule	 that	 blocks	 the	 activity	 of	
immune	cells,	but	rather	an	immune	modulator	that	permits	an	effective	immune	reaction,	while	at	
the	 same	 time	 limits	 an	excessive	 inflammatory	 response,	 induces	 immunological	 tolerance	 that	 is	
persisting	 and	 specific,	 protects	 noninvolved	 bystander	 cells,	 and	 moreover	 has	 anti-microbial	
properties.	These	unique	features	together	with	the	outstanding	safety	profile	for	AAT	augmentation	
therapy	as	seen	for	AAT	deficiency	321	make	AAT	an	attractive	candidate	for	the	treatment	of	diseases	
with	an	underlying	inflammatory	or	autoimmune	pathology.	Indeed,	as	recombinant	AAT	is	currently	
being	tested	in	clinical	trials	for	indications	such	as	COPD	and	pulmonary	fibrosis,	new-onset	diabetes	
type	1,	 cystic	 fibrosis,	 sarcoidosis,	 solid	 organ	 and	 islet	 cell	 transplantation,	HIV	disease	 and	GvHD	
with	very	promising	results	so	far	319,321–324,	it	represents	an	excellent	candidate	molecule	to	combine	
with	MSC-based	approaches	for	the	potential	treatment	of	chronic	airway	disorders.	
1.5. Summary and rationale of the present study 
• Chronic	inflammatory	diseases	such	as	COPD	are	a	major	health	problem	today	and	pose	an	
increasing	burden	on	individuals,	patients	and	economies.	COPD	is	the	third	leading	cause	of	
mortality	worldwide	to	date	and	affects	more	than	300	million	people,	and	since	there	is	no	
cure	today,	novel	therapeutic	approaches	are	desperately	needed.		
• MSCs	 have	 been	 shown	 to	 exert	 extremely	 potent	 immunomodulatory	 and	 regenerative	
functions	on	a	variety	of	cells	in	response	to	inflammatory	stimuli.	Moreover,	they	have	been	
proven	to	be	anti-microbial	and	hypoimmunogenic	when	used	in	an	allogeneic	setting.	They	
are	 currently	 being	 investigated	 in	 more	 than	 500	 clinical	 trials,	 most	 of	 them	 related	 to	
inflammatory	diseases	 including	COPD,	with	 very	promising	 results	 and	 an	excellent	 safety	
profile	so	far.	Compared	to	other	stem	cell	types	or	small	molecules	and	biologics,	MSCs	have	
several	advantages	regarding	their	clinical	usability.		
• AAT	 is	 an	 acute	 phase	 protein	 and	 the	 prototypic	 serine	 protease	 inhibitor	 in	 the	 human	
body,	 protecting	 tissues	 from	 the	 damaging	 effect	 of	 enzymes	 secreted	 by	 immune	 cells	
during	 inflammation.	Moreover,	AAT	has	 lately	also	been	recognized	as	a	protein	with	very	
potent	regenerative,	anti-inflammatory	and	immunoregulatory	functions	affecting	all	parts	of	
the	 immune	 system.	 It	 has	 also	 been	 shown	 to	 efficiently	 prevent	 viral	 and	 bacterial	
infections.	AAT	has	been	used	for	the	chronic	treatment	of	AAT	deficiency	for	almost	three	
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decades	now,	with	an	outstanding	safety	profile	and	a	beneficial	effect	on	emphysema,	and	
is	currently	tested	for	a	plethora	of	inflammatory	and	autoimmune	diseases	in	clinical	trials.		
• Cell-based	 gene	 therapy	 has	 yielded	 striking	 results	 in	 the	 treatment	 of	 various	 previously	
incurable	 diseases	 during	 the	 last	 years.	 This	 innovative	 therapeutic	 approach	 offers	 the	
possibility	of	combining	the	function	of	one	or	more	transgenes	with	the	cells’	endogenous	
properties,	 resulting	 in	a	more	potent	cell	product	 for	 the	treatment	of	various	diseases.	 It	
was	only	very	recently	 that	the	first	ex	vivo	 stem	cell-based	gene	therapy	product	received	
market	authorization	by	the	European	Commission	for	the	treatment	of	the	so	far	hopeless	
disease	 adenosine	 deaminase-deficient	 severe	 combined	 immunodeficiency	 (ADA-
SCID)182,325.	
	
Taken	 together,	 our	 hypothesis	 is	 that	 for	 the	 treatment	 of	 diseases	 as	 complex	 as	
emphysematous	COPD,	for	which	no	cure	exists	so	far,	the	effects	of	MSCs	or	AAT	alone	might	
not	be	sufficient	to	achieve	an	amelioration	of	the	illness,	but	that	combining	the	properties	of	
MSCs	with	those	of	AAT	may	achieve	a	therapeutic	benefit	(Figure	2).	Thus,	this	pilot	study	was	
aimed	at	finding	a	way	to	modify	MSCs	using	viral	vectors	to	optimally	express	transgenic	AAT,	
and	to	deliver	a	first	proof	of	concept	that	this	cell	product	could	show	benefit	for	the	treatment	
of	inflammatory	lung	diseases	such	as	COPD.		
	
	
Figure	2:	Overview	of	the	synergistic	mechanisms	of	a	combination	of	AAT	and	MSCs	(AAT-MSCs)	
using	the	example	of	inflammatory	lung	diseases.		
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1.6. Specific aims and scope 
The	following	specific	goals	provided	a	framework	for	the	present	work:	
• Design	of	gamma-retroviral	constructs	for	the	permanent	expression	of	SERPINA1	and	pac	
in	primary	human	MSCs.	To	generate	an	optimized	construct	 for	the	transgenic	expression	
of	AAT	in	MSCs,	eight	gamma-retroviral	vectors	were	planned	and	would	be	compared	with	
regards	 to	 viral	 titers,	 transduction	 efficacy,	 and	 AAT	 expression.	 Three	 different	 human	
physiological	 gene	 promoters	would	 be	 tested	 in	 parallel	 for	 driving	 SERPINA1	 expression.	
The	pac	gene	enabling	selection	of	gene-modified	cells	using	the	antibiotic	puromycin	should	
be	 driven	 either	 by	 a	 second	 promoter,	 or	 expressed	 via	 an	 internal	 ribosome	 entry	 site	
(IRES)	 sequence	 3’	 of	 the	SERPINA1	 gene.	 In	 case	of	 constructs	 containing	 two	promoters,	
different	 configurations	 of	 the	 expression	 cassettes	 should	 be	 assessed,	 i.e.	 the	 SERPINA1	
cassette	would	be	placed	5’	of	the	pac	cassette	in	some	constructs,	and	3’	in	others.		
• Generation	 of	 functional	 viral	 supernatants	 and	 titration	 on	 HT1080	 fibrosarcoma	 cells.	
Viral	 supernatants	of	 the	eight	 transfer	plasmids	 in	combination	with	the	respective	helper	
plasmids	 should	 be	 generated,	 and	 their	 functionality	 and	 titers	 determined	 first	 by	
transduction	of	HT1080	fibrosarcoma	cells.	Later,	primary	human	MSCs	should	be	transduced	
at	comparable	multiplicities	of	infection	(MOIs).	
• Selection	of	the	expression	cassette	lead	candidate.	Depending	on	transduction	of	primary	
human	MSCs	and	transgenic	AAT	expression,	the	best	constructs	will	be	subjected	to	testing	
in	further	experiments.		
• Comparison	 of	 best	 expression	 cassette	 in	 gamma-retroviral	 vs.	 lentiviral	 backbone.	 To	
assess	 if	 the	 performance	 of	 the	 expression	 cassette	 lead	 candidate	 in	 a	 gamma-retroviral	
vector	could	be	further	improved,	the	cassette	will	be	cloned	into	a	lentiviral	backbone,	and	
the	plasmids	compared	regarding	transduction	efficacy	and	AAT	expression.		
• In	vitro	confirmation	of	functionality	of	transgenic	AAT	expressed	from	MSCs.	To	assess	 if	
AAT	 transgenically	expressed	 from	MSCs	 is	 functional	with	 regards	 to	 its	protease	 inhibitor	
capacity,	an	 in	vitro	assay	should	be	established,	and	MSC-AAT	compared	to	natural	human	
AAT	isolated	from	plasma.		
• Process	up-scaling,	batch	production	and	characterization.	Large	scale	procedures	for	MSC	
transduction,	antibiotic	selection	and	expansion	should	be	established	to	be	able	to	provide	
high	numbers	of	gene-modified	MSCs	from	the	same	batch	for	in	vivo	studies.		
• Confirmation	of	 efficacy	 of	AAT-MSCs	 in	 an	 in	 vivo	model	 of	 lung	 emphysema.	 Finally,	 it	
should	 be	 assessed	 if	 therapy	 with	 AAT-MSCs	 was	 able	 to	 improve	 lung	 function	 and	
histological	parameters	in	a	mouse	model	of	elastase-induced	pulmonary	emphysema.		
	
Material and Methods   
	
20 
2. Materials and Methods 
2.1. Materials 
2.1.1. Bacteria 
Name	 Company	and	genotype	
MAX	Efficiency	DH5α	Competent	Cells	
Genotype	
Thermo	Fisher	Scientific	
F-	Φ80lacZΔM15	Δ(lacZYA-argF)	U169	recA1	endA1	hsdR17	(rk-,	
mk+)	phoA	supE44	λ-thi-1	gyrA96	relA1	
One	Shot	Stbl3	Chemically	Competent	E.	
coli	
Genotype	
Thermo	Fisher	Scientific	
F-mcrB	mrrhsdS20(rB-,	mB-)	recA13	supE44	ara-14	galK2	lacY1	
proA2	rpsL20(StrR)	xyl-5	λ-leumtl-1	
2.1.2. Restriction enzymes 
Name	 Company	
AgeI	 New	England	Biolabs	
BamHI	 New	England	Biolabs	
ClaI	 New	England	Biolabs	
PacI	 New	England	Biolabs	
PmeI	 New	England	Biolabs	
SalI	 New	England	Biolabs	
SnaBI	 New	England	Biolabs	
2.1.3. Primers 
Primers	were	designed	 following	general	primer	design	 rules	 326,	 checked	 for	hairpin	 structure	and	
dimer	 formation	 using	 Metabion’s	 Oligonucleotide	 Properties	 Calculator	
(http://www.metabion.com/biocalc/index.html),	and	ordered	from	Metabion.		
	
Application	 Name	 Sequence	
Insertion	of	a	PacI	
recognition	site		
Mutagenesis_PacI_F	 5'-AACTGAGCAGATCTTAATTAAAATTCCTGCAGTAAA-3'	
Mutagenesis_PacI_R	 5'-TTTACTGCAGGAATTTTAATTAAGATCTGCTCAGTT-3'	
Mutagenesis_Vector_F	 5'-TCA	GTG	GAA	CGA	AAA	CTC	ACG	TTA	AGG	GAT-3'	
Mutagenesis_Vector_R	 5'-ATC	CCT	TAA	CGT	GAG	TTT	TCG	TTC	CAC	TGA-3'	
Transfer	of	optimized	
cassette	into	lentiviral	
backbone	
Inf_EFS_SERPINA1_F	 5'-TTCAAAATTTTATCGATGGCTCCGGTGCCCGTCAG-3'	
Inf_EFS_SERPINA1_R	 5'-TCATTGGTCTTAAAGGTACCGACAACACCACGGAATTATC-3'	
Primers	and	probe	for	
VCN	determination	
human_FVII_for	 5'-GCCAAGCAAGGCACTATCTC-3'	
human_FVII_rev	 5'-GGCTGTGCCGAAGTAGATTC-3'	
FVII	Probe	 5'-Yakima	Yellow-AGGACCTCCGCCAGGGTTCA-BHQ1-3'	
oPRE_WPRE_VCN	fw	 5'-GCTATTGCTTCCCGTACG-3'	
WPRE	(Roche)	rev	 5'-AAAGAGACAGCAACCAGGATTT-3'	
Probe	#63	Roche	UPL	 Proprietary	(Roche)	
Primers	and	probe	for	
RCR	determination	
gag_eu_fw	 5'-AGAGGAGAACGGCCACTATTG-3'	
gag_eu_rev	 5'-ACTCCACTACCTCGCAGGCAT-3'	
gag_eu_probe	 5'-TGTCCGTTTCCTCCTGCGCGG-3'	
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Primers	and	probe	for	
RCL	determination	
HIV-1	gag	F	 CAGAATGGGATAGAGTGCATCCA	
HIV-1	gag	R	 TACTGGGATAGGTGGATTATGTGT	
HIV-1	gag	P	 5'-FAM-AGTTCCTGCTATGTCACTTCCCCTTG-TAMRA-3'	
	
2.1.4. Plasmids 
Number	 Name	 Application	
#110		 pSERS11_pPGK_IFNb_fw_IRES_pac	
Backbone	used	for	"1st	generation"	constructs	
#112		 pSERS11_pEF1a_IFNb_fw_IRES_pac	
#153	 pMA-RQ_pEFS_pPGK_Kozak_pac	 GeneArt	plasmid	containing	promoter,	Kozak	and	pac	sequences	
#168		 pSERS11_pEFS_luc2_P2A_eGPF_IRES_pac	 Corrected	backbone	used	for	"2nd	generation"	constructs	
#172		 pCCL-c-EFS-hADA_WPRE	 Plasmid	providing	lentiviral	backbone	
#70	 pcDNA3-MLV-gagpol	 Helper	plasmids	for	production	of	gamma-retroviral	
supernatants	#39	 pALF-PERV	A_GaLV	
#170	 pCMV-dR8.91	 Helper	plasmids	for	production	of	lentiviral	
supernatants	#171		 pCAGGS-VSVG	
#154	 pSERS11_pPGK_SERPINA1	
Intermediates	#155	 pSERS11_pEF1a_SERPINA1	
#156	 pSERS11_pEFS_SERPINA	
#159	 pSERS11_pPGK_SERPINA1_pEFS_pac	
Final	gamma-retroviral	SERPINA1	expression	constructs	
#160	 pSERS11_pEFS_SERPINA1_pPGK_pac	
#161	 pSERS11_pEF1a_SEPRINA1_pPGK_pac	
#162	 pSERS11_pEFS_pac_pPGK_SERPINA1	
#163	 pSERS11_pPGK_pac_pEFS_SERPINA1	
#164	 pSERS11_pPGK_pac_pEF1a_SERPINA1	
#193	 pSERS11_pPGK_SERPINA1_IRES_pac	
#194	 pSERS11_pEFS_SERPINA1_IRES_pac	
#215	 pCCL_pEFS_SERPINA1_IRES_pac	 Final	lentiviral	SERPINA1	expression	construct	
	
2.1.5. Kits 
Name	 Company	
Calcium	Phosphate	Transfection	Kit	 Sigma	
CompactPrep	Plasmid	Midi	Kit	 Qiagen	
DNeasy	Blood	&	Tissue	Kit	 Qiagen	
GeneArt	Site-Directed	Mutagenesis	PLUS	Kit	 Thermo	Fisher	Scientific	
GeneJET	Plasmid	Miniprep	Kit	 Thermo	Fisher	Scientific	
Human	alpha	1	Antitrypsin	ELISA	Kit	(SERPINA1)	 abcam	
Immunoperoxidase	Assay	for	Determination	of	Alpha	1-Antitrypsin	in	
Human	Samples	 GenWay	
In-Fusion	HD	Cloning	Kit	 Clontech	
Microsart	RESEARCH	Mycoplasma	Detection	Kit	for	qPCR	 Sartorius	
Neutrophil	Elastase	Inhibitor	Screening	Kit	(Fluorometric)	 abcam	
Plasmid	Plus	Maxi	Kit	 Qiagen	
Plasmid	Plus	Midi	Kit	 Qiagen	
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QIAprep	Spin	Miniprep	Kit	 Qiagen	
QIAquick	Gel	Extraction	Kit	 Qiagen	
Quick	Ligation	Kit	 NEB	
	
2.1.6. Reagents 
Reagent	 Company	
10%	Formalin,	neutral	buffered	 Sigma	Aldrich	
100X	GlutaMAX	 Gibco	
2-Propanol	99.9%	 Carl	Roth	
6X	Orange	DNA	Loading	Dye	 Fermentas	
Alizarin	Red	S	 Sigma	Aldrich	
Alpha	1	Antitrypsin,	Human	Plasma	 Athens	Research	&	Technology	
Ampicillin	 Genaxxon	Biosciences	
BacT/ALERT	SA,	Standard	Aerobic	 bioMérieux	
BacT/ALERT	SN,	Standard	Anaerobic	 bioMérieux	
Chloroquine	 Sigma	Aldrich	
Circlegrow	Bacterial	Growth	Medium	 MP	Biomedicals	
Cytofix/Cytoperm	Fixation	and	Permeabilization	Solution	 BD	Biosciences	
DMEM,	+D-glucose[1.0g/L],	+	stable	glutamine,	no	phenol	red	 Merck	Millipore	
DMEM,	+D-glucose[4.5g/L],	+	stable	glutamine	 Merck	Millipore	
DMEM,	low	glucose,	pyruvate,	no	glutamine,	no	phenol	red	 Gibco	
DMSO	 WAK-Chemie	Medical	GmbH	
Elastase	from	porcine	pancreas	 Sigma	Aldrich	
EMEM,	with	stable	L-glutamine	 ATCC	
Ethidiumbromid	 Genaxxon	Biosciences	
FBS,	Origin:	EU-approved	countries	 Merck	Millipore	
GeneJet	Wash	Solution	 Thermo	Fisher	Scientific	
Glycerol	 Carl	Roth	
GolgiPlug	Protein	Transport	Inhibitor	 BD	Biosciences	
H2O	ROTIPURAN	-	low	organic	 Carl	Roth	
HA	([50g/L]	in	isotonic	saline	solution)	 Baxter	
HAES	(10%	in	isotonic	saline	solution)	 Fresenius	Kabi	
HEPES	Buffer	Solution	[1M]	 Gibco	
Kanamycin	 Genaxxon	Biosciences	
LB-Agar	Powder	according	to	Miller	 Genaxxon	Biosciences	
LB-Medium	-	high	salt	 Genaxxon	Biosciences	
LightCycler	480	Probes	Master	 Roche	
Mayer’s	Hematoxylin	 Sigma	Aldrich	
MEM	Non-Essential	Amino	Acids	Solution	(100X)	 Gibco	
Natural	human	alpha	1	Antitrypsin	protein	 abcam	
O’GeneRuler	100bp	 Fermentas	
O’GeneRuler	1kb	 Fermentas	
Oil	Red	O	 Sigma	Aldrich	
PBS	 Merck	Millipore	
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peqGREEN	(DNA	&	RNA	Dye)	 Peqlab	
Perm/Wash	Buffer	 BD	Biosciences	
PLL	solution	0.01%	[100µg/mL],	sterile-filtered	 Sigma	Aldrich	
Puromycin	dihydrochloride	from	Streptomyces	alboniger	 Sigma	Aldrich	
RPMI	 Lonza	
SeaKem	LE	Agarose	 Lonza	
Sodium	Pyruvate	 Gibco	
Sodium	Pyruvate	[100	mM]	 Gibco	
StemMACS	AdipoDiff	Media,	human	 Miltenyi	Biotec	
StemMACS	OsteoDiff	Media,	human	 Miltenyi	Biotec	
T4	DNA	Ligase	 NEB	
TAE	buffer	(50X)	 Genaxxon	Biosciences	
Trypan	Blue	 Sigma	Aldrich	
TrypLE	select	 Gibco	
	
2.1.7. Antibodies 
Antibody	name	 Company	
Goat	polyclonal	to	alpha	1	Antitrypsin	(FITC),	human	 abcam	
CD45-ECD	 Beckman-Coulter	
HLA-DR-ECD	 Beckman-Coulter	
IgG1-ECD	 Beckman-Coulter	
CD3-FITC	 Beckman-Coulter	
CD41-FITC	 Beckman-Coulter	
CD90-FITC	 Beckman-Coulter	
CD235a-FITC	 Beckman-Coulter	
IgG1-FITC	 Beckman-Coulter	
CD19-PC7	 Beckman-Coulter	
CD34-PC7	 Beckman-Coulter	
CD61-PC7	 Beckman-Coulter	
IgG1-PC7	 Beckman-Coulter	
CD14-PE	 Beckman-Coulter	
CD73-PE	 BD	Pharmingen	
CD105-PE	 Beckman-Coulter	
IgG1-PE	 Beckman-Coulter	
IgG2a-PE	 Beckman-Coulter	
IgG3-PE	 Southern	Biotech	
7-AAD	 Beckman-Coulter	
	
2.1.8. Consumable materials 
Consumable	 Company	
1.5mL,	2mL,	and	5mL	microcentrifuge	tubes	 Eppendorf,	Sarstedt	
10cm	dishes,	TC-treated	 Corning	
10µL,	20µL,	100µL,	200µL,	and	1000µL	pipette	tips	 Greiner	Bio	One	
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15mL	and	50mL	centrifuge	tubes	 Corning	
2mL,	5mL,	10mL,	25mL,	and	50mL	serological	pipettes	 Corning	
6-,	12-,	24-,	48-,	and	96-well	plates,	TC-treated	 Corning	
96-well	flat	clear	bottom	black	polystyrene	plates	 Greiner	Bio	One	
C-Chip	Disposable	Hemocytometer	 NanoEnTek	
CellSTACK	cell	culture	chambers	(1,	2	or	5	chambers)	 Corning	
LightCycler	480	Multiwell	Plate	96	 Roche	
Syringe	filters	0.22µM	and	0.45µM	 Merck	Millipore	
T25,	T75,	T175,	and	T225	culture	flasks,	TC-treated	 Corning	
	
2.1.9. Equipment 
Equipment	 Company	
Buxco	forced	pulmonary	maneuver	system	 DSI	
BX51	microscope	 Olympus	
Centrifuge	5810R	 Eppendorf	
Centrifuge	Heraeus	Fresco	21	 Thermo	Fisher	Scientific	
Cytomics	FC500	flow	cytometer	 Beckman	Coulter	
DMI6000B	microscope	 Leica	
Incubator	Heraeus	BBD6220	 Thermo Fisher Scientific 
Incubator	Heraeus	Function	Line	 Thermo Fisher Scientific 
Incubator	MCO-20AIC	 Sanyo 
Incubator	shaker	KS-15	A	Control	 Edmund	Bühler	GmbH	
Laminar	air	flow	Herasafe	HS15		 Thermo Fisher Scientific 
LightCycler	480	Instrument	II	 Roche	
Mr.	Frosty	Freezing	Container	 Thermo	Fisher	Scientific	
NanoPhotometer	 Implen	
Plate	Reader	Spark	10M	 TECAN	
Precision	scale	EW	600	2M	 Kern	
Sub-Cell	GT	electrophoresis	system	 Bio-Rad	
Uvipro	Chemi	gel	documentation	system	 Biometra	
Water	bath	 Memmert	WNB	14	
	
2.1.10. Tumor cell lines 
Name	and	cell	type	 Company	
HT1080	human	fibrosarcoma	cells	 ATCC	
293T	human	embryonic	kidney	cells	 ATCC	
	
2.1.11. Software 
Software	name	 Company	
Kaluza	 Beckman	Coulter	
Las	X	 Leica	
Lasergene	12	Core	Suite	 DNASTAR	
LightCycler	480	Software	 Roche	
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Mendeley	Desktop	free	reference	manager	 Mendeley	Ltd.		
new-CAST	 Visiopharm	
Prism	6	 GraphPad	Software,	Inc.	
SnapGene	Viewer	 GSL	Biotech	LLC	
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2.2. Methods 
2.2.1. Design and molecular cloning strategy of viral expression plasmids 
2.2.1.1. Gamma-retroviral plasmids 
The	 in	vitro	synthesized	5’	UTR	and	CDS	of	the	human	SERPINA1	cDNA	transcript	1	were	purchased	
from	GeneArt,	with	 the	 following	 sequence	modifications:	A	BamHI	 restriction	enzyme	 recognition	
site	present	in	the	5’UTR	was	destroyed	by	replacing	a	cytosine	by	an	adenine	at	position	181	of	the	
5’	UTR	(GGATCA	instead	of	GGATCC).	A	modified	Kozak	consensus	sequence	(GCCACC)	was	inserted	
at	 the	 3’	 end	 of	 the	 5’UTR	 sequence,	 immediately	 5’	 of	 the	 SERPINA1	 start	 codon	 for	 efficient	
initiation	 of	 translation	 327.	 The	SERPINA1	 CDS	was	 codon	optimized	 for	Homo	 sapiens	 to	 increase	
protein	production.	Two	additional	stop	codons	were	added	3’	of	the	SERPINA1	stop	codon	to	ensure	
efficient	 release	 of	 the	 amino	 acid	 chain	 from	 the	 ribosome	 during	 translation.	 An	 AgeI	 site	 was	
added	to	the	5’	end	of	the	cassette,	and	a	PacI	site	to	the	3’	to	enable	easy	transfer	of	this	expression	
cassette	 into	 retroviral	 expression	 plasmids	 containing	 different	 promoters	 that	 were	 previously	
cloned	at	apceth.	Figure	3	shows	a	schematic	of	the	SERPINA1	expression	cassette.		
	
	
Figure	3:	Schematic	of	the	SERPINA1	expression	cassette.	
Cloning	of	“1st	generation”	AAT	constructs	
Plasmid	numbers	 represent	 apceth’s	 internal	plasmid	denomination	and	will	 be	used	hereafter	 for	
simplicity.	The	gamma-retroviral	backbone	used	to	generate	all	transfer	plasmids	is	pSERS11	328.	The	
5’-LTR	 comprises	 a	 simian	 vacuolating	 virus	 40	 (SV40)	 enhancer	 fused	 to	 the	 Rous	 sarcoma	 virus	
(RSV)	promoter,	and	the	spleen	focus	forming	virus	 (SFFVp)	R	and	U5	regions.	The	3’	 long	terminal	
repeat	 (LTR)	 contains	 an	 SFFVp	 U3	 region	 that	 has	 a	 deletion	 and	 thus	 renders	 the	 vector	 self-
inactivating,	 SFFV	 R	 and	 U5	 regions	 as	 well	 as	 a	 PolyA	 signal.	 To	 clone	 plasmid	 #114	
pSERS11_pPGK_SERPINA1_IRES_pac,	 in	a	first	step	a	unique	PacI	restriction	site	was	generated	in	a	
plasmid	 previously	 cloned	 at	 apceth	 (#110	 pSERS11_pPGK_IFN-beta_fw_IRES_pac,	 Supplemental	
figure	 1)	 by	 site-directed	 mutagenesis	 using	 the	 GeneArt	 Site-Directed	Mutagenesis	 PLUS	 Kit	 and	
primers	 Mutagenesis_PacI_F,	 Mutagenesis_PacI_R,	 Mutagenesis_Vector_F,	 Mutagenesis_Vector_R	
(cf.	 2.1.3	 for	 sequences).	Utilizing	 this	 newly	 created	 restriction	 site	3’	 of	 the	 interferon-beta	 (IFN-
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beta)	 cassette	 present	 in	 plasmid	 #110,	 the	 IFN-beta	 cassette	 was	 replaced	 by	 the	 SERPINA1	
expression	 cassette	 ordered	 from	 GeneArt	 using	 restriction	 enzymes	 PacI	 and	 AgeI.	 After	 the	
integrity	 of	 this	 first	 construct	was	 confirmed	 by	 analytical	 restriction	 enzyme	 digestion,	 in	 a	 next	
step	 the	 phosphoglycerate	 kinase	 (PGK)	 promoter	 was	 replaced	 by	 the	 eukaryotic	 translation	
elongation	factor	1	alpha	1	(EF1a)	promoter	present	in	another	plasmid	previously	cloned	at	apceth,	
#112	pSERS11_pEF1a_IFN-beta_fw_IRES_pac	 Supplemental	 figure	2),	 using	 the	 restriction	 sites	 SalI	
and	AgeI,	 yielding	 construct	#115	pSERS11_pEF1a_SERPINA1_IRES_pac.	 In	order	 to	 clone	 construct	
#116	 in	which	 the	 SERPINA1	 cDNA	 is	 driven	 by	 the	 CAG	 promoter,	 in	which	 the	 CMV	 enhancer	 is	
followed	by	the	chicken	beta	actin	promoter	and	the	rabbit	beta	globin	splice	acceptor,	a	cassette	of	
the	 configuration	 SalI-pCAG-AgeI	 was	 ordered	 from	 GeneArt	 and	 transferred	 to	 plasmid	 #114	 by	
digesting	both	plasmids	with	SalI	and	AgeI,	 thereby	replacing	the	PGK	promoter	present	 in	plasmid	
#114	with	the	CAG	promoter.	The	same	strategy	was	used	to	generate	the	fourth	construct,	#129,	in	
which	the	short	 intron-less	 form	of	EF1a	(EFS	329)	 is	driving	the	SERPINA1	 cDNA.	The	SalI-pEFS-AgeI	
cassette	 was	 ordered	 from	 GeneArt	 with	 one	 modification	 (A79T)	 compared	 to	 the	 published	
sequence	to	remove	an	AgeI	site	present	 in	pEFS,	and	SalI	and	AgeI	were	used	to	remove	the	PGK	
promoter	 present	 in	 plasmid	 #114	 and	 to	 insert	 the	 EFS	 promoter.	 Before	 maxipreps	 and	 viral	
supernatants	were	generated,	all	four	plasmids	were	sequenced	to	confirm	their	integrity.		
Cloning	of	“2nd	generation”	AAT	constructs	
In	 order	 to	 clone	 plasmids	 #159–164	 listed	 in	 Figure	 6,	 a	 pac	 gene	 expression	 cassette	 of	 the	
following	configuration	was	ordered	 from	GeneArt	 (plasmid	#153	pMA-RQ_pEFS_pPGK_Kozak_pac,	
Figure	4):	
	
Figure	4:	Schematic	representation	of	the	pac	gene	expression	cassette.		
In	a	first	step,	plasmids	#114,	#115,	and	#129	described	above	were	digested	using	SalI	and	PacI,	and	
the	 resulting	 insert	 (promoter_SERPINA1)	 was	 transferred	 to	 the	 optimized	 retroviral	 backbone	
(plasmid	 #139	 pSERS11_Leader_MCS_oPRE,	 Supplemental	 figure	 3)	 that	 had	 been	 linearized	 using	
the	 same	 restriction	 enzymes.	 The	 resulting	 intermediate	 constructs	 were	 #154	
pSERS11_pPGK_SERPINA1,	#155	pSERS11_pEF1a_SERPINA1,	and	#156	pSERS11_pEFS_SERPINA1.	To	
remove	pEFS	and	pPGK	from	GeneArt	cassette	#153,	the	plasmid	was	digested	with	ClaI	and	SnaBI,	
respectively,	 and	 the	 remaining	 plasmid	 was	 re-ligated.	 The	 promoter_pac	 cassettes	 were	 then	
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transferred	 to	 plasmids	 #154,	 #155,	 and	 #156.	 To	 insert	 them	 5’	 of	 the	 SERPINA1	 cassette,	 both	
plasmids	were	digested	with	AfeI	and	SalI,	to	insert	them	3’	of	the	SERPINA1	cassette,	enzymes	PmeI	
and	BamHI	were	used.	To	generate	plasmids	#193	and	#194,	plasmid	#168	(Supplemental	 figure	4)	
previously	cloned	at	apceth	was	utilized.	Plasmid	#168	was	derived	from	the	corrected	and	optimized	
retroviral	backbone	(c.f.	3.1.3)	and	contains	the	following	elements:	pEFS_Luc_P2A_eGFP_IRES_pac.	
Digestion	of	this	plasmid	with	AgeI	and	PacI	results	in	the	generation	of	a	backbone	including	the	EFS	
promoter	 (pSERS11_pEFS_IRES_pac),	digestion	with	SalI	and	PacI	yields	a	backbone	only	containing	
the	IRES	and	the	pac	gene	(pSERS11_IRES_pac).	The	SERPINA1	cassette	was	then	transferred	to	these	
plasmids	by	restriction	enzyme	digest	of	plasmid	#159	with	AgeI	and	PacI	to	generate	plasmid	#194	
pSERS11_pEFS_SERPINA1_IRES_pac,	 and	 with	 SalI	 and	 PacI	 to	 generate	 plasmid	 #193	
pSERS11_pPGK_SERPINA1_pac.		
2.2.1.2. Lentiviral plasmid 
The	 pEFS_SERPINA1_IRES_pac_oPRE	 cassette	 was	 transferred	 from	 plasmid	 #194	 to	 the	 lentiviral	
pCCL	 backbone	 194,330	 by	 In-Fusion	 Cloning	 using	 the	 In-Fusion	 HD	 Cloning	 Kit.	 The	 pCCL	 5’-LTR	
contains	a	cytomegalovirus	(CMV)	promoter	and	the	HIV-1	R	and	U5	regions,	followed	by	the	HIV-1	
packaging	signal	(Y).	The	3’-LTR	comprises	an	HIV-1	U3	region	that	has	a	deletion	and	thus	renders	
the	vector	self-inactivating,	an	HIV-1	R	and	U5	region	as	well	as	a	PolyA	signal.	The	lentiviral	construct	
#172	pCCL-c-EFS-hADA_WPRE	 (Supplemental	 figure	 5)	was	 kindly	 provided	by	Donald	Kohn,	UCLA,	
and	 linearized	using	 the	 restriction	enzymes	KpnI	 and	ClaI.	 The	primer	design,	 PCR,	 recombination	
reaction	(using	100ng	of	purified	PCR	fragment	and	100ng	of	linearized	vector),	and	transformation	
of	 bacteria	 were	 all	 carried	 out	 following	manufacturer’s	 specifications	 (Protocol	 I),	 with	 the	 only	
modification	 that	 50ng	 of	 plasmid	 #194	 template	 were	 used	 in	 the	 PCR	 reaction	 to	 generate	
homology	arms	on	the	insert	instead	of	1ng	as	recommended	(Table	2).	For	primer	sequences	please	
cf.	 2.1.3.	 A	 plasmid	 map	 of	 the	 resulting	 lentiviral	 AAT	 transfer	 plasmid	 #215	
pCCL_pEFS_SERPINA1_IRES_pac	is	depicted	in	Supplemental	figure	18.	
Table	2:	PCR	master	mix	composition	and	cycling	conditions	for	the	In-Fusion	cloning	PCR.		
PCR	In-Fusion	cloning	#215	 	 	 	 Cycling	conditions	 	
Component	 Amount	[µL]	
Final	
concentration	 	 Temperature	 Time	 	
CloneAmp	HiFi	PCR	Premix	(2X)	 12,5	 1X	 	 98°C	 10	sec	 30	
cycles	Primer	1	[10µM]	 0,5	 [200nM]	 	 55°C	 10	sec	
Primer	2	[10µM]	 0,5	 [200nM]	 	 72°C	 20	sec	
Template	(Plasmid	DNA)	 1,0	 50ng	 	 	 	 	
H2O	 10,5	 	 	 	 	 	
Total	volume	 25,0	 	 	 	 	 	
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2.2.2. Molecular cloning 
2.2.2.1. Production of LB medium/circlegrow medium for E.coli 
25g	 of	 high	 salt	 Luria-Bertani	 (LB)	 medium	 powder	 or	 40g	 of	 circlegrow	 medium	 powder,	
respectively,	were	weighed	into	a	1	liter	(L)	bottle,	1L	deionized	water	was	added,	and	the	medium	
was	 autoclaved.	 When	 required,	 medium	 was	 allowed	 to	 cool	 down	 to	 <60°C,	 and	 antibiotics	 –	
Ampicillin	to	a	final	concentration	of	[100µg/mL],	Kanamycin	to	a	final	concentration	of	[50µg/mL]	–	
were	added.		
2.2.2.2. Production of agar plates 
40g	 of	 LB	Agar	 Powder	were	 added	 to	 a	 1L	 shaking	 flask,	 1L	 deionized	water	was	 added,	 and	 the	
mixture	 was	 autoclaved.	 The	 agar	 solution	 was	 allowed	 to	 cool	 down	 to	 <60°C.	 When	 required,	
antibiotics	were	added	to	the	same	final	concentrations	as	mentioned	above,	and	the	agar	solution	
was	poured	into	10cm	Æ	petri	dishes	at	approximately	20	milliliter	(mL)	per	dish.	After	the	agar	had	
hardened,	plates	were	packaged	into	plastic	bags	and	stored	at	4°C.		
2.2.2.3. Cultivation of E.coli 
Generally,	DH5α	and	Stbl3	cells	were	cultured	in	LB	medium	at	37°C	and	225	revolutions	per	minute	
(rpm)	 shaking.	 When	 problems	 cultivating	 E.coli	 in	 LB	 medium	 occurred,	 the	 richer	 circlegrow	
medium	was	used	instead.		
2.2.2.4. Preparation and inoculation of glycerol stocks 
For	the	long-term	storage	of	bacteria,	glycerol	stocks	were	prepared	by	mixing	250µL	of	autoclaved	
glycerol	with	750µL	of	an	overnight	bacterial	culture.	The	mix	was	stored	at	-80°C	until	re-initiation	of	
the	 culture.	 To	 inoculate	 a	 new	 culture	 from	 the	 glycerol	 stock,	 the	 vial	 was	 removed	 from	 the	
freezer	 without	 letting	 it	 thaw.	 Using	 an	 inoculation	 loop,	 a	 small	 amount	 of	 frozen	 bacteria	 was	
streaked	out	onto	an	agar	plate	containing	the	respective	antibiotic.	After	an	overnight	incubation	at	
37°C,	a	single	bacterial	colony	was	picked	to	inoculate	a	small-scale	liquid	culture.		
2.2.2.5. Restriction enzyme digestion 
All	 restriction	 enzymes	 and	 reaction	 buffers	 used	 in	 this	work	were	 purchased	 from	New	 England	
Biolabs.	 Restriction	 enzyme	 digests	 were	 performed	 according	 to	 the	 following	 table	 (Table	 3)	
provided	by	the	manufacturer.	If	<1µg	DNA	was	digested,	volumes	were	down-scaled	accordingly;	if	
>1µg	DNA	was	used	in	the	reaction,	volumes	were	up-scaled.		
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Table	 3:	 Composition	 of	 a	 typical	 restriction	 enzyme	 digestion	 reaction	 (from:	
https://www.neb.com/protocols/2012/12/07/optimizing-restriction-endonuclease-reactions).	
Component	 Amount	
Restriction	Enzyme	 10	units	is	sufficient,	generally	1µL	is	used	
DNA	 1µg	
10X	NEBuffer	 5µL	(1X)	
Total	Reaction	Volume	 50µL	
Incubation	Time	 1	hour	
Incubation	Temperature	 Enzyme-dependent,	generally	37°C	
	
2.2.2.6. Gel electrophoresis 
DNA	samples	were	mixed	with	the	respective	volume	of	6X	loading	dye	before	gel	electrophoresis.	A	
100	 base	 pair	 (bp)	 or	 1	 kilobase	 (kb)	 ladder	 was	 also	 run	 on	 the	 gel	 for	 sizing	 and	 approximate	
quantification	of	the	DNA	bands.	Agarose	gels	were	prepared	by	mixing	agarose	with	1X	TAE	Buffer	in	
a	 shaking	 flask	 and	 bringing	 the	 solution	 to	 a	 boil.	 Percentages	 of	 agarose	 gels	 were	 chosen	
depending	on	the	expected	DNA	fragment	sizes;	generally,	concentrations	ranging	from	0.8%	to	2%	
were	used.	After	a	short	cool-down	of	the	liquid	gel,	ethidium	bromide	or	peqGREEN	were	added	at	
concentrations	 recommended	 by	 the	manufacturers	 for	 visualization	 of	DNA	 in	 the	 gel.	 Gels	were	
cast	and	run	using	the	BIO-RAD	Horizontal	Electrophoresis	Systems	at	voltages	ranging	from	100V	to	
120V	depending	on	the	size	of	the	gel.	Gels	were	imaged	on	a	Biometra	UviproChemi	system.		
2.2.2.7. Gel extraction 
Gel	pieces	of	interest	were	cut	out	of	the	agarose	gel	using	a	scalpel,	and	subsequent	gel	extraction	
was	performed	according	to	manufacturer’s	instructions.		
2.2.2.8. Determination of DNA concentration 
Measurement	 of	 DNA	 concentration	was	 performed	 using	 Implen’s	 NanoPhotometer	 according	 to	
manufacturer’s	instructions	for	use.		
2.2.2.9. Ligation 
For	all	 ligation	reactions	performed,	NEB’s	Quick	Ligation	Kit	was	used	according	to	manufacturer’s	
recommendations	with	the	only	modification	that	a	5-fold	molar	excess	of	insert	was	used	instead	of	
a	3-fold	molar	excess	as	suggested.		
2.2.2.10. Transformation 
Transformation	 of	 DH5α	 as	 well	 as	 Stbl3	 E.coli	 was	 carried	 out	 following	 manufacturer’s	
specifications.	When	bacteria	were	being	transformed	with	ligation	reactions,	the	maximum	volume	
of	ligation	reaction	used	was	1/10	of	the	bacterial	volume.	
2.2.2.11. Miniprep/Midiprep/Maxiprep 
Minipreps,	 midipreps,	 and	 maxipreps	 were	 performed	 according	 to	 manufacturer’s	 instructions.	
Bacterial	 culture	 sizes	used	were	generally	3mL	 for	minipreps,	 40mL	 for	midipreps,	 and	200mL	 for	
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maxipreps.	 For	 the	 inoculation	 of	 midi-	 and	 maxipreps,	 a	 small-scale	 bacterial	 overnight	 culture	
(started	from	a	single	colony	on	the	agar	plate)	was	used	at	a	ratio	of	1:500–1:1000.		
2.2.2.12. Sequencing of plasmids 
All	 transfer	 plasmids	 used	 to	 generate	 viral	 supernatants	were	 fully	 sequenced	 at	Microsynth	 AG,	
using	custom	primers	(listed	in	Table	4).		
Table	4:	Primers	used	for	sequencing	final	viral	expression	plasmids.		
Sequence	 Name	
5'-GTAAAACGACGGCCAG-3'	 M13for	
5'-CAGGAAACAGCTATGAC-3'	 M13rev	
5'-CCGACGGCAGTTGGGATTC-3'	 SeqRANTESPromfor	
5'-AAGCTTTCATATTCTGTAACTTTTGTG-3'	 RANTESPromfor	
5'-GGACAAACCACAACTAGAATGC-3'	 SeqZSG2rev	
5'-GACATTGATTATTGACTAGTTATTAATAGTAATCAATTACG-3'	 pCAGfor	
5'-CCAAGTAGGAAAGTCCCATAAGG-3'	 SeqpCAG2rev	
5'-ACTCATGGTTATGGCAGCACTGC-3'	 Amp_for	
5'-CGAAAGGGAAACCAGAGGAGC-3'	 plentiPACKfor	
5'-GAGCTCGGTACCTTTAAGACCAATGAC-3'	 plenti3´LTRfor	
5'-GGAATGTGTGTCAGTTAGGGT-3'	 pBABErev	
5'-ACCCTAACTGACACACATTCC-3'	 pBABErevneu	
5'-AAAGAGACAGCAACCAGGATTT-3'	 WPRE(Roche)rev	
5'-GATATTCTTAACTATGTTGCTCC-3'	 wPRE_for	
5'-TCATAAAGAGACAGCAACCAGG-3'	 wPRE_Rev	
5'-AAGAACTGACGAGTTCGTATTCC-3'	 gPsi_for	
5'-CAAAAAGTCCGACTCGGGTAGG-3'	 gPsi_rev	
5'-GCCGCTTACCGGATACCTGTCC-3'	 Backb_for1	
5'-CATACCTCGCTCTGCTAATCC-3'	 Backb_rev1	
5'-GATATCAAGCTTAACACGAGCC-3'	 3ÕLTR_for	
5'-ATTTCGTTCATCCATAGTTGCC-3'	 Backb_for2	
5'-CAATAGCGGCTGCTCAGCGG-3'	 Seqpgkfor	
5'-CGGTCACAGCTTGTCTGTAAGC-3'	 bactBB2_for	
5'-GTCGGCCACCCACACTTTGCC-3'	 pac_rev2	
5'-TGTATCCGCTCATGAGACAAT-3'	 SeqblaF	
5'-GAGTAAACTTGGTCTGACAG-3'	 SeqKanR	
5'-ACCGTGAACTTCGGCGACAC-3'	 serpina1_for	
5'-ATCTGCACACTGGTATTTCGG-3'	 EF1alpha_for	
5'-AGAGTTCGAGGCCTTGCG-3'	 EF1alpha_1	
5'-TGAAGGCGAACTCGGCCA-3'	 serpina1_2_rev	
5'-TGGCCGAGTTCGCCTTCA-3'	 serpina1_2_for	
5'-ACCGTGAAGGTGCCCATGAT-3'	 serpina1_3_for	
5'-ACCAGTACCACCACGAACAAG-3'	 IRES_f	
5'-ATCGAGAGAGTGACCGAGCT-3'	 pac_f	
5'-ACGCTCTGTTCCTGTTAATCAA-3'	 PRE_f	
5'-TACAATGACTCCTTTCGGTAAGT-3'	 SERPINA1_5UTR_f	
5'-AACCTGCCCTTCTACGAGC-3'	 pac_f_2	
Material and Methods   
	
32 
5'-GGTGTTCCGCATTCTGCAAGC-3'	 IFNbeta_f	
5'-CATCTTCGCCATCTTCCGGCA-3'	 IFNbeta	
5'-TTAATTGCGTTGCGCTCACTGC-3'	 bactBB3_for	
5'-GTCTTGTCTGCTGCAGCATCG-3'	 EFS_Defensin_f	
5'-CCGTCTTTTGGCAATGTGAGG-3'	 IRES_pac_f	
5'-CCTGGATGGAGTGGGACAGAGAAAT-3'	 pCCL_fw	
5'-AGTGAGGAGGCTTTTTTGGAGGCCT-3'	 pCCL_fw2	
5'-GGAGCTAGAACGATTCGCAGTTA-3'	 pCCL_fw3	
5'-GGTTGTAGCTGTCCCAGTATTTGTC-3'	 pCCL_fw4	
5'-GATGGCCCACTACGTGAAC-3'	 pCCL_rev	
5'-CTTTCGCTTTCTTCCCTTCC-3'	 pCCL_fw5	
	
2.2.3. Production of gamma-retroviral and lentiviral supernatants 
Gamma-retroviral	 supernatants	 were	 generated	 by	 transient	 triple	 transfection	 of	 293T	 human	
embryonic	kidney	cells.	Cells	were	seeded	on	the	day	prior	to	transfection	at	5x106	cells/10cm	Æ	dish	
in	10mL	293T	medium.	On	 the	day	of	 transfection,	medium	was	exchanged	 for	5mL	293T	medium	
containing	25µM	chloroquine,	and	cells	were	cultured	 in	the	presence	of	chloroquine	for	at	 least	1	
hour	before	transfection.	Transfection	was	performed	using	Sigma’s	Calcium	Phosphate	Transfection	
Kit	 according	 to	manufacturer’s	 instructions.	 12.5µg	 pCDNA3-MLV-gagpol	 (Supplemental	 figure	 6),	
2.0µg	pALF-PERV	A_GaLV	envelope	plasmid	(Supplemental	figure	7),	and	7.5µg	of	retroviral	transfer	
plasmid	were	used	for	the	transfection	of	one	10cm	Æ	dish.	Medium	was	replaced	with	6mL	basal	
293T	medium	6	hours	after	addition	of	calcium	phosphate-DNA	precipitates.	Viral	supernatants	were	
collected	2	days	after	transfection	for	the	first	time;	6mL	fresh	293T	medium	was	added	to	cells,	and	
collected	 supernatants	 were	 stored	 at	 4°C	 until	 the	 second	 harvest,	 one	 day	 later.	 Supernatants	
collected	on	both	days	were	pooled,	 filtered	using	a	0.45µM	syringe	 filter	and	cryopreserved	 in	1–
2mL	aliquots	at	-80°C.		
Lentiviral	supernatants	were	produced	as	described	above;	lentiviral	packaging	plasmids	#170	pCMV-
dR8.91	 (10µg,	 Supplemental	 figure	 8)	 expressing	 HIV-1	 gagpol	 and	 #171	 pCAGGS-VSVG	 (2µg,	
Supplemental	 figure	9)	encoding	the	VSV.G	envelope	(both	kindly	provided	by	Donald	Kohn,	UCLA)	
were	used	in	combination	with	10µg	lentiviral	transfer	plasmid	#215	pCCL_pEFS_SERPINA1_IRES_pac	
for	triple	transfection	of	one	10cm	Æ	dish.		
2.2.4. Titration of gamma-retroviral and lentiviral supernatants on HT1080 cells 
In	order	to	determine	viral	titers,	2x104	HT1080	fibrosarcoma	cells	were	seeded	in	a	volume	of	1mL	
HT1080	medium	per	well	of	a	12-well	plate	on	day	1	and	incubated	at	37°C,	5%	CO2	in	a	humidified	
atmosphere	overnight.	To	be	able	to	accurately	determine	cell	numbers	on	the	day	of	transduction,	
three	extra	wells	were	plated	as	counting	controls.	On	day	2,	cells	 in	the	three	counting	wells	were	
enzymatically	 detached	 using	 TrypLE	 Select,	 1mL	 PBS	 was	 added	 to	 each	 well,	 and	 cells	 were	
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transferred	to	a	1.5mL	microcentrifuge	tube	and	pelleted	by	centrifugation	at	500xg	for	5	minutes.	
Supernatants	were	 removed	 carefully,	 and	 cell	 pellets	 were	 resuspended	 in	 50µL	 PBS	 each.	 Exact	
volumes	were	determined	by	using	a	micropipette.	10µL	of	each	cell	suspension	were	counted	using	
a	Neubauer	hemocytometer,	and	cell	numbers	were	recorded.	The	average	of	the	three	counts	was	
used	 to	 calculate	 viral	 titers	 later	 on.	 For	 transduction,	 viral	 supernatants	 were	 diluted	 in	 293T	
medium	over	a	 range	 from	1:2–1:200,	and	at	 least	 three	different	dilutions	were	 test	 in	duplicate;	
medium	on	HT1080	cells	was	discarded	and	replaced	with	800µL	diluted	viral	supernatant.	Two	wells	
were	kept	as	non-transduced	negative	controls,	and	800µL	293T	medium	was	added	to	each	of	those	
wells.	 Cells	were	 incubated	 at	 37°C,	 5%	 CO2	 in	 a	 humidified	 atmosphere	 overnight.	 On	 day	 three,	
diluted	viral	supernatants	and	293T	medium,	respectively,	were	replaced	with	fresh	HT1080	medium.	
Three	 days	 after	 transduction,	 transduction	 efficiency	 was	 analyzed	 by	 an	 intracellular	 flow	
cytometry	assay	detecting	transgenic	human	AAT	protein.	
Titers	in	[transducing	units	(TU)/mL]	were	calculated	as	follows:	
	
Titer	
TU
mL
=
%	AAT	positive	cells ∗ number	of	cells	seeded ∗ dilution
100 ∗ 0.8	 volume	of	viral	supernatant
	
	
2.2.5. Isolation of primary human MSCs from human bone marrow 
Bone	 marrow	 was	 harvested	 from	 healthy	 donors	 after	 informed	 consent	 had	 been	 obtained.	
Routinely,	 tests	 for	 sterility,	white	blood	 cell	 (WBC)	 count,	 assessment	of	 the	morphology	of	bone	
marrow	cells,	and	CFU	assay	were	performed	by	apceth’s	Quality	Control	Department	to	assess	the	
quality	of	the	bone	marrow.		
Cells	were	then	seeded	in	cell	stack	chambers	in	Bio-1	medium	(cf.	Table	5).	A	first	complete	medium	
change	was	conducted	3–5	days	after	seeding,	and	every	3–5	days	thereafter	half	of	the	medium	was	
exchanged	for	fresh	medium.	After	a	culture	period	of	10–14	days,	when	multiple	 large	colonies	of	
adherent,	 spindle-shaped	 cells	were	 visible,	 cells	were	enzymatically	 detached	using	 TrypLE	 select,	
and	cryopreserved	in	either	90%	FBS	+	10%	dimethyl	sulfoxide	(DMSO)	or	apceth’s	cryopreservation	
solution	 consisting	 of	 45%	 of	 hydroxyethyl	 starch	 (HAES)	 injection	 solution	 (10%	 in	 isotonic	 saline	
solution),	45%	human	albumin	 (HA)	 injection	solution	 ([50g/L]	 in	 isotonic	 saline	solution),	and	10%	
DMSO	in	aliquots	of	1x106-5x106	cells	(P0).		
2.2.6. Culture of primary human MSCs 
MSCs	were	generally	cultured	in	Bio-M	or	Bio-1	culture	medium	(cf.	Table	5)	at	37°C	and	5%	CO2	in	a	
humidified	 atmosphere.	 Care	was	 taken	 to	 never	 let	MSCs	 grow	 to	 complete	 confluency	 to	 avoid	
contact	 inhibition	of	growth	and	differentiation	of	the	cells.	 In	order	to	propagate	MSCs,	cells	were	
washed	once	with	PBS	before	enzymatic	detachment	using	TrypLE	select	for	10	minutes	at	37°C.	The	
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reaction	was	stopped	using	Bio-M	culture	medium.	Cells	were	then	either	diluted	in	Bio-M/Bio-1	(if	
volume	 of	 fresh	 medium	 was	 at	 least	 5	 times	 the	 initial	 volume)	 or	 centrifuged	 at	 300xg	 for	 5	
minutes,	 and	 the	 cell	 pellet	 resuspended	 in	 fresh	medium	before	 seeding	 into	 appropriate	 culture	
vessels.		
Table	5:	Culture	and	cryopreservation	media	used	for	MSCs	and	tumor	cell	lines.		
	
Manufacturer	 Final	Concentration	
Bio-M	
	 	DMEM	low	glucose	 Biochrom	 87.5%	
FBS	 Biochrom	 10%	
HEPES	[1M]	 Gibco	 25mM	
	 	 	Bio-1	 apceth's	proprietary	cell	culture	medium	
	 	 	293T	medium	
	 	DMEM	high	glucose	 Biochrom	 90%	
FBS	 Biochrom	 10%	
	 	 	HT1080	medium	
	 	EMEM	 Lonza	 90%	
FBS	 Biochrom	 10%	
	 	 	Cryopreservation	solution	
	 	HAES	10%	 Fresenius	Kabi	 45%	
HA	 Baxter	 45%	
DMSO	 Wak-Chemie	 10%	
	
2.2.7. Culture of tumor cell lines 
Tumor	cell	lines	were	cultured	under	equal	conditions	as	MSCs	in	their	respective	medium	(Table	5)	
and	cryopreserved	in	90%	FBS	+	10%	DMSO.		
2.2.8. Cell counting 
Determination	 of	 cell	 numbers	 was	 performed	 by	 manual	 counting	 using	 a	 Neubauer	
hemocytometer	 in	 all	 experiments	 performed.	 In	 some	 experiments,	 cells	 were	 diluted	 in	 Trypan	
Blue	before	counting	to	analyze	cell	viability.		
2.2.9. Cryopreservation of cells 
MSCs	were	cryopreserved	in	either	90%	FBS	+	10%	DMSO	or	cryopreservation	solution	(Table	5)	at	a	
concentration	of	5x106	cells/mL;	aliquot	sizes	were	ranging	from	1–5x106	cells/vial.	Tumor	cell	 lines	
were	frozen	in	90%	FBS	+	10%	DMSO	at	the	same	concentration	and	aliquot	sizes	as	MSCs.	Cryovials	
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containing	cells	 in	their	respective	cryopreservation	solution	were	immediately	transferred	to	a	Mr.	
Frosty	Freezing	Container	and	stored	at	 -80°C	overnight	before	being	moved	to	the	vapor	phase	of	
liquid	nitrogen	the	next	day.		
2.2.10. Thawing of cells 
Vials	were	 quickly	 removed	 from	 the	 liquid	 nitrogen	 tank	 and	 immediately	 transferred	 to	 a	water	
bath	pre-heated	to	37°C.	When	still	some	small	 ice	clumps	were	visible	in	the	vial,	 it	was	moved	to	
the	 laminar	 air	 flow	 cabinet,	 and	 the	 cell	 solution	was	 pipetted	 into	 the	 respective	 culture	 vessel	
already	containing	culture	medium.		
2.2.11. Transduction of MSCs by centrifugation of viral supernatants onto PLL-coated 
plates 
Wells	 of	 6-	 or	 12-well	 plates	 were	 coated	 with	 Poly-L-Lysin	 (PLL)	 diluted	 1:10	 in	 PBS	 to	 a	 final	
concentration	 of	 [10µg/mL]	 for	 at	 least	 one	 hour.	 PLL	 was	 discarded,	 and	 wells	 were	 carefully	
washed	with	PBS	before	viral	 supernatant	was	added.	The	amount	of	viral	 supernatant	needed	 for	
transduction	was	calculated	based	on	 the	cell	number	 to	be	 transduced,	 the	desired	MOI,	and	 the	
titer	 of	 the	 viral	 supernatant.	 Viral	 supernatant	 was	 added	 to	 the	 PLL-coated	 plates;	 in	 some	
experiments,	the	supernatant	was	diluted	with	293T	medium.	293T	medium	only	was	added	to	two	
wells	 serving	 as	 negative	 control	 wells	 later,	 one	 as	 a	 control	 for	 intracellular	 flow	 cytometry	 to	
analyze	transduction	efficacy,	the	other	one	as	control	for	antibiotic	selection.	Plates	containing	viral	
supernatant	and	293T	medium	were	centrifuged	in	a	pre-cooled	centrifuge	at	2000xg	and	4°C	for	30	
minutes.	During	the	centrifugation,	cells	to	be	transduced	were	enzymatically	detached	and	counted.	
After	completion	of	the	centrifugation	step,	viral	supernatant	and	293T	medium,	respectively,	were	
removed	from	the	wells	carefully,	and	cells	resuspended	in	Bio-M	were	added.	Cells	were	incubated	
overnight,	and	medium	was	exchanged	for	fresh	Bio-M	the	next	day.	
2.2.12. Transduction of MSCs by direct seeding 
Cells	were	enzymatically	detached	using	TrypLE	select,	resuspended	in	PBS,	counted,	spun	down	at	
300xg	 for	 5	 minutes,	 and	 resuspended	 in	 PBS.	 The	 amount	 of	 viral	 supernatant	 needed	 for	
transduction	was	 calculated	 based	 on	 the	 cell	 number,	 the	 desired	MOI,	 and	 the	 titer	 of	 the	 viral	
supernatant.	 In	a	 first	 step,	PLL	 [100µg/mL]	was	added	 to	 the	viral	 supernatant	at	a	 ratio	of	1:100	
yielding	a	final	concentration	of	PLL	of	[1µg/mL].	 In	the	next	step,	the	cells	were	added	to	the	PLL-
viral	supernatant	mixture,	and	the	transduction	mix	was	seeded	into	appropriate	culture	vessels.	One	
small	 extra	 flask	 of	 transduced	 cells	 was	 usually	 plated	 for	 the	 flow	 cytometric	 assessment	 of	
transduction	 efficacy	 before	 antibiotic	 selection,	 so	 that	 the	 transduced	 batch	 did	 not	 have	 to	 be	
disturbed	for	this	analysis.	After	three	hours	of	incubation,	the	same	amount	of	culture	medium	was	
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added	to	the	2X	transduction	mix,	and	the	cells	were	cultured	overnight.	Non-transduced	cells	were	
seeded	into	two	wells	of	a	6-well	plate	to	serve	as	a	negative	control	for	flow	cytometric	analyses	and	
as	a	control	for	the	subsequent	antibiotic	selection.	
2.2.13. Detection of transgenic AAT by intracellular flow cytometry 
Cells	 were	 analyzed	 for	 the	 expression	 of	 transgenic	 intracellular	 (ic)	 AAT	 48–72	 hours	 after	
transduction.	To	enhance	the	detection	of	the	protein,	HT1080	cells	were	treated	with	1µL	and	MSCs	
with	 10µL,	 respectively,	 of	 GolgiPlug	 Protein	 Transport	 Inhibitor	 per	mL	medium	 for	 16–24	 hours	
before	the	staining,	so	that	proteins	were	accumulated	in	the	Golgi	complex	and	not	secreted.	Cells	
were	detached	by	 trypsinization,	 counted,	washed	once	with	1mL	PBS,	 and	up	 to	1x106	 cells	were	
permeabilized	 using	 250µL	 BD	 Cytofix/Cytoperm	 Fixation	 and	 Permeabilization	 Solution	 for	 20	
minutes	 at	 4°C.	 After	 2	washes	with	 1mL	 1X	 Perm/Wash	 Buffer	 and	 centrifugation	 at	 500xg	 for	 5	
minutes	 each,	 the	 cell	 pellet	 was	 resuspended	 in	 100µL	 Perm/Wash	 Buffer	 and	 stained	 with	 a	
polyclonal	 FITC-conjugated	 Anti-alpha	 1	 Antitrypsin	 antibody	 (1µL	 antibody/100µL	 cell	 suspension)	
for	 20–30	 minutes	 at	 4°C	 in	 the	 dark.	 After	 the	 incubation,	 cells	 were	 washed	 with	 1mL	 1X	
Perm/Wash	 Buffer,	 resuspended	 in	 400µL	 PBS,	 and	 analyzed	 on	 a	 Beckman	 Coulter	 FC500	 flow	
cytometer.	Non-transduced	cells	were	treated	as	described	above	and	used	as	negative	controls	for	
gating.	 In	 titration	 experiments,	 only	 values	 <25%	 intracellular	 AAT-positive	 cells	were	 included	 in	
titer	calculations.		
2.2.14. Antibiotic selection 
Antibiotic	selection	of	 transduced	cells	was	started	48–72	hours	after	 transduction.	Puromycin	was	
diluted	 in	 fresh	Bio-M	medium	 to	a	 final	 concentration	of	 [3µg/mL],	 and	medium	on	 the	 cells	was	
replaced	 with	 medium	 containing	 puromycin.	 Medium	 was	 exchanged	 for	 fresh	 puromycin-
containing	 medium	 after	 2–3	 days,	 and	 cells	 were	 selected	 for	 a	 total	 of	 5	 days.	 After	 visual	
inspection	 of	 the	 control	 well	 and	 confirmation	 that	 all	 plated	 non-transduced	 MSCs	 were	 dead,	
medium	was	replaced	with	regular	Bio-M	for	subsequent	expansion	of	the	cells.		
2.2.15. Determination of VCN 
DNA	of	transduced,	puromycin-selected	MSCs	and	non-transduced	control	cells	was	extracted	using	
Qiagen’s	DNeasy	Blood	&	Tissue	Kit	 following	manufacturer’s	 recommendations.	 To	determine	 the	
average	 vector	 copy	 number	 (VCN)	 in	 the	 bulk	 cell	 population,	 two	 singleplex	 quantitative	
polymerase	chain	reactions	(qPCRs)	were	carried	out	for	each	DNA	sample:	One	primer	and	probe	set	
was	detecting	 the	optimized	posttranscriptional	 regulatory	element	 (oPRE)	 sequence,	a	part	of	 the	
viral	 vector	 that	 is	 integrated	 into	 the	 genome	 of	 the	 cell	 after	 transduction,	 a	 second	 set	 was	
recognizing	 factor	 VII	 (FVII),	 a	 human	 single	 copy	 gene,	 that	 was	 utilized	 as	 a	 reference	 gene	 to	
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correct	 for	 variability	 in	DNA	amounts	used	 in	 the	qPCR.	Plasmid	 standard	 curves	 ranging	 from	1–
1x105	copies	were	included	in	the	experiments	to	determine	qPCR	efficiencies	of	the	two	primer	and	
probe	 sets.	 Sequences	 of	 the	 primers	 are	 listed	 in	 2.1.3,	 composition	 of	 master	 mixes	 as	 well	 as	
cycling	conditions	are	mentioned	in	Table	6	and	Table	7.	All	samples	were	measured	in	triplicate	on	a	
LightCycler	480	Instrument	II.	A	calibrator	DNA	extracted	from	an	HT1080	cell	clone	with	one	single	
viral	 integration	 as	 confirmed	 by	 linear	 amplification	 mediated	 (LAM)	 PCR	 was	 included	 in	 each	
experiment.	 After	 completion	 of	 the	 qPCR	 run,	 VCNs	 were	 calculated	 by	 means	 of	 relative	
quantification	and	comparison	of	the	calculated	values	to	that	derived	from	the	calibrator	(set	to	be	
VCN	=	1).		
Table	6:	Composition	of	qPCR	master	mixes	for	oPRE	and	FVII	for	VCN	determination.	
oPRE	 µL	[1	reaction]	 final	conc.	
H2O	 4.10	 	
Primer	275	(oPRE_WPRE_VCN	fw)	[20µM]	 0.30	 [300nM]	
Primer	142	(WPRE	rev)	[20µM]	 0.30	 [300nM]	
Probe	63	(UPL)	[10µM]	 0.30	 [150nM]	
2X	Probes	Master	480	 10.00	 1X	
DNA	[4-60ng/µL]	 5.00	 	
Sum	 20.00	 	
	 	 	
FVII	 µL	[1	reaction]	 final	conc.	
H2O	 4.25	 	
Primer	91	(FVII	for)	[20µM]	 0.30	 [300nM]	
Primer	92	(FVII	rev)	[20µM]	 0.30	 [300nM]	
Probe	187	(FVII	probe)	[20µM]	 0.15	 [150nM]	
2X	Probes	Master	480	 10.00	 1X	
DNA	[4-60ng/µL]	 5.00	 	
Sum	 20.00	 	
Table	7:	Cycling	conditions	for	VCN	qPCR	(oPRE	and	FVII).	
Step	 Temperature	 Duration	 Cycles	
Initial	denaturation	 95°C	 10	minutes	 1	
Denaturation	 95°C	 10	seconds	
45	
Annealing/Elongation	 60°C	 30	seconds	
Cooling	 40°C	 30	seconds	 1	
	
2.2.16. AAT ELISA 
Transduced,	puromycin-selected	MSCs	were	seeded	at	a	concentration	of	1x104	cells	and	250µL	Bio-
M/cm2	 in	wells	of	6-,	12-	or	24-well	plates.	After	cells	had	adhered	 (approximately	4–6	hours	after	
seeding),	medium	was	replaced	with	fresh	Bio-M.	Cells	were	then	incubated	for	48	hours	at	37°C	and	
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5%	CO2	in	a	humidified	atmosphere.	After	incubation,	supernatants	were	cryopreserved	in	aliquots	at	
-80°C	 until	 further	 use.	 On	 the	 day	 of	 the	 experiment,	 supernatants	 were	 thawed	 on	 ice	 and	
centrifuged	at	3000xg	for	10	minutes	to	remove	cell	debris.	The	AAT	ELISA	was	performed	according	
to	manufacturer’s	instructions;	sample	pre-dilutions	were	usually	1:200	in	Diluent	N.	
2.2.17. Neutrophil elastase inhibitor screening assay 
2.2.17.1. Production of cell culture supernatants for neutrophil elastase inhibitor screening 
assay 
Transduced	and	puromycin-selected	MSCs	were	seeded	at	a	concentration	of	1x104	cells	and	250µL	
Bio-M/cm2	in	an	appropriate	culture	vessel.	After	cells	had	grown	to	90–100%	confluency,	cells	were	
washed	5	times	with	PBS	to	remove	any	residual	bovine	AAT	present	 in	FBS	that	would	have	been	
picked	 up	 by	 the	 assay.	 Cells	 were	 cultured	 in	 Dulbecco's	 Modified	 Eagle's	 Medium	 (DMEM)	
supplemented	with	1X	GlutaMAX	and	1mM	Sodium	Pyruvate	for	16–24	hours	at	37°C	and	5%	CO2	in	
a	 humidified	 atmosphere.	 After	 incubation,	 supernatants	 were	 cryopreserved	 in	 aliquots	 at	 -80°C	
until	 further	 use.	 In	 some	 experiments,	 supernatants	 were	 concentrated	 using	 Amicon	 Ultra	 4mL	
Centrifugal	Filters	before	cryopreservation.		
2.2.17.2. Neutrophil elastase inhibitor screening assay 
The	 neutrophil	 elastase	 inhibitor	 screening	 assay	 was	 performed	 according	 to	 manufacturer’s	
instructions	with	minor	modifications,	 i.e.	 instead	of	 the	positive	control	 included	 in	the	kit	 (SPCK),	
active	natural	AAT	 full	 length	protein	purified	 from	human	plasma	 in	 four	different	 concentrations	
ranging	from	[250–2000ng/µL]	was	used	as	a	more	commensurable	positive	control.		
In	brief,	neutrophil	elastase	(NE)	assay	buffer	and	substrate	included	in	the	kit	were	thawed;	aliquots	
were	 prepared	 and	 stored	 at	 -20°C.	 Neutrophil	 elastase	 was	 reconstituted	 in	 220µL	 of	 NE	 assay	
buffer;	aliquots	were	prepared	and	stored	at	-80°C.	Active	AAT	full	length	protein	was	reconstituted	
in	 ddH2O	 to	 yield	 a	 concentration	 of	 [1µg/µL];	 aliquots	 were	 prepared	 and	 stored	 at	 -80°C	 until	
further	use.	On	the	day	of	the	assay,	MSC	supernatants	were	thawed,	and	dilutions	were	prepared	in	
DMEM	 supplemented	 with	 1X	 GlutaMAX	 and	 1mM	 Sodium	 Pyruvate.	 Active	 full	 length	 AAT	 was	
thawed	and	diluted	in	DMEM	supplemented	with	1X	GlutaMAX	and	1mM	Sodium	Pyruvate	to	yield	
concentrations	of	[2000ng/mL],	[1000ng/mL],	[500ng/mL],	and	[250ng/mL].	Undiluted,	concentrated	
supernatant	 from	 non-transduced	 MSCs	 was	 included	 as	 a	 negative	 control.	 The	 substrate	 was	
diluted	 1:12.5	 in	 NE	 assay	 buffer	 and	 kept	 at	 room	 temperature	 in	 the	 dark	 until	 further	 use.	
Immediately	before	starting	the	assay,	neutrophil	elastase	was	diluted	1:25	 in	NE	assay	buffer,	and	
50µL	 diluted	 elastase	 working	 solution	 were	 added	 per	 well	 of	 a	 96-well	 flat	 clear	 bottom	 black	
polystyrene	 plate.	 25µL	 of	 positive	 and	 negative	 control	 samples	 and	MSC	 supernatant	 dilutions,	
respectively,	were	added	and	mixed	by	pipetting	up	and	down	carefully.	All	samples	were	measured	
in	duplicate.	After	an	incubation	of	5	minutes	at	37°C,	25µL	diluted	substrate	working	solution	were	
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added	to	each	well,	and	the	fluorescence	output	R1	(Ex/Em	=	400/505nm)	was	measured	on	a	TECAN	
plate	 reader	 immediately.	 The	 plate	 was	 then	 incubated	 for	 20	 minutes	 at	 37°C,	 and	 after	 that	
measured	 again	 at	 Ex/Em	 =	 400/505nm	 (R2).	 The	 relative	 fluorescence	 units	 (RFU)	 generated	 by	
hydrolyzation	of	the	substrate	was	calculated	as	ΔRFU	=	R2	–	R1.	The	ΔRFU	of	the	negative	control	
(DMEM)	was	set	as	 the	100%	relative	activity	value,	and	the	relative	remaining	neutrophil	elastase	
activity	after	treatment	with	potential	inhibitors	was	calculated	as	follows:		
	
RFU	test	inhibitor	(𝑒. 𝑔. AAT − MSC	supernatant)
RFU	DMEM
∗ 100	
	
2.2.18. Generation of large MSC batches for in vitro and in vivo experiments 
2.2.18.1. Process description 
P0-MSCs	 were	 generally	 thawed	 on	 a	 Friday,	 and	 the	 cells	 were	 cultured	 in	 750mL	 Bio-1	 in	 a	
CellSTACK	cell	culture	system	with	5	chambers.	Cells	were	transduced	as	described	in	“Transduction	
of	 primary	 human	 MSCs	 by	 direct	 seeding”	 on	 the	 following	 Tuesday.	 Transduction	 efficacy	 was	
analyzed	by	 intracellular	flow	cytometry	for	AAT	protein	72	hours	after	transduction	using	the	cells	
plated	 in	 the	 extra	 flask	 on	 the	 day	 of	 transduction.	 On	 the	 same	 day,	 puromycin	 selection	 was	
started.	Depending	on	the	confluency	rate,	cells	were	expanded	either	already	also	on	Friday	or	on	
the	following	Monday.	For	propagation,	cells	were	enzymatically	detached,	spun	down	at	300xg	for	5	
minutes,	and	distributed	 in	3–6	CellSTACK	cell	culture	systems	with	5	chambers	 in	Bio-1	containing	
puromycin	each.	Cells	received	fresh	Bio-1	containing	puromycin	again	on	Monday.	When	the	cells	in	
the	 selection	 control	 well	 (non-transduced	 MSCs)	 were	 completely	 dead	 (usually	 after	 5	 days	 of	
selection),	 medium	 was	 exchanged	 for	 basal	 Bio-1.	 Cells	 were	 cultured	 to	 confluency,	 when	 they	
were	harvested,	checked	for	complete	antibiotic	selection	by	intracellular	staining	for	AAT	and	flow	
cytometric	analysis	and	cryopreserved	in	aliquots	ranging	from	1x106–5x106	cells	in	cryopreservation	
medium.		
To	generate	large	batches	of	non-transduced	MSCs,	cells	from	the	same	thawing	process	were	used,	
and	the	same	culture	and	splitting	scheme	as	described	above	was	followed:	On	Tuesday,	2.5x106–
1x107	cells	were	seeded	in	a	CellSTACK	culture	system	with	5	chambers	in	Bio-1,	on	Friday	or	Monday	
MSCs	were	expanded	onto	3–6	CellSTACK	systems	and	cryopreserved	after	growing	to	confluency	in	
cryopreservation	solution.		
2.2.18.2. Quality control assays for batches 
To	assess	if	MSCs	fulfilled	apceth’s	quality	standards,	one	vial	of	cryopreserved	MSCs	of	each	batch	
was	 thawed,	 and	 a	 panel	 of	 standard	 quality	 control	 assays	 was	 performed.	 Standard	 assays	 and	
required	specifications	are	listed	in	Table	8.	In	addition	to	these	tests	which	were	carried	out	for	all	
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batches	 produced,	 genetically	modified	 batches	were	 additionally	 analyzed	 for	 percentage	 of	 AAT	
positive	MSCs	pre-	and	post-selection,	VCN,	amount	of	AAT	protein	expressed	per	1x105	cells	 in	48	
hours	 normalized	 to	 VCN,	 capability	 of	 the	 cells	 to	 inhibit	 neutrophil	 elastase	 in	 comparison	 to	
natural	AAT	purified	from	human	plasma,	and	the	presence	of	replication-competent	retrovirus	(RCR)	
and	lentivirus	(RCL).		
Table	8:	Standard	quality	control	assays	performed	for	each	batch	of	MSCs	produced.		
Parameter	 Result	
Sterility	 No	growth	of	bacteria	and	fungi	
Surface	marker	expression	 All	surface	makers	within	specification	
Adipogenic	differentiation	 Several	adipocytes	visible	
Osteogenic	differentiation	 Osteogenic	mineralization	visible		
Testing	for	Mollicutes	 Negative	
Sterility	
MSCs	were	cultured	for	at	 least	48	hours	after	thawing,	and	10mL	of	cell	supernatant	was	 injected	
into	BacT/ALERT	Culture	Media	Standard	Aerobic	and	Standard	Anaerobic	bottles,	respectively,	and	
sent	to	synlab	for	analysis.	
MSC	surface	marker	flow	cytometry	
MSCs	were	enzymatically	detached,	counted,	washed	once	with	1mL	PBS,	and	resuspended	in	PBS	so	
that	 5x104–2x105	 cells	 were	 added	 to	 each	 of	 five	 microcentrifuge	 tubes	 in	 a	 volume	 of	 100µL.	
Fluorescently	labeled	antibodies	were	added	to	the	tubes	according	to	the	scheme	depicted	in	Table	
9,	the	tubes	were	vortexed	and	incubated	for	20	±	5	minutes	at	room	temperature	in	the	dark.	After	
the	incubation,	cells	were	washed	with	1mL	PBS,	and	the	pellets	were	resuspended	in	100µL	of	a	1:5	
dilution	of	7-AAD	Viability	Dye	in	PBS	each.	After	a	10-minute	incubation	step	at	room	temperature	
in	 the	dark,	200–400µL	of	PBS	were	added	to	each	sample,	and	cells	were	analyzed	on	a	Beckman	
Coulter	FC500	flow	cytometer.		
Table	9	Antibody	mixes	for	immunofluorescent	staining	of	MSC	surface	markers.	
Tube	1	 Amount	[µL]	 Tube	2	
Amount	
[µL]	 Tube	3	
Amount	
[µL]	 Tube	4	
Amount	
[µL]	 Tube	5	
Amount	
[µL]	
IgG1-
FITC	 20	
CD90-
FITC	 20	
CD235a-
FITC	 20	
CD3-
FITC	 20	
CD41-
FITC	 20	
IgG1-
PE	 20	
CD73-
PE	 20	 CD105-PE	 20	
CD14-
PE	 20	 CD105-PE	 20	
IgG2a-
PE	 20	
CD45-
ECD	 10	 CD45-ECD	 10	
CD45-
ECD	 10	
HLA-DR-
ECD	 10	
IgG3-
PE	 10	
CD34-
PC7	 10	 CD34-PC7	 10	
CD19-
PC7	 10	 CD61-PC7	 10	
IgG1-
ECD	 10	 	 	 	 	 	 	 	 	
IgG1-
PC7	 10	 	 	 	 	 	 	 	 	
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Adipogenic	and	osteogenic	differentiation	
Plating	and	differentiation	of	MSCs	
3x104	 MSCs	 were	 seeded	 per	 well	 in	 5	 wells	 each	 of	 two	 24-well	 plates	 (one	 for	 adipogenic	
differentiation,	one	for	osteogenic	differentiation)	in	1mL	Bio-M	or	Bio-1	and	cultured	until	complete	
confluency	 (1–3	 days).	 Bio-M/Bio-1	 was	 then	 replaced	 by	 1mL	 of	 StemMACS	 AdipoDiff	Media	 for	
adipogenic	 differentiation	 and	 1mL	 of	 StemMACS	 OsteoDiff	 Media	 for	 osteogenic	 differentiation,	
respectively,	on	three	wells	per	respective	plate.	Two	wells	served	as	control	wells	and	received	fresh	
Bio-M/Bio-1.	Fresh	differentiation	media	and	Bio-M/Bio-1,	respectively,	were	added	every	3–5	days	
for	a	minimum	of	 two	weeks.	Cells	were	 then	stained	with	Oil	Red	O	 to	assess	differentiation	 into	
adipocytes,	and	with	Alizarin	Red	to	confirm	osteogenic	mineralization.	
Oil	Red	O	Staining	(adipogenic	differentiation)	
All	 fixation	 and	 staining	 steps	 were	 performed	 at	 room	 temperature.	 Oil	 Red	 O	 staining	 working	
solution	 was	 prepared	 by	 mixing	 6mL	 filtered	 Oil	 Red	 O	 staining	 stock	 solution	 [3mg/mL	 in	 2-
Propanol]	with	4mL	de-ionized	water.	 The	 solution	was	 incubated	 for	10	minutes	after	mixing	and	
then	 filtered.	Cells	on	 the	24-well	plate	 for	adipogenic	differentiation	were	washed	 twice	with	PBS	
and	 fixed	with	 2mL	 10%	 Formalin	 for	 30–45	minutes.	 In	 a	 second	 step,	 the	 Formalin	 solution	was	
removed;	cells	were	washed	twice	with	2mL	tap	water,	and	fixed	again	with	1mL	60%	2-Propanol	for	
3–5	minutes.	After	discarding	the	60%	2-Propanol,	1mL	Oil	Red	staining	working	solution	was	added	
to	 each	 well,	 and	 cells	 were	 incubated	 for	 5–10	 minutes.	 After	 2	 washes	 with	 PBS,	 1mL	 filtered	
Mayer’s	Hematoxylin	staining	solution	was	added	and	kept	on	the	cells	 for	1–5	minutes.	After	 two	
washes	with	2mL	tap	water	each,	1mL	PBS	was	added	to	each	well,	and	photos	were	taken	using	a	
Leica	DMI6000B	microscope	and	LAS	X	software.	
Alizarin	Red	Staining	(osteogenic	differentiation)	
All	 fixation	and	staining	steps	were	performed	at	 room	temperature.	Cells	on	 the	24-well	plate	 for	
osteogenic	differentiation	were	washed	twice	with	PBS	and	fixed	with	2mL	10%	Formalin	for	30–45	
minutes.	After	discarding	the	Formalin	solution,	cells	were	washed	twice	with	2mL	de-ionized	water,	
and	1mL	filtered	Alizarin	Red	staining	solution	[20mg/mL	in	de-ionized	water]	was	added	and	kept	on	
the	 cells	 for	 30–45	minutes.	After	 incubation,	 the	Alizarin	Red	 staining	 solution	was	 removed,	 and	
cells	were	washed	4	times	with	1mL	de-ionized	water.	1mL	PBS	was	added	to	each	well,	and	photos	
were	taken	using	a	Leica	DMI6000B	microscope	and	LAS	X	software.	
Testing	for	Mollicutes	
Detection	 of	 possible	 Mollicutes	 (Mycoplasma,	 Acholeplasma,	 Spiroplasma)	 contamination	 in	 cell	
cultures	was	performed	using	the	Microsart	RESEARCH	Mycoplasma	Detection	Kit	for	qPCR	following	
manufacturer’s	 recommendations	using	DNA	extracted	 from	MSCs	 (isolated	using	Qiagen’s	DNeasy	
Blood	&	Tissue	Kit	according	to	manufacturer’s	instructions)	as	template.	
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Testing	for	RCR/RCL	
MSC-DNA	 was	 extracted	 using	 Qiagen’s	 DNeasy	 Blood	 &	 Tissue	 Kit	 following	 manufacturer’s	
recommendations.	To	test	for	RCR/RCL,	qPCR	assays	detecting	the	gag	sequence	of	MLV	and	HIV-1,	
respectively,	using	50-400ng	of	template	DNA	were	performed.	Sequences	of	the	primers	are	listed	
in	2.1.3;	compositions	of	master	mixes	as	well	as	cycling	conditions	are	mentioned	 in	Table	10	and	
Table	11.	All	 samples	were	measured	 in	 triplicate	on	a	LightCycler	480	 Instrument	 II.	Commercially	
available	 human	 genomic	 DNA	 and	DNA	 extracted	 from	HT1080	 cells	 served	 as	 negative	 controls,	
pCDNA3-MLV-gagpol	 and	 pCMV-dR8.91	 plasmid	 DNA	 [5	 copies/µL],	 respectively,	 was	 used	 as	 a	
positive	 control.	 After	 completion	 of	 the	 qPCR	 run,	 crossing	 point	 (Cp)	 values	 were	 calculated	 by	
means	of	absolute	quantification.	Samples	yielding	Cp	values	<39	were	considered	negative.		
Table	10:	Master	mix	compositions	for	MLV	gag	and	HIV-1	gag	qPCRs	for	detection	of	RCR/RCL.	
RCR	 µL	[1	reaction]	 final	conc.	
H2O	 3.90	 	
Primer	214	gag_eu_for	[20µM]	 0.60	 [600nM]	
Primer	215	gag_eu_rev	[20µM]	 0.30	 [300nM]	
Probe	216	gag_eu_probe	[20µM]	 0.20	 [200nM]	
2X	Probes	Master	480	 10.00	 	
DNA	[10-80ng/µL]	 5.00	 	
Sum	 20.00	 	
	 	 	
RCL	 µL	[1	reaction]	 final	conc.	
H2O	 3.90	 	
Primer	376	HIV-1	gag	F	[20µM]	 0.60	 [600nM]	
Primer	377	HIV-1	gag	R	[20µM]	 0.30	 [300nM]	
Probe	375	HIV-1	gag	P	[20µM]	 0.20	 [200nM]	
2X	Probes	Master	480	 10.00	 	
DNA	[10-80ng/µL]	 5.00	 	
Sum	 20.00	 	
Table	11:	Cycling	conditions	for	MLV	gag	and	HIV-1	gag	qPCRs.	
Step	 Temperature	 Duration	 Cycles	
Initial	denaturation	 95°C	 10	minutes	 1	
Denaturation	 95°C	 10	seconds	
45	
Annealing/Elongation	 60°C	 30	seconds	
Cooling	 40°C	 30	seconds	 1	
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2.2.19. In vivo experiments 
The	mouse	experiments	were	performed	in	collaboration	with	Dr.	Yildirim	from	the	Comprehensive	
Pneumology	Center	at	the	Helmholtz	Zentrum	München.		
2.2.19.1. Preparation of cells 
For	each	of	the	two	cell	applications,	three	vials	[5x106	cells/vial]	each	of	a	quality-controlled	native	
MSC	 batch	 and	 a	 quality-controlled	 batch	 of	MSCs	 transduced	with	 gamma-retroviral	 supernatant	
#194,	 respectively,	were	 thawed	and	cultured	 in	one	CellSTACK	culture	system	with	5	chambers	 in	
750mL	 Bio-M	 each	 for	 48	 hours.	 Cells	 were	 enzymatically	 detached	 using	 TrypLE,	 counted,	
resuspended	 in	 PBS	 to	 yield	 a	 concentration	 of	 5x106	 cells/mL,	 and	 transferred	 to	 the	 Helmholtz	
Zentrum	on	ice	for	immediate	intratracheal	injection.	
2.2.19.2. Elastase-induced emphysema mouse model 
Female	 C57BL/6N	 mice	 aged	 8–10	 weeks	 were	 housed	 under	 specific	 pathogen	 free	 conditions,	
exposed	to	a	12-hour	light	cycle	with	access	to	food	and	water	ad	libitum,	in	rooms	maintained	at	a	
constant	temperature	and	humidity.	Mice	were	divided	into	4	groups	consisting	of	6	mice	per	group	
(Table	 12).	 Mice	 in	 groups	 2–4	 were	 oropharyngeally	 exposed	 to	 a	 single	 application	 of	 40	
units/kilogram	(kg)	body	weight	porcine	pancreatic	elastase	 in	80μL	volume	on	day	0.	Control	mice	
were	 treated	 with	 80μL	 of	 PBS.	 On	 day	 7,	 mice	 in	 groups	 3	 and	 4	 were	 treated	 with	 one	
oropharyngeal	application	of	5x105	native	MSCs	or	5x105	MSCs	transduced	with	a	gamma-retroviral	
vector	 to	express	AAT.	Mice	 in	 control	 groups	1	and	2	 received	 saline	 instead	of	 the	 cells.	Mice	 in	
groups	3	 and	4	were	 additionally	 treated	with	 a	 second	oropharyngeal	 application	of	 5x105	native	
MSCs	or	5x105	AAT-MSCs	on	day	14	after	elastase	treatment.	All	mice	were	analyzed	on	day	21.		
Table	12:	Mouse	groups	and	respective	treatments.		
Group	 Treatment	1	 Treatment	2	 Cell	dose/	mouse	
Application	volume	
cells/mouse	[µL]	
Administration		
route	
Animals/	
group	
1	 PBS	 Saline	 N.a.	 100	 Oropharyngeal	 6	
2	 Elastase	 Saline	 N.a.	 100	 Oropharyngeal	 6	
3	 Elastase	 MSCs	 5x105	(2x)	 100	 Oropharyngeal	 6	
4	 Elastase	 AAT-MSCs	 5x105	(2x)	 100	 Oropharyngeal	 6	
	
2.2.19.3. Pulmonary function measurements 
Mice	 were	 anesthetized	 with	 an	 intraperitoneal	 injection	 of	 130	 mg/kg	 ketamine	 and	 8.5	 mg/kg	
xylazine	to	maintain	spontaneous	breathing	under	anesthesia.	Tracheostomy	was	performed	with	a	
standard	catheter.	After	intubation,	mice	were	placed	in	a	body	plethysmograph	and	connected	to	a	
computer-controlled	ventilator	 (forced	pulmonary	maneuver	system,	Buxco	research	systems).	This	
laboratory	 set-up	 semi-automatically	 provides	 three	 different	 maneuvers:	 Boyle’s	 Law	 functional	
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residual	capacity,	quasistatic	pressure	volume	and	fast	flow	volume	maneuver.		
A	 breathing	 frequency	 of	 150	 breaths/minute	was	 imposed	 by	 pressure	 control	 ventilation	 until	 a	
regular	 breathing	 pattern	 and	 complete	 expiration	 at	 each	 breathing	 cycle	 were	 obtained.	 To	
measure	functional	residual	capacity	(FRC),	ventilation	was	stopped	at	the	end	of	expiration	with	an	
immediate	 closure	 of	 a	 valve	 located	proximally	 to	 the	 endotracheal	 tube.	 Spontaneous	 breathing	
maneuvers	 against	 a	 closed	 valve	 with	 consequent	 pressure	 changes	 were	 then	 recorded.	 To	
measure	inspiratory	capacity	(IC)	and	vital	capacity	(VC),	the	quasistatic	pressure	volume	maneuver	
was	 performed,	 which	 inflates	 the	 lungs	 to	 a	 standard	 pressure	 of	 +30cm	 H2O	 and	 then	 slowly	
exhales	 until	 a	 negative	 pressure	 of	 -30cm	 H2O	 is	 reached.	With	 the	 fast	 flow	 volume	maneuver,	
lungs	were	 first	 inflated	 to	+30cm	H2O	and	 immediately	afterwards	connected	to	a	highly	negative	
pressure	 in	 order	 to	 enforce	 expiration.	 Forced	 vital	 capacity	 (FVC),	 forced	 expiratory	 volume	 at	
100ms	 (FEV100ms),	 and	 peak	 expiratory	 flow	 (PEF)	 were	 recorded	 during	 this	 maneuver.	 In	 every	
animal,	each	maneuver	was	repeated	until	three	acceptable	measurements	were	recorded,	of	which	
the	average	was	then	calculated.	
2.2.19.4. BALF and serum 
Bronchoalveolar	 lavage	 fluid	 (BALF)	 was	 obtained	 for	 total	 and	 differential	 cell	 counts	 to	 assess	
inflammatory	 cell	 recruitment	 of	macrophages,	 neutrophils	 and	 lymphocytes	 to	 the	 lungs.	 Lavage	
was	performed	using	3×500μL	of	PBS.	Cells	were	pelleted	at	400xg,	the	supernatant	stored	at	–80°C,	
and	the	cells	were	resuspended	 in	RPMI-1640	medium	for	total	cell	count	using	a	hemocytometer.	
Cytospins	of	 the	 cell	 suspension	were	prepared	and	 stained	using	May–Grünwald–Giemsa	 staining	
mixes	 for	 differential	 cell	 counting	 (200	 cells/sample)	 using	 morphological	 criteria.	 Serum	 was	
collected	 for	chemokine	and	cytokine	analysis.	Mice	were	bled	 from	the	 femoral	artery;	blood	was	
left	 to	 clot	 for	 several	 hours	 and	 then	 centrifuged	 at	 1300xg	 for	 15	minutes.	 Serum	was	 stored	 in	
aliquots	at	-80°C.		
2.2.19.5. Lung processing 
The	left	lung	was	fixed	under	a	constant	pressure	of	20cm	fluid	column	by	intratracheal	instillation	of	
6%	paraformaldehyde	and	embedded	into	paraffin	for	hematoxylin	and	eosin	(H&E)	staining	analysis	
using	systematic	uniform	random	sampling	according	to	standard	methods	as	described	by	Yildirim	
and	colleagues	331.		
2.2.19.6. Histology 
Emphysema	scoring	
To	 quantify	 emphysema	 development,	 an	 emphysema	 state	 was	 ascribed	 to	 each	 H&E-stained	
sample	 in	 a	 blinded	 fashion	 by	 a	 pathologist.	 The	 score	 of	 elastase	 induced-emphysema	 was	
determined	 as	 follows:	 0	 –	 normal;	 1	 –	 up	 to	 10%	 loss	 of	 septal	 tissue;	 2	 –	 11-20%	 loss	 of	 septal	
tissue;	3	–	21-40%	loss	of	septal	tissue;	4	–	41-60%	loss	of	septal	tissue;	5	–	>60%	loss	of	septal	tissue.	
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The	slides	were	randomly	examined	in	more	than	10	fields	of	view	in	a	blinded	fashion.	
Inflammation	scoring	
To	quantify	the	inflammatory	state,	an	inflammatory	score	was	assigned	to	each	H&E-stained	sample	
in	a	blinded	fashion	by	a	pathologist.	The	score	of	peribronchiolar	and	perivascular	inflammation	was	
determined	as	follows:	0	–	normal;	1	–	few	cells;	2	–	a	ring	of	inflammatory	cells	one	to	two	cell	layer-
deep;	 3	 –	 a	 ring	 of	 inflammatory	 cells	 three	 or	 more	 than	 three	 cell	 layer-deep.	 The	 slides	 were	
randomly	examined	in	more	than	10	fields	of	view	in	a	blinded	fashion.	
2.2.20. Statistical analyses 
Data	 is	 depicted	 as	 mean	 ±	 standard	 deviation	 (SD).	 Statistical	 analyses	 were	 performed	 using	
GraphPad	 Prism	 Version	 7.0.	 Tests	 for	 statistical	 significance	 are	 indicated	 in	 the	 text.	 Statistical	
significance	levels	are	expressed	as	*	P	<	0.05,	**	P	<	0.01,	***	P	<	0.001,	****	P	<	0.0001.	
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3. Results 
3.1. Design and cloning of gamma-retroviral AAT expression constructs 
3.1.1. Design of the SERPINA1 expression cassette 
For	the	design	of	the	AAT	expression	cassette,	the	human	SERPINA1	cDNA	transcript	variant	1	(NCBI	
Reference	Sequence:	NM_000295.4)	was	chosen	from	the	11	transcript	variants	of	SERPINA1	 listed	
on	NCBI’s	Nucleotide.	This	transcript	variant	encodes	for	the	same	protein	as	the	other	10	variants	of	
the	gene;	all	10	additional	variants	differ	solely	in	the	5’	UTR	as	compared	to	transcript	variant	1.	The	
coding	 sequence	 (CDS)	 comprises	 bases	 262	 to	 1518	 of	 the	 full	 reference	 sequence	 published	 at	
http://www.ncbi.nlm.nih.gov/nuccore/NM_000295.4.	 Bases	 1	 to	 261	 were	 included	 in	 the	
expression	cassette	 to	preserve	 the	physiological	SERPINA1	 transcript	variant	1	5’	UTR.	The	3’	UTR	
was	 not	 included	 due	 to	 size	 restrictions	 of	 the	 viral	 backbone.	 To	 increase	 protein	 expression,	 a	
Kozak	consensus	sequence	327	was	inserted	5’	of	the	SERPINA1	start	codon,	and	the	cDNA	was	codon-
optimized	for	Homo	sapiens.	For	a	graphical	representation,	please	cf.	Figure	3.	
3.1.2. Cloning of four “1st generation” gamma-retroviral expression plasmids 
Plasmid	 numbers	mentioned	 throughout	 this	work	 represent	 apceth’s	 internal	 plasmid	 numbering	
and	will	be	used	below	for	the	sake	of	simplicity.		
As	the	influence	of	different	promoters	on	the	expression	of	transgenic	AAT	from	primary	MSCs	was	
one	 variable	 to	 be	 tested	 in	 this	work,	 the	 first	 four	 constructs	 cloned	made	use	 of	 four	 different	
promoters	(pPGK,	pEF1a,	pCAG,	and	pEFS)	to	drive	the	SERPINA1	expression	cassette,	followed	by	an	
IRES	sequence	and	the	pac	gene	in	the	pSERS11	backbone	328.	The	plasmids	were	cloned	as	described	
in	2.2.1.	Briefly,	an	IFN-beta	expression	cassette	present	in	a	plasmid	previously	cloned	at	apceth	for	
a	 different	 project	 was	 replaced	 with	 the	 SERPINA1	 expression	 cassette,	 yielding	 plasmid	 #114	
pPGK_SERPINA1_IRES_pac;	as	a	next	step,	the	PGK	promoter	present	in	plasmid	#114	was	exchanged	
for	 promoters	 EF1a,	 CAG,	 or	 EFS,	 resulting	 in	 plasmids	 #115,	 #116,	 and	 #129.	 Figure	 5	 shows	 a	
schematic	representation	of	the	4	gamma-retroviral	plasmids.		
After	 transduction	 of	 primary	 human	MSCs	 with	 the	 four	 viral	 supernatants	 generated	 using	 the	
plasmids	described	above,	it	was	possible	to	confirm	transgenic	AAT	expression	by	intracellular	flow	
cytometry,	but	selection	of	the	cells	with	puromycin	in	concentrations	ranging	from	[0.5–3.0µg/mL]	
lead	to	a	complete	kill	of	the	cells	(data	not	shown).	These	experiments	indicated	that	the	pac	gene	
was	 not	 expressed	 in	 sufficient	 amounts.	 After	 a	 thorough	 investigation	 and	 the	 performance	 of	
multiple	 experiments,	 it	 was	 discovered	 that	 this	 phenomenon	 was	 due	 to	 a	 non-functional	 IRES	
sequence	used	to	design	and	clone	the	original	retroviral	plasmid	containing	the	IFN-beta	expression	
cassette.	 Consequently,	 the	 retroviral	 backbone	 was	 corrected	 using	 a	 published	 IRES	 sequence	
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derived	 from	 the	 encephalomyocarditis	 virus	 (EMCV)	 332,333,	 and	 the	 integrity	 of	 the	 complete	
backbone	checked	by	sequencing.	Additional	modifications	to	improve	the	backbone	were	included,	
such	as	exchanging	 the	wPRE	 sequence	 for	an	optimized	version,	 the	oPRE	 sequence	described	by	
Schambach	 and	 colleagues	 334.	 This	 optimized	 backbone	 was	 subsequently	 used	 to	 clone	 all	 “2nd	
generation”	constructs.		
	
	
Figure	5:	Schematic	representation	of	the	“1st	generation”	plasmids.	Four	different	promoters	were	
used	to	drive	the	expression	of	SERPINA1	and	pac	(pPGK,	pEF1a,	pCAG,	and	pEFS),	which	were	linked	
by	an	IRES	sequence.	A	wPRE	sequence	was	cloned	3’	of	the	pac	gene	to	increase	mRNA	stability	and	
protein	yield.	Y:	Packaging	Signal;	SD:	Splice	Donor.		
3.1.3. Cloning of eight “2nd generation” gamma-retroviral expression plasmids 
Titration	 and	 preliminary	 transduction	 experiments	 were	 performed	 in	 order	 to	 compare	 the	
different	 constructs	 using	 the	 four	 “1st	 generation”	 gamma-retroviral	 supernatants.	 The	 results	
indicated	that	although	the	CAG	promoter	led	to	high	levels	of	AAT	expression	as	was	expected	335,	
the	 titer	 of	 supernatant	 #116	 as	 well	 as	 transduction	 efficacies	 achieved	 on	 MSCs	 using	 that	
supernatant	were	unacceptably	 low	(data	not	shown).	Thus,	 it	was	decided	to	not	 include	the	CAG	
promoter	 in	subsequent	cloning	strategies.	 Instead	the	 influence	of	the	remaining	three	promoters	
on	AAT	expression	were	analyzed,	while	at	the	same	time	different	configurations	of	the	SERPINA1	
and	pac	 expression	 cassettes	were	 assessed.	 In	 the	 first	 three	 “2nd	 generation”	 constructs	 cloned,	
pPGK,	 pEFS,	 and	 pEF1a	were	 used	 to	 drive	SERPINA1	 gene	 expression,	 followed	 by	 either	 pEFS	 or	
pPGK	expressing	pac	(constructs	#159,	#160,	and	#161).	To	avoid	unwanted	recombination	events	in	
the	 viral	 vector,	 the	 same	 promoter	was	 never	 used	 twice	 in	 one	 plasmid.	 To	 determine	 possible	
position	effects	of	the	expression	cassettes	within	the	viral	vector	on	AAT	expression,	a	second	set	of	
three	 plasmids	 was	 cloned	 in	 which	 the	 pac	 cassette	 was	 positioned	 5’	 of	 the	 SERPINA1	 cassette	
(constructs	 #162,	 #163,	 and	 #164).	 To	 circumvent	 the	 possible	 problem	 of	 transcriptional	
interference	336,337,	two	more	constructs	were	cloned	in	which	an	EMCV	IRES	sequence	was	used	to	
initiate	 cap-independent	 translation	 of	 the	 pac	mRNA,	 thereby	 eliminating	 the	 need	 for	 a	 second	
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promoter.	 The	 detailed	 cloning	 strategy	 is	 described	 in	 2.2.1.	 Figure	 6	 shows	 a	 schematic	
representation	 of	 the	 eight	 “2nd	 generation”	 gamma-retroviral	 transfer	 plasmids;	 more	 detailed	
plasmid	maps	are	depicted	in	the	supplementary	material	(6.4).		
	
	
Figure	 6:	 Schematic	 representation	 of	 the	 eight	 “2nd	 generation”	 plasmids.	 Three	 different	
promoters	 (pPGK,	 pEFS,	 and	 pEF1a)	 were	 used	 to	 drive	 the	 expression	 of	 SERPINA1;	 pac	 was	
expressed	from	either	pPGK	or	pEFS,	depending	on	which	promoter	was	used	for	the	expression	of	
SEPRINA1.	 In	constructs	#159,	#160,	and	#161,	the	SERPINA1	expression	cassette	was	positioned	5’	
of	 the	 pac	 cassette,	 in	 constructs	 #162,	 #163,	 and	 #164,	 the	 cassettes	 were	 swapped,	 so	 that	
SERPINA1	was	now	3’	of	pac.	Two	more	constructs	were	cloned	in	which	SERPINA1	was	either	driven	
by	pPGK	(construct	#193)	or	pEFS	(construct	#194),	and	pac	was	linked	by	an	EMCV	IRES	sequence.	
An	oPRE	sequence	was	added	3’	of	the	expression	cassette(s)	to	increase	expression	and	viral	titers.	
Y:	Packaging	Signal;	SD:	Splice	Donor.	
	
3.2. Comparison of constructs and selection of lead candidate 
3.2.1. Viral vectors are functional on HT1080 cells 
In	the	next	set	of	experiments,	the	general	goal	was	to	determine	which	of	the	constructs	described	
above	was	most	suitable	for	the	transduction	of	human	cells	and	the	expression	of	transgenic	AAT.	
Thus,	 as	 a	 first	 step,	 gamma-retroviral	 supernatants	 of	 all	 2nd	 generation	 transfer	 plasmids	 cloned	
were	produced	by	transient	triple	transfection	of	293T	cells	as	described	in	detail	in	2.2.3.	To	be	able	
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to	transduce	human	MSCs	with	comparable	MOIs	 in	subsequent	experiments,	viral	 titers	were	first	
determined	 by	 transduction	 of	 HT1080	 fibrosarcoma	 cells	 with	 a	 minimum	 of	 three	 different	
dilutions	in	duplicate	per	each	supernatant.	Transduction	efficacies	were	analyzed	by	flow	cytometry	
to	detect	transgenic	intracellular	human	AAT	protein,	and	viral	titers	were	calculated	as	described	in	
2.2.4.	All	viral	supernatants	generated	were	functional	on	the	HT1080	cells.	As	depicted	in	Figure	7A,	
the	 highest	 average	 titer	 of	 [3x105	 TU/mL]	 was	 achieved	 for	 viral	 supernatant	 #159	
(pPGK_SERPINA1_pEFS_pac),	 followed	 by	 #160	 (pEFS_SERPINA1_pPGK_pac),	 #163	
(pPGK_pac_pEFS_SERPINA1),	 #194	 (pEFS_SERPINA1_IRES_pac),	 and	 #193	
(pPGK_SERPINA1_IRES_pac);	 supernatant	 #162	 (pEFS_pac_pPGK_SERPINA1)	 yielded	 intermediate	
results,	and	titers	of	viral	supernatants	#161	and	#164	(both	constructs	in	which	pEF1a	was	used	to	
drive	SERPINA1	expression)	were	almost	two	log	units	lower	as	compared	to	the	highest	titer.	Due	to	
the	size	of	the	full-length	EF1a	promoter	–	these	plasmids	are	approximately	1000	bases	larger	than	
the	other	constructs	(Figure	7B)	–	we	compared	plasmid	sizes	with	viral	titers	and	found	a	negative	
correlation	 (Figure	 7C,	 R²	 =	 0.78,	 P	 =	 0.035).	 This	 result	 suggests	 that	 higher	 genetic	 payload	 and	
resulting	 larger	 transfer	plasmids	can	 lead	to	decreased	titers	and	 is	 in	 line	with	 findings	published	
for	retroviral	vectors	338,339.		
3.2.2. Viral vectors are functional on primary human MSCs 
3.2.2.1. Constructs containing the EFS promoter to drive SERPINA1 expression yield the 
highest transduction efficacy 
In	the	next	step,	the	viral	supernatants	titrated	above	were	used	for	transduction	of	primary	human	
MSCs	at	comparable	MOIs	to	assess	which	construct	would	yield	best	transduction	efficacy	and	AAT	
expression.	Primary	human	MSCs	were	produced	as	described	in	detail	in	2.2.5	and	transduced	at	a	
constant	MOI	of	0.25	using	viral	supernatants	#159–#194	by	either	direct	seeding	or	centrifugation	of	
viral	supernatants	onto	PLL-coated	plates.	To	assess	transduction	efficacies	achieved	with	the	various	
viral	supernatants,	cells	were	 intracellularly	stained	for	transgenic	human	AAT	protein	48–72	hours	
post-transduction.	 The	 results	 are	 provided	 in	 Figure	 8A.	 Normalized	 transduction	 efficacies	 were	
comparable	 for	 constructs	 #160,	 #163,	 #194	 (the	 three	 vectors	 containing	 pEFS	 for	 SERPINA1	
expression),	 and	 #193	 (pPGK_SERPINA1_IRES_pac).	 Results	 seen	 with	 #159	 and	 #162	 (constructs	
containing	pPGK	to	drive	SERPINA1	expression)	showed	a	decreased	efficiency	of	approximately	30%,	
and	 transduction	 efficacies	 using	 supernatants	 #161	 and	 #164	 (constructs	 in	 which	 SERPINA1	 is	
driven	by	pEF1a)	were	only	30%	(P	<	0.01)	and	10%	(P	<	0.001),	respectively,	of	those	achieved	with	
the	best	supernatants.	This	was	unexpected	as	the	same	amount	of	viral	particles	had	been	used	for	
each	 transduction;	 however,	 the	 volumes	 of	 the	 supernatants	 that	 had	 to	 be	 used	 to	 achieve	
comparable	MOIs	were	different	by	up	to	factor	~30	due	to	the	enormous	differences	in	viral	titers.	
By	comparing	viral	titers	with	the	transduction	efficacies	achieved,	a	positive	correlation	was	found	
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(Figure	8B,	R²	=	0.73,	P	=	0.0066),	suggesting	that	the	number	of	viral	particles	used	for	transduction	
determined	transduction	efficacies,	but	that	there	was	a	potential	negative	impact	of	large	volumes	
of	viral	supernatant	on	transduction.	
	
	
Figure	 7:	Viral	 vectors	 are	 functional.	A:	 Titers	 of	 viral	 supernatants	 #159-#194.	Constructs	 #159,	
#160,	 163,	 #193,	 and	 #194	 yielded	 comparable	 titers	 on	 HT1080	 fibrosarcoma	 cells,	 while	 titers	
achieved	with	constructs	#161	and	164	were	almost	two	log	units	 lower;	titers	of	viral	supernatant	
#162	 were	 intermediate.	 Viral	 titers	 were	 determined	 by	 transduction	 of	 HT1080	 cells	 and	 flow	
cytometry	 for	 intracellular	AAT	protein.	 Symbols	 represent	 average	 values	 from	4–13	 independent	
transductions	 per	 viral	 vector	 ±	 standard	 deviation	 (SD).	 Small	 numbers	 below	 the	 graph	 indicate	
number	 of	 transductions	 performed	 for	 each	 supernatant.	 B:	 Payload	 sizes	 of	 2nd	 generation	
gamma-retroviral	transfer	constructs.	pEF1a	plasmids	are	~1kb	larger	than	pPGK	and	pEFS	vectors.	
Colors	of	bars	represent	the	promoter	driving	SERPINA1	(pPGK:	dark	gray;	pEFS:	medium	gray;	pEF1a:	
light	 gray).	C:	 Titers	 of	 viral	 supernatants	 and	 expression	 cassette	 sizes	 are	 inversely	 correlated.	
Correlation	 analysis	 of	 expression	 cassette	 sizes	 and	 average	 viral	 titers	 revealed	 a	 negative	
correlation	(R²	=	0.78,	P	=	0.0035).	Statistical	correlation	was	determined	by	calculating	the	Pearson	
correlation	coefficient.	Gaussian	distribution	was	confirmed	using	the	D'Agostino	&	Pearson	omnibus	
normality	test.		
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Figure	8:	Normalized	transduction	efficacies	of	primary	human	MSCs.	A:	Transduction	efficacies	are	
highest	 in	MSCs	 transduced	with	 viral	 supernatants	 #160,	 #163,	 #194,	 and	#193.	 Transduction	of	
primary	human	MSCs	was	highest	when	supernatants	#160,	#163,	#194	(constructs	in	which	pEFS	is	
driving	 SERPINA1	 expression),	 and	 #193	 (pPGK_SERPINA1_IRES_pac)	 were	 used.	 Primary	 human	
MSCs	 derived	 from	 two	 healthy	 donors	 were	 transduced	 with	 viral	 supernatants	 #159–#194,	 and	
transduction	efficacies	were	assessed	by	intracellular	flow	cytometry	for	AAT	protein.	Bars	represent	
average	 values	 of	 4–8	 independent	 transduction	 experiments	 ±	 SD.	 Due	 to	 high	 variance	 in	
transduction	 results	 depending	 on	 the	 donor,	 values	were	 normalized	 to	 the	 highest	 transduction	
achieved	 in	 each	 experiment	 (=	 100%).	 Small	 numbers	 below	 the	 graph	 indicate	 the	 number	 of	
separate	 experiments	 performed	 for	 each	 viral	 construct.	 Statistical	 significance	 of	 differences	
between	 the	 construct	 yielding	 the	 highest	 value	 (#194)	 that	 was	 used	 as	 a	 control	 and	 all	 other	
constructs	was	calculated	applying	the	Kruskal-Wallis	test	(P	<	0.0001),	followed	by	Dunn's	multiple	
comparisons	test	(194	vs.	159:	ns,	194	vs.	160:	ns,	194	vs.	161:	**,	194	vs.	162:	*,	194	vs.	163:	ns,	194	
vs.	164:	***,	194	vs.	193:	ns).	*	P	<	0.05,	**	P	<	0.01,	***	P	<	0.001.	B:	Transduction	efficacies	and	
viral	 titers	 are	 positively	 correlated.	 Correlation	 analysis	 of	 expression	 cassette	 sizes	 and	 average	
viral	 titers	 revealed	 a	 strong	 correlation	 between	 these	 two	 variables	 (R²	 =	 0.73,		
P	=	0.0066).	Statistical	correlation	was	determined	by	calculating	the	Pearson	correlation	coefficient.	
Gaussian	distribution	was	confirmed	using	the	Kolmogorov-Smirnov	test.		
3.2.2.2. EF1a and EFS promoters yield higher AAT expression than pPGK 
To	 analyze	 the	 strength	 of	 AAT	 expression	 yielded	 after	 transduction	 of	 human	 MSCs	 with	 the	
different	 constructs,	 expression	 of	 AAT	 in	 bulk	MSC	 populations	 was	 assessed	 by	 flow	 cytometric	
analysis	 and	 mean	 fluorescence	 intensities	 (MFIs)	 of	 AAT-positive	 cells.	 All	 constructs	 in	 which	
SERPINA1	was	driven	by	either	pEFS	or	pEF1a	yielded	comparable	high	MFIs,	whereas	AAT	expression	
in	cells	transduced	with	constructs	#159	and	#162,	in	which	SERPINA1	 is	expressed	from	pPGK,	was	
lower	by	about	~30%	each	(P	<	0.05	and	P	<	0.01,	respectively).	Construct	#193,	in	which	SERPINA1	
was	 driven	 by	 pPGK,	 but	 using	 an	 IRES	 sequence	 instead	 of	 a	 second	 promoter,	 yielded	 AAT	
expression	comparable	to	pEFS	and	pEF1a	constructs	(Figure	9).		
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Figure	9:	AAT	expression	from	pEF1a	and	pEFS	 is	higher	as	compared	to	pPGK.	Transduction	with	
viral	 supernatants	 generated	 from	constructs	 in	which	SEPRINA1	 is	driven	by	either	pEF1a	or	pEFS	
resulted	in	higher	AAT	expression	as	compared	to	values	achieved	with	pPGK.	Primary	human	MSCs	
derived	 from	 two	 healthy	 donors	 were	 transduced	 with	 viral	 supernatants	 #159–#194,	 and	 MFIs	
were	assessed	by	intracellular	flow	cytometry	for	AAT	protein.	Bars	represent	average	values	of	4–8	
independent	transduction	experiments	±	SD.	Small	numbers	below	the	graph	indicate	the	number	of	
separate	 experiments	 performed	 for	 each	 viral	 construct.	 Statistical	 significance	 of	 differences	
between	 the	 construct	 yielding	 the	 highest	 MFI	 (#194)	 that	 was	 used	 as	 a	 control	 and	 all	 other	
constructs	was	calculated	applying	the	Kruskal-Wallis	test	(P	=	0.0009),	followed	by	Dunn's	multiple	
comparisons	test	(194	vs.	159:	*,	194	vs.	160:	ns,	194	vs.	161:	ns,	194	vs.	162:	**,	194	vs.	163:	ns,	194	
vs.	164:	ns,	194	vs.	193:	ns).	*	P	<	0.05;	**	P	<	0.01.	
3.2.3. Viral vectors allow for long-term modification of MSCs and sustained AAT 
expression after antibiotic selection and expansion 
3.2.3.1. Constructs in which SEPRINA1 and pac are linked via an IRES sequence yield 
highest VCNs after antibiotic selection and long-term culture of MSCs 
After	 transduction	 efficacies	 and	 AAT	 expression	 were	 characterized	 in	 non-selected	 cells	 shortly	
after	 transduction,	 in	 a	 next	 set	 of	 experiments	 we	 wanted	 to	 analyze	 if	 transduction	 of	 primary	
human	MSCs	with	the	viral	constructs	led	to	stable	genetic	modification	of	the	cells	as	well	as	long-
lasting	 AAT	 expression	 after	 antibiotic	 selection	 and	 expansion	 of	 the	 cells.	 These	 processes	 are	
needed	for	the	generation	of	a	cell	therapy	product	for	clinical	use.	Thus,	bulk	populations	of	MSCs	
transduced	with	the	eight	different	supernatants	were	subjected	to	antibiotic	selection	to	yield	pure	
populations	of	 gene-modified	 cells.	 Figure	10	 shows	a	 representative	 example	of	 intracellular	 flow	
cytometry	stains	of	transduced	cells	before	and	after	antibiotic	selection.		
After	 completion	 of	 the	 selection	 process,	 cells	 were	 expanded	 in	 Bio-M	 or	 Bio-1	 for	 usually	 two	
weeks,	 when	 cell	 numbers	 sufficient	 to	 perform	 further	 experiments	 were	 reached.	 The	 DNA	 of	
selected	cells	was	extracted,	and	VCNs	were	determined	by	qPCR	and	comparison	with	a	reference	
cell	 clone	 containing	 a	 single	 viral	 integration	 as	 described	 in	 2.2.15.	 MSCs	 transduced	 with	
supernatants	 #193,	 #194	 (the	 two	 constructs	 containing	 an	 IRES	 sequence),	 and	 #160	
(pEFS_SERPINA1_pPGK_pac)	 had	 the	 highest	 average	 values	 of	 ~4–5	 viral	 integrations	 per	 cell,	
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followed	by	cells	modified	with	 supernatants	#159,	#162	 (the	 two	constructs	 in	which	SERPINA1	 is	
driven	by	pPGK),	 and	#163	 (pPGK_pac_pEFS_SEPRINA1)	which	had	mean	VCNs	of	2.3,	2.8,	 and	3.2	
(Figure	11).	Average	VCNs	achieved	with	supernatant	#161	(pEF1a_SERPINA1_pPGK_pac)	were	~10-
fold	 lower	as	compared	to	constructs	#193	and	#194	(P	<	0.05),	and	only	 in	one	experiment	out	of	
four	 performed,	was	 it	 possible	 to	 harvest	 cells	 for	VCN	measurement	 after	 antibiotic	 selection	of	
cells	 transduced	 with	 supernatant	 #164	 (pPGK_pac_pEFa1_SERPINA1);	 in	 the	 three	 other	
experiments	 no	 cells	 survived	 the	 antibiotic	 selection.	 Taken	 together,	 the	 VCN	 results	 generated	
after	 antibiotic	 selection	 and	 long-term	 culture	 of	 selected	 cells	 support	 the	 ones	 achieved	 by	
intracellular	flow	cytometry	before	selection	and	expansion,	confirming	that	constructs	#160,	#163,	
#194	 (all	 constructs	 in	 which	 pEFS	 is	 driving	 SERPINA1	 expression),	 and	 #194	
(pPGK_SERPINA1_IRES_pac)	 resulted	 in	 the	 highest	 degree	 of	 genetic	modification	 of	 the	 primary	
human	MSCs,	and	thus,	were	further	assessed	to	select	the	favored	expression	cassette.	
	
	
Figure	10:	Representative	 flow	cytometry	results	 for	 intracellular	AAT	stains	achieved	before	and	
after	antibiotic	selection.	Antibiotic	 selection	of	 transduced	cells	with	puromycin	yields	>95%	pure	
populations	of	MSCs	expressing	AAT.	Primary	human	MSCs	were	transduced	with	viral	vector	#194,	
and	 intracellular	 staining	 for	 AAT	 and	 subsequent	 flow	 cytometric	 measurement	 were	 performed	
before	 and	 after	 a	 5-day	 selection	with	 [3µg/mL]	 puromycin.	 Representative	 flow	 cytometry	 plots	
show	~30%	AAT+	cells	72	hours	after	transduction	and	a	highly	pure	(>95%	AAT+)	population	of	AAT-
expressing	MSCs	after	selection.	Non-transduced	MSCs	from	the	same	donor	were	stained	with	the	
same	antibody	and	used	as	negative	controls	for	gating.	
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Figure	11:	Highest	VCNs	achieved	 in	 cells	modified	with	 supernatants	#193	and	#194.	Analysis	of	
VCNs	 after	 antibiotic	 selection	 and	 long-term	 culture	 of	 the	 cells	 yielded	 highest	 values	 for	MSCs	
transduced	 with	 viral	 supernatants	 #193	 (pPGK_SERPINA1_IRES_pac)	 and	 #194	
(pEFS_SERPINA1_IRES_pac),	 followed	 by	 #160,	 and	 #163	 (constructs	 in	 which	 pEFS	 is	 driving	
SERPINA1	expression,	and	a	second	promoter	is	used	to	drive	pac	expression).	Primary	human	MSCs	
derived	from	two	healthy	donors	were	transduced	with	viral	supernatants	#159–#194,	selected	with	
puromycin,	 expanded,	 and	 harvested	 for	 DNA	 preparation.	 VCNs	 were	 determined	 by	 qPCR	 and	
comparison	to	a	reference	cell	clone	with	a	single	viral	integration.	Bars	represent	average	values	of	
1–6	independent	experiments	±	SD.	Small	numbers	below	the	graph	indicate	the	number	of	separate	
experiments	 performed	 for	 each	 viral	 construct.	 Statistical	 significance	 of	 differences	 between	
control	 construct	 #194	 and	 all	 other	 constructs	 was	 calculated	 applying	 the	 Kruskal-Wallis	 test		
(P	=	0.0041),	followed	by	Dunn's	multiple	comparisons	test	(194	vs.	159:	ns,	194	vs.	160:	ns,	194	vs.		
161:	*,	194	vs.	162:	ns,	194	vs.	163:	ns,	194	vs.	164:	ns,	194	vs.	193:	ns).	*	P	<	0.05.	
3.2.3.2. EF1a and EFS promoters lead to higher AAT expression than pPGK after antibiotic 
selection and long-term expansion of MSCs 
In	the	next	step	the	stability	of	AAT	expression	in	transduced	MSCs	was	determined	after	antibiotic	
selection	 and	 cell	 expansion.	 The	AAT	protein	 content	 in	 cell	 culture	 supernatants	of	 selected	 and	
expanded	 MSCs	 was	 measured	 by	 ELISA	 and	 compared	 to	 flow	 cytometry	 expression	 data	
determined	by	MFI	of	 intracellularly	stained	AAT	 in	cells	prior	 to	antibiotic	selection.	MSCs	derived	
from	 two	 donors	 were	 transduced	 with	 the	 eight	 gamma-retroviral	 supernatants,	 subjected	 to	
antibiotic	 selection,	 expanded,	 and	 seeded	 for	harvest	of	 supernatants.	After	 48	hours	 cell	 culture	
supernatants	were	 collected,	 and	 the	 concentration	of	 secreted	AAT	protein	determined	by	ELISA.	
Consistent	with	MFI	data	measured	before	antibiotic	 selection,	AAT	expression	after	 selection	and	
long-term	culture	was	highest	 in	 cell	 culture	 supernatants	derived	 from	cells	 transduced	with	 viral	
vectors	using	either	the	EFS	or	the	full-length	EF1a	promoter	to	drive	SERPINA1	expression,	with	an	
average	 AAT	 yield	 of	 ~500ng/1x105	 cells/viral	 integration	 in	 48	 hours	 (Figure	 12).	 AAT	 content	 in	
supernatants	 after	 transduction	of	MSCs	with	 vectors	 #159	and	#162	 (constructs	 in	which	pPGK	 is	
driving	 SERPINA1	 expression)	 was	 significantly	 lower	 (~95ng/1x105	 cells/VCN/48h;	 P	 <	 0.05);	 viral	
supernatant	#193	(pPGK_SERPINA1_IRES_pac)	yielded	 intermediate	results.	 In	only	one	experiment	
out	 of	 four	 was	 it	 possible	 to	 determine	 AAT	 concentration	 in	 cell	 culture	 supernatants	 after	
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transduction	with	vector	#164	(pPGK_pac_pEF1a_SERPINA1)	as	there	was	complete	cell	death	of	the	
MSCs	in	the	other	three	experiments.		
	
	
Figure	 12:	 AAT	 expression	 is	 markedly	 higher	 from	 pEF1a	 and	 pEFS	 as	 compared	 to	 pPGK	 as	
determined	 by	 ELISA.	 Transduction	 of	MSCs	with	 viral	 supernatants	 generated	 from	 constructs	 in	
which	SERPINA1	 is	driven	by	either	pEF1a	or	pEFS	yielded	higher	amounts	of	AAT	secreted	into	the	
cell	 culture	supernatant	as	compared	 to	constructs	 in	which	AAT	 is	driven	by	pPGK	after	antibiotic	
selection	and	long-term	expansion	of	selected	cells.	Primary	human	MSCs	derived	from	two	healthy	
donors	were	transduced	with	viral	supernatants	#159–#194,	selected	with	puromycin,	expanded	and	
seeded	 at	 a	 concentration	 of	 1x104	 cells	 and	 250µL	medium/cm².	 Cell	 culture	 supernatants	 were	
collected	 after	 48	 hours,	 and	 AAT	 protein	 content	was	 assessed	 by	 ELISA.	 Bars	 represent	 average	
values	of	1–6	independent	transduction	experiments	±	SD,	normalized	to	1x105	cells	and	divided	by	
VCN.	 Small	numbers	below	 the	graph	 indicate	 the	number	of	 separate	experiments	performed	 for	
each	 viral	 construct.	 Statistical	 significance	 of	 differences	 between	 control	 construct	 #194	 and	 all	
other	 constructs	 was	 calculated	 applying	 the	 Kruskal-Wallis	 test	 (P	 =	 0.0006),	 followed	 by	 Dunn's	
multiple	comparisons	test	(194	vs.	159:	*,	194	vs.	160:	ns,	194	vs.	161:	ns,	194	vs.	162:	*,	194	vs.	163:	
ns,	194	vs.	164:	ns,	194	vs.	193:	ns).	*	P	<	0.05.		
Because	AAT	expression	was	lowest	when	transducing	MSCs	with	vectors	#159	and	#162	(constructs	
in	which	pPGK	is	used	to	drive	SERPINA1	expression	and	which	contain	a	second	promoter	to	drive	
pac	expression),	and	use	of	supernatants	#161	and	#164	(constructs	in	which	SERPINA1	is	driven	by	
pEF1a)	 led	 to	 low	 transduction	 efficacies	 and	 markedly	 decreased	 cell	 numbers	 after	 antibiotic	
selection	 (data	 not	 shown),	 these	 four	 constructs	 were	 excluded	 from	 subsequent	 experiments.	
Constructs	#160,	#163,	and	#194	(all	 three	constructs	 in	which	SERPINA1	 is	driven	by	pEFS)	yielded	
comparable	 results	 regarding	 transduction	 efficacy	 and	 expression	 and	 were	 subjected	 to	 further	
evaluation.	Construct	#193	 (pPGK_SERPINA1_IRES_pac)	was	also	 included	as	 this	 vector	had	 led	 to	
good	results	in	previous	experiments.	It	was	the	only	remaining	vector	in	which	SERPINA1	was	driven	
by	a	promoter	that	is	not	EFS.		
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3.2.4. Constructs containing an IRES sequence yield higher MSC numbers after 
antibiotic selection as compared to constructs containing two promoters 
As	 described	 above,	 transduction	 efficacies	 and	 AAT	 expression	 were	 comparable	 among	 the	
remaining	 vectors	 #160,	 #163,	 #193,	 and	 #194	before	 and	 after	 antibiotic	 selection	 and	 long-term	
expansion	 of	 the	 selected	 cells.	 However,	 it	 had	 been	 noted	 that	 cell	 numbers	 after	 antibiotic	
selection	 varied	markedly	 between	 the	 constructs	 even	when	 transduction	 efficacies	were	 similar.	
When	generating	an	optimized	 cell	 product	 for	 clinical	use,	 it	 is	 crucial	 to	achieve	a	maximum	cell	
yield.	Thus,	experiments	were	performed	to	assess	MSC	numbers	achieved	after	 transduction	with	
the	different	viral	supernatants	at	a	constant	MOI	and	subsequent	selection	with	puromycin.	MSCs	
were	transduced	with	the	four	remaining	gamma-retroviral	supernatants	#160,	#163,	#193,	and	#194	
at	MOI	0.25,	subjected	to	antibiotic	selection,	and	expanded	until	confluency	was	reached	and	cell	
numbers	were	determined	by	manual	counting	using	a	Neubauer	hemocytometer	 in	duplicate.	Cell	
numbers	after	transduction	with	viral	vectors	containing	an	IRES	sequence	to	link	SERPINA1	and	pac	
genes	(#193	and	#194)	were	markedly	higher	as	compared	to	those	achieved	after	transduction	with	
constructs	in	which	pac	was	expressed	from	a	second	promoter	(#160	and	#163;	Figure	13).	The	most	
striking	difference	was	noticeable	when	comparing	constructs	#160	(pEFS_SERPINA1_pPGK_pac)	and	
#194	(pEFS_SERPINA1_IRES_pac):	Cell	numbers	were	decreased	by	~70%	after	transduction	with	viral	
vector	#160	(P	<	0.01).		
Taken	 together,	 these	 results	 demonstrated	 that	 the	 retroviral	 expression	 plasmid	 #194	was	 best	
when	compared	to	the	other	seven	constructs	tested	with	regards	to	transduction	efficacy	and	AAT	
expression	 as	 well	 as	 cell	 yield.	 Thus,	 construct	 #194	 was	 selected	 as	 the	 lead	 candidate	 for	
transgenic	AAT	expression	in	primary	human	MSCs	and	subjected	to	further	testing.		
	
	
Figure	13:	Antibiotic	selection	of	MSCs	after	transduction	with	supernatants	#160,	#163,	#193,	and	
#194	at	comparable	transduction	efficacies	results	in	different	cell	gain.	Transduction	of	MSCs	with	
construct	 #194	 results	 in	 higher	 cell	 yields	 after	 antibiotic	 selection	 when	 compared	 to	 cells	
transduced	 with	 #160,	 #163,	 and	 #193,	 despite	 similar	 transduction	 efficacies	 before	 selection.	
Primary	human	MSCs	were	transduced	with	viral	supernatants	#160,	#163,	#193,	and	#194,	selected	
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with	 puromycin	 at	 a	 concentration	 of	 [3µg/mL],	 and	 expanded	 until	 confluency,	 when	 cells	 were	
counted.	 Bars	 represent	 average	 values	 of	 4	 independent	 transduction	 experiments	 ±	 SD.	 Due	 to	
different	sizes	of	culture	vessels	used	for	expansion	in	different	experiments,	values	were	normalized	
to	the	highest	cell	number	yielded	in	each	experiment	(=	100%).	Statistical	significance	of	differences	
between	 cell	 numbers	 recorded	 for	 control	 construct	 #194	 and	 the	 three	 other	 constructs	 was	
calculated	applying	the	Kruskal-Wallis	test	(P	<	0.0001),	followed	by	Dunn's	multiple	comparisons	test	
(194	vs.	160:	**,	194	vs.	163:	ns,	194	vs.	193:	ns).	**	P	<	0.01.		
3.3. Comparison of best expression cassette in gamma-retroviral and lentiviral 
backbone 
In	the	first	stage	of	this	work,	the	best	performing	expression	cassette	with	regards	to	transduction,	
AAT	expression,	and	cell	yield	was	selected	from	the	eight	candidates.	In	the	next	step,	we	assessed	if	
a	 different	 viral	 backbone	 could	 potentially	 further	 increase	 transduction	 efficacy	 and	 AAT	
expression.	 To	 this	 end,	 we	 chose	 a	 lentiviral	 system	 to	 compare	 with	 the	 gamma-retroviruses.	
Lentiviruses	 have	 the	 advantage	 of	 being	 able	 to	 transduce	 non-dividing	 cells,	 thus	 potentially	
enhancing	transduction	efficacies.	Moreover,	lentiviral	vectors	are	used	for	clinical	applications	and	–	
like	gamma-retroviruses	–	also	permanently	 integrate	their	genetic	 information	into	the	genome	of	
the	host	cell,	thus	allowing	a	stable	genetic	modification	of	the	target	cell	and	its	progeny.	
3.3.1. Titers achieved using the lentiviral backbone are four-fold higher 
Accordingly,	 the	 expression	 cassette	 pEFS_SERPINA1_IRES_pac_oPRE	 was	 transferred	 from	 the	
gamma-retroviral	 backbone	 (pSERS11)	 to	 a	 lentiviral	 pCCL	 backbone	 by	 In-Fusion	 cloning	 as	
described	 in	 2.2.1.2.	 Briefly,	 an	 expression	 cassette	 present	 in	 pCCL	 was	 removed	 by	 restriction	
enzyme	digestion,	homology	arms	were	created	5’	and	3’	of	the	SERPINA1-pac-cassette	by	PCR,	and	
the	 cassette	 was	 transferred	 to	 pCCL	 by	 recombination.	 A	 comparison	 of	 the	 schematic	 of	 both	
plasmids	is	depicted	in	Figure	14.	
	
Figure	 14:	 Schematic	 representation	 of	 gamma-retroviral	 expression	 vector	 #194	 and	 lentiviral	
expression	vector	#215.	
Two	batches	of	viral	 supernatant	#215	were	produced	by	transient	 triple	 transfection	of	293T	cells	
and	 titers	were	determined	on	HT1080	 fibrosarcoma	cells	as	described	 in	detail	 in	2.2.3	and	2.2.4.	
Two	batches	of	viral	supernatant	#194	were	generated	for	subsequent	experiments.	Consistent	with	
published	data	 340,	 the	average	 lentiviral	 titer	was	higher	 than	the	retroviral,	 in	our	case	~four-fold	
(#194:	[2.9x105	TU/mL];	#215:	[1.2x106	TU/mL];	Figure	15).		
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Figure	15:	For	transfer	plasmids	containing	the	same	expression	cassette,	lentiviral	titers	are	higher	
than	retroviral.	Viral	titers	determined	on	HT1080	cells	were	~4-fold	higher	for	the	lentiviral	vector	
as	 compared	 to	 the	 gamma-retroviral	 vector.	 Expression	 cassette	 pEFS_SERPINA1_IRES_pac_oPRE	
was	cloned	 into	 the	 lentiviral	pCCL	backbone,	2	batches	of	 supernatants	of	 transfer	plasmids	#194	
and	#215	each	were	generated	using	the	respective	helper	plasmids,	and	titers	were	determined	on	
HT1080	 cells.	 Symbols	 represent	 average	 values	 from	 8–14	 independent	 transductions	 per	 viral	
vector	 ±	 SD.	 Small	 numbers	 below	 the	 graph	 indicate	 numbers	 of	 independent	 transductions	
performed	for	each	supernatant.	Statistical	significance	was	calculated	using	the	unpaired	t	test	with	
Welch's	correction	(P	<	0.0001).	****	P	<	0.0001.	Gaussian	distribution	of	the	data	was	confirmed	by	
D'Agostino	&	Pearson	omnibus	normality	test.		
3.3.2. Transduction behavior differs between gamma-retro- and lentiviral vector 
3.3.2.1. Transduction efficacy 
To	analyze	potential	differences	in	transduction	efficacy	between	the	gamma-retroviral	and	lentiviral	
vector	 and	 to	 assess	 a	 dose	 response,	 primary	 human	 MSCs	 derived	 from	 three	 donors	 were	
transduced	with	both	viral	supernatants	at	four	MOIs,	ranging	from	0.25	to	5.0.	Cells	were	analyzed	
by	intracellular	flow	cytometry	for	AAT	protein	72	hours	after	transduction.	Due	to	high	inter-donor	
variability	 in	 transduction,	 results	 were	 normalized	 to	 the	 highest	 transduction	 achieved	 in	 the	
respective	experiment	(=	100%).	In	all	experiments	performed,	transduction	efficacies	at	lower	MOIs	
(0.25	 and	 0.75)	 were	 higher	 when	 the	 gamma-retroviral	 supernatant	 was	 used.	 At	MOI	 0.25,	 the	
average	 normalized	 transduction	 efficacy	was	 ~50%	of	 the	maximal	 transduction	 achieved	 in	 each	
experiment	 using	 supernatant	 #194	 and	 ~20%	 using	 vector	 #215	 (P	 <	 0.05;	 Figure	 16).	 However,	
when	MSCs	were	gene-modified	at	 the	 ten-fold	higher	MOI	of	 2.5,	 average	 transduction	efficacies	
achieved	with	the	gamma-retroviral	supernatant	increased	only	modestly	(from	~50%	at	MOI	0.25	to	
~53%	 at	 MOI	 2.5),	 whereas	 average	 normalized	 transduction	 was	 improved	 more	 than	 four-fold	
when	cells	were	transduced	with	the	lentiviral	vector	(from	~20%	at	MOI	0.25	to	~90%	at	MOI	2.5).	
Transduction	 of	 human	 MSCs	 at	 MOI	 2.5	 was	 thus	 almost	 twice	 as	 high	 with	 the	 lentiviral	
supernatant	 as	 compared	 to	 the	 gamma-retroviral	 vector	 (P	 <	 0.01;	 Figure	 16).	 Using	 lentiviral	
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supernatant	#215	at	the	highest	tested	MOI	of	5.0	resulted	in	absolute	transduction	efficacies	as	high	
as	~80%	for	two	out	of	three	donors	analyzed	(data	not	shown),	while	retroviral	transduction	did	not	
increase	to	more	than	¾	of	what	was	reached	with	the	lentiviral	supernatant.	When	linear	regression	
analysis	was	 performed	 to	 assess	 if	 the	 two	dose	 response	 curves	 generated	 by	 fitting	 the	means	
were	 different,	 there	was	 a	 significant	 distinction	 regarding	 the	 slope	 (P	 =	 0.0006),	 indicating	 that	
transduction	behavior	differs	markedly	between	gamma-retro-	and	lentiviral	vectors.		
	
Figure	16:	Dose	response	curve	 fits	of	average	 transduction	values	of	human	MSCs	with	gamma-
retro-	and	lentiviral	vectors	at	MOIs	ranging	from	0.25–5.0	are	different.	At	the	lowest	MOI	(0.25),	
transduction	 with	 the	 gamma-retroviral	 supernatant	 was	 more	 than	 twice	 as	 high	 as	 the	 one	
achieved	 using	 the	 lentiviral	 vector	 (P	 <	 0.05);	 however,	 using	 a	 10-fold	 higher	MOI,	 transduction	
efficacy	with	 lentiviral	 supernatant	 #215	was	 increased	more	 than	4-fold,	 resulting	 in	 transduction	
efficacies	 almost	 twice	 as	 high	 as	 the	 ones	 achieved	 with	 the	 gamma-retroviral	 vector	 #194		
(P	 <	 0.01).	 When	 comparing	 the	 2	 dose	 response	 curves,	 there	 was	 a	 statistically	 significant	
difference	in	the	slopes	(P	=	0.0006).	Symbols	represent	the	average	of	5	independent	transduction	
experiments	 for	 MOIs	 0.25,	 0.75,	 and	 2.5,	 and	 3	 for	 MOI	 5.0	 ±	 SD.	 Due	 to	 high	 variance	 in	
transduction	 results	 depending	 on	 the	 donor,	 values	were	 normalized	 to	 the	 highest	 transduction	
achieved	 in	each	experiment	 (=	100%).	Statistical	significance	of	differences	between	transductions	
with	both	supernatants	at	the	same	MOI	was	calculated	using	Sidak’s	multiple	comparisons	test	(194	
vs.	215:	MOI	0.25:	*,	MOI	0.75:	ns,	MOI	2.5:	**,	MOI	5.0:	ns).	*	P	<	0.05;	**	P	<	0.01.		
3.3.2.2. Vector Copy Number 
To	 assess	 the	 influence	 of	 the	 viral	 vector	 on	 transduced	 MSCs	 having	 undergone	 more	 ex	 vivo	
manipulation	 procedures	 and	 longer	 culture	 periods,	 the	 cells	 generated	 in	 the	 dose	 response	
experiment	 described	 above	were	 subjected	 to	 antibiotic	 selection	 and	 long-term	 expansion;	DNA	
was	extracted,	and	VCNs	were	determined.	A	graphic	representation	of	the	results	is	shown	in	Figure	
17.	 The	 data	 were	 congruent	 with	 the	 flow	 cytometry	 findings:	 Average	 VCNs	 were	 higher	 after	
transduction	with	the	gamma-retroviral	vector	at	 lower	MOIs	 (MOI	0.25:	#194:	2.6,	#215:	1.6;	MOI	
0.75:	 #194:	 2.9,	 #215:	 2.2);	 then,	 a	 trend	 reversal	 was	 observed.	 At	 the	 highest	 MOI	 of	 5.0,	
transduction	using	the	lentiviral	supernatant	yielded	average	VCNs	almost	twice	as	high	as	achieved	
with	 the	 retroviral	 vector	 (MOI	 5.0:	 #194:	 3.2,	 #215:	 6.1;	 P	 <	 0.01)	 while	 VCNs	 measured	 after	
transduction	 with	 the	 gamma-retroviral	 vector	 did	 not	 increase	 at	 all	 with	 increasing	 MOIs		
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(R²	=	0.07).	Linear	regression	analysis	assessing	if	the	two	dose	response	curves	generated	by	fitting	
the	 means	 were	 different	 confirmed	 that	 there	 was	 a	 significant	 distinction	 in	 the	 slope		
(P	 =	 0.0003).	 Thus,	 VCN	 results	 support	 the	 transduction	 efficacy	 data	 described	 above,	 indicating	
that	the	gamma-retroviral	and	lentiviral	AAT	constructs	display	a	significantly	different	transduction	
behavior	in	primary	human	MSCs:	While	retroviral	transduction	seems	to	be	at	the	maximum	already	
at	MOI	0.25	and	no	further	increase	in	VCN	is	achievable,	lentiviral	transduction	follows	a	clear	dose	
response	curve	(R²	=	0.72).		
	
Figure	 17:	 Dose	 response	 curve	 fits	 of	 average	 VCNs	 after	 transduction	 of	 human	 MSCs	 with	
gamma-retro-	and	lentiviral	vectors	at	MOIs	ranging	from	0.25–5.0	are	different.	At	the	lowest	MOI	
(0.25),	transduction	with	the	gamma-retroviral	supernatant	was	~1	vector	copy	higher	than	the	one	
achieved	using	the	lentiviral	vector;	however,	using	a	20-fold	higher	MOI	of	5.0,	transduction	efficacy	
with	#215	was	increased	~4-fold	as	compared	to	MOI	0.25,	resulting	in	VCNs	almost	twice	as	high	as	
the	ones	achieved	with	#194	(P	<	0.01).	When	comparing	the	two	dose	response	curve	fits,	there	was	
a	 statistically	 significant	 difference	 in	 the	 slopes	 (P	 =	 0.0003).	 Symbols	 represent	 the	 average	 of	 5	
independent	 transduction	 experiments	 for	 MOIs	 0.25,	 0.75,	 and	 2.5,	 and	 3	 for	 MOI	 5.0	 ±	 SD.	
Statistical	significance	of	differences	between	transductions	with	both	supernatants	at	the	same	MOI	
was	 calculated	 using	 Sidak’s	 multiple	 comparisons	 test	 (194	 vs.	 215:	MOI	 0.25:	 ns,	 MOI	 0.75:	 ns,		
MOI	2.5:	ns,	MOI	5.0:	**).	**	P	<	0.01.		
3.3.2.3. Expression of transgenic AAT 
We	 next	 wanted	 to	 assess	 whether	 levels	 of	 AAT	 expression	 changed	 when	 using	 the	 same	
expression	cassette	in	different	viral	backbones.	AAT	expression	for	both	vectors	was	determined	by	
analysis	of	the	MFIs	yielded	in	the	dose	response	experiments	described	above.	The	results	mirrored	
the	results	seen	when	comparing	transduction	efficacies:	At	the	lower	MOIs	tested	(0.25	and	0.75),	
AAT	expression	from	the	pEFS_SERPINA1_IRES_pac	cassette	 in	the	gamma-retroviral	backbone	was	
higher	(at	MOI	0.25	~85%	of	the	maximum	MFI	yielded	in	each	experiment	as	compared	to	~55%	for	
lentiviral	 vector	#215,	P	 <	0.001;	87%	vs.	 63%	at	MOI	0.75,	P	 <	0.01),	whereas	at	 the	highest	MOI	
tested	(5.0),	AAT	expression	achieved	using	the	lentiviral	supernatant	was	highest	in	all	experiments	
(100%),	with	even	a	minor	decrease	in	MFI	detected	for	vector	#194	(82%,	Figure	18).	Again,	when	
comparing	the	linear	regression	curves	produced	by	fitting	mean	MFIs,	there	was	a	highly	significant	
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difference	 between	 the	 vectors	 (P	 <	 0.0001):	 For	 gamma-retroviral	 vector	 #194,	 there	 was	 no	
correlation	between	MOI	and	MFI	achieved	(R²	=	0.51),	indicating	that	AAT	expression	was	the	same	
no	matter	how	many	viral	particles	were	used	for	transduction	at	MOIs	ranging	from	0.25–5.0,	while	
MFIs	after	transduction	with	the	lentiviral	supernatant	#215	followed	a	precise	dose	response	(R²	=	
1.00).		
	
	
Figure	18:	Dose	response	curve	fits	of	average	AAT	expression	from	human	MSCs	transduced	with	
gamma-retro-	 and	 lentiviral	 vectors	 at	 MOIs	 ranging	 from	 0.25–5.0	 as	 measured	 by	 MFI	 are	
different.	 At	 the	 lower	 MOIs	 analyzed	 (0.25	 and	 0.75),	 MFIs	 achieved	 with	 the	 gamma-retroviral	
supernatant	were	~25%	higher	than	the	ones	measured	after	transduction	with	the	lentiviral	vector	
(P	 <	 0.01	 and	 P	 <	 0.001,	 respectively);	 however,	 MFIs	 were	 highest	 for	 MSCs	 transduced	 with	
lentiviral	vector	#215	at	MOI	5.0	in	all	3	experiments.	When	comparing	the	2	linear	regression	curves,	
there	 was	 a	 statistically	 significant	 difference	 in	 the	 slopes	 (P	 <	 0.0001).	 Symbols	 represent	 the	
average	of	5	independent	transduction	experiments	for	MOIs	0.25,	0.75,	and	2.5,	and	3	for	MOI	5.0	±	
SD.	Due	 to	 different	 flow	 cytometer	 settings	 used	 for	 acquiring	 the	 data	 in	 different	 experiments,	
values	 were	 normalized	 to	 the	 highest	 MFI	 measured	 in	 each	 experiment	 (=	 100%).	 Statistical	
significance	 of	 differences	 between	MFIs	 generated	with	 both	 supernatants	 at	 the	 same	MOI	was	
calculated	 using	 Sidak’s	 multiple	 comparisons	 test	 (194	 vs.	 215:	 MOI	 0.25:	 ***,		
MOI	0.75:	**,	MOI	2.5:	ns,	MOI	5.0:	ns).	**	P	<	0.01;	***	P	<	0.001.		
In	the	next	step,	the	expression	data	generated	by	flow	cytometry	was	confirmed	by	measurement	of	
transgenic	 AAT	 secreted	 from	 pure	 populations	 of	 transduced,	 selected	 MSCs	 after	 long-term	
expansion.	As	detailed	in	2.2.16,	selected	cells	were	seeded	at	defined	numbers,	supernatants	were	
collected	 after	 48	hours,	 and	AAT	 content	was	determined	by	 ELISA.	 Figure	 19	depicts	 a	 graphical	
representation	of	the	results.	AAT	expression	from	selected	MSCs	measured	by	ELISA	correlated	well	
with	 MFI	 data.	 At	 lower	 MOIs,	 AAT	 expression	 from	 cells	 transduced	 with	 the	 gamma-retroviral	
vector	was	 higher	 by	 the	 factor	 ~1.8	 for	MOI	 0.25	 and	 ~1.5	 for	MOI	 0.75	when	 compared	 to	 the	
results	achieved	with	the	lentiviral	supernatant.	However,	AAT	expression	seemed	to	be	close	to	the	
maximum	already	at	those	MOIs	for	retrovirally	transduced	cells,	and	there	was	only	a	very	modest	
increase	in	average	AAT	secretion	observed	with	rising	MOIs	(from	~2200ng	AAT/1x105	cells/48h	at	
MOI	0.25	 to	~2800ng	AAT/1x105	 cells/48h	at	MOI	5.0).	 In	 contrast,	AAT	yield	 increased	more	 than	
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3.5-fold	from	~1250ng	AAT/1x105	cells/48h	at	MOI	0.25	to	~4500ng	AAT/1x105	cells/48h	at	MOI	5.0	
in	supernatants	harvested	from	lentivirally	modified	MSCs.	However,	none	of	the	differences	of	AAT	
content	at	the	same	MOI	for	both	vectors	reached	statistical	significance,	probably	due	to	high	inter-
donor	 variability.	 However,	 when	 comparing	 the	 linear	 regression	 fits	 of	 the	 average	 AAT	 yields,	
there	 again	 was	 a	 significant	 difference	 between	 both	 regression	 curves,	 confirming	 the	 results	
described	above	in	that	there	is	a	profound	difference	in	gamma-retroviral	and	lentiviral	transduction	
patterns	(P	=	0.0494).		
	
Figure	19:	Dose	response	curve	fits	of	AAT	yield	[ng/1x105	cells/48h]	from	human	MSCs	transduced	
with	 gamma-retro-	 and	 lentiviral	 vectors	 at	MOIs	 ranging	 from	0.25–5.0	as	determined	by	ELISA	
are	different.	At	the	lower	MOIs	analyzed	(0.25	and	0.75),	AAT	contents	achieved	with	the	gamma-
retroviral	 supernatant	 were	 higher	 than	 the	 ones	 measured	 after	 transduction	 with	 the	 lentiviral	
vector	(by	the	factor	of	~1.8	at	MOI	0.25	and	~1.5	at	MOI	.075,	respectively);	however,	AAT	yield	was	
highest	 for	MSCs	 transduced	with	 the	 lentiviral	 supernatant	 at	MOI	 5.0	 in	 all	 experiments.	When	
comparing	the	2	linear	regression	curves,	there	was	a	statistically	significant	difference	in	the	slopes	
(P	 =	 0.0494).	 Symbols	 represent	 the	 average	of	 3	 independent	 transduction	 experiments	 for	MOIs	
0.25,	0.75,	and	2.5,	and	2	for	MOI	5.0	±	SD.	Due	to	the	accidental	use	of	medium	containing	human	
plasma	 and	 thus	 AAT	 for	 the	 production	 of	 cell	 culture	 supernatants	 in	 one	 experiment,	 AAT	
expression	 data	 could	 not	 be	 generated	 for	 one	 of	 the	 donors	 tested	 in	 all	 previous	 experiments.	
Statistical	significance	of	differences	between	AAT	concentrations	generated	with	both	supernatants	
at	the	same	MOI	was	calculated	using	Sidak’s	multiple	comparisons	test	(194	vs.	215:	MOI	0.25:	ns,	
MOI	0.75:	ns,	MOI	2.5:	ns,	MOI	5.0:	ns).	
A	 further	 set	 of	 experiments	 sought	 to	 determine	 if	 AAT	 expression	 per	 viral	 integration	 differed	
depending	on	which	vector	backbone	was	used.	Figure	20	shows	a	graphical	representation	of	AAT	
expression	data	normalized	 to	VCNs.	Average	AAT	expression	per	vector	copy	 in	 samples	collected	
after	 gamma-retroviral	 transduction	 appeared	 slightly	 higher	 than	 that	measured	 for	 the	 lentiviral	
vector	 (gamma-retroviral	 vector:	 [829ng	 AAT/1x105	 cells/48h/VCN];	 lentiviral	 vector:	 [754ng	
AAT/1x105	 cells/48h/VCN]);	 however,	 the	 results	 did	not	 reach	 statistical	 significance	 (P	 =	 0.4856),	
indicating	 that	once	 the	 transgene	cassette	 is	 integrated	 into	 the	host	genome,	gene	expression	 is	
fairly	independent	of	the	viral	backbone	used.	This	finding	is	consistent	with	published	data	329.		
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Figure	 20:	AAT	 yield	 [ng/1x105	 cells/48h]	 from	 human	MSCs	 transduced	with	 gamma-retro-	 and	
lentiviral	vectors	normalized	to	VCN	 is	similar.	AAT	content	 in	supernatants	derived	 from	gamma-
retrovirally	and	lentivirally	transduced	MSCs	was	determined	by	ELISA	(Figure	19)	and	normalized	to	
VCN	(Figure	17).	There	was	no	statistically	significant	difference	between	AAT	yields/VCN	from	both	
vectors.	Symbols	represent	 independent	transduction	experiments,	and	the	horizontal	 lines	denote	
mean.	 Statistical	 significance	was	 calculated	 by	 unpaired	 two-tailed	 t	 test	with	Welch’s	 correction		
(P	 =	 0.4856).	 Gaussian	 distribution	 of	 the	 data	 was	 confirmed	 by	 D'Agostino	 &	 Pearson	 omnibus	
normality	test.		
3.3.2.4. Summary 
These	 results	demonstrate	 that	 transduction	with,	 and	AAT	expression	 from,	 the	gamma-retroviral	
vector	#194	at	varying	MOIs	follows	a	markedly	different	pattern	as	compared	to	the	lentiviral	vector	
#215	 carrying	 the	 same	 expression	 cassette.	 Transduction	 with	 the	 latter	 shows	 a	 steep	 dose	
response	curve	with	low	transduction	efficacies	and	VCNs	at	low	MOIs	and	extremely	high	absolute	
transduction	values	of	close	to	80%	and	VCNs	of	up	to	eight	using	high	MOIs.	The	same	trend	is	true	
for	AAT	expression.	In	contrast,	the	dose	response	curve	generated	by	transduction	with	the	gamma-
retroviral	vector	is	flatter,	indicating	a	less	MOI-dependent	mechanism	of	transduction:	Transduction	
efficacies	 and	 VCNs	 were	 already	 considerably	 high	 even	 at	 low	 MOIs,	 reaching	 an	 average	
normalized	value	of	~50%	of	the	maximum	transduction	possible	and	an	average	VCN	of	2.6	at	MOI	
0.25;	however,	these	values	did	not	appreciably	increase	even	when	20-fold	more	viral	particles	were	
used	 for	 genetic	 modification,	 suggesting	 that	 retroviral	 transduction	 was	 close	 to	 the	 maximum	
possible	already	at	low	MOIs.	This	pattern	was	reflected	by	the	AAT	expression	data	generated	from	
gamma-retrovirally	transduced	MSCs	as	determined	by	MFI	and	AAT	protein	determination	by	ELISA.	
When	 analyzing	 AAT	 expression	 normalized	 to	 viral	 integrations,	 though,	 there	 was	 no	 difference	
between	 the	 vectors,	 indicating	 that	 the	 variations	 observed	 are	 solely	 resulting	 from	 differing	
transduction	characteristics.	
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3.4. Confirmation of functionality of AAT expressed from MSCs 
3.4.1. Transgenic AAT secreted from MSCs is functional 
To	assess	if	AAT	secreted	from	transduced	MSCs	was	functional	with	regards	to	its	actions	as	a	serine	
protease	 inhibitor,	 a	 neutrophil	 elastase	 inhibitor	 screening	 assay	 was	 performed	 as	 detailed	 in	
2.2.17.	Briefly,	 supernatants	of	gamma-retrovirally	and	 lentivirally	 transduced	MSCs	were	collected	
and	 incubated	with	 neutrophil	 elastase	 before	 the	 addition	 of	 a	 fluorescent	 elastase	 substrate.	 In	
case	 of	 inhibition	 of	 neutrophil	 elastase	 by	 the	 supernatant,	 hydrolyzation	 of	 the	 substrate	 was	
reduced,	 resulting	 in	 a	 decreased	 RFU	 output.	 To	 compare	 transgenic	 AAT	 expressed	 from	
transduced	MSCs	 to	 physiological,	 non-transgenic	AAT,	 natural	 full	 length	AAT	 from	human	 serum	
was	 tested	 in	 the	 assay	 as	 a	 commensurable	 positive	 control;	 DMEM	 and	 supernatant	 from	 non-
transduced	MSCs	served	as	negative	controls.		
During	the	establishment	of	the	assay	it	was	determined	that	for	the	test	to	yield	reliable	results,	it	
was	critical	to	generate	cell	culture	supernatants	free	of	serum	as	the	neutrophil	elastase	included	in	
the	kit	is	inhibited	by	the	bovine	AAT	present	in	FBS.	Thus,	the	MSCs	were	subjected	to	five	washes	
with	 PBS	 before	 serum-free	 DMEM	 was	 added.	 During	 the	 16-24-hour	 incubation	 in	 serum-free	
DMEM	many	 of	 the	 cells	 died,	 and	 AAT	 expression	was	 ~four-fold	 lower	 as	 compared	 to	 the	 AAT	
protein	content	usually	generated	from	the	same	number	of	plated	cells	in	medium	containing	serum	
(data	 not	 shown).	 Hence,	 the	 supernatants	 were	 concentrated	 to	 a	 concentration	 of	 [³2000ng	
AAT/mL]	as	measured	by	ELISA.		
Supernatants	collected	from	three	different	batches	of	MSCs	transduced	with	viral	vector	#194	and	
#215,	 respectively,	 were	 analyzed	 using	 the	 neutrophil	 elastase	 inhibitor	 screening	 assay	 and	
compared	to	natural	AAT	from	human	plasma	at	concentrations	ranging	from	[250–2000ng/mL].	 In	
all	experiments,	AAT	secreted	from	MSCs	potently	inhibited	neutrophil	elastase	at	values	comparable	
to	[2000ng/mL]	natural	AAT	(Figure	21).	
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Figure	 21:	 Transgenic	 AAT	 secreted	 from	 primary	 human	 MSCs	 is	 functional.	 Concentrated	
supernatants	 collected	 from	 MSCs	 transduced	 with	 vector	 #194	 and	 #215,	 respectively,	 potently	
inhibit	neutrophil	elastase	comparable	to	[2000ng/mL]	natural	human	AAT.	Supernatants	harvested	
from	 transduced	 and	 native	 MSCs	 derived	 from	 two	 donors	 were	 analyzed	 using	 the	 neutrophil	
elastase	 inhibitor	 screening	 kit	 and	 compared	 to	 natural	 human	 full	 length	 AAT	 protein	 in	
concentrations	 from	 [250–2000ng/mL].	 DMEM	 was	 used	 as	 a	 negative	 control	 yielding	 100%	
neutrophil	 elastase	 activity.	 Bars	 represent	 average	 values	 from	 3	 independent	 transductions	 and		
3–7	independent	supernatant	collections	per	viral	vector	±	SD.	Statistical	significance	of	differences	
between	negative	control	DMEM	and	all	other	samples	tested	was	calculated	applying	the	Kruskal-
Wallis	 test	 (P	 =	 0.0002),	 followed	 by	 Dunn's	 multiple	 comparisons	 test	 (DMEM	 vs.		
[2000ng/mL	AAT]:	 **,	 DMEM	 vs.	 [1000ng/mL	AAT]:	 ns,	 DMEM	 vs.	 [500ng/mL	AAT]:	 ns,	 DMEM	 vs.	
[250ng/mL	 AAT]:	 ns,	 DMEM	 vs.	 SN	 MSCs:	 ns,	 DMEM	 vs.	 SN	 MSCs	 #194:	 *,	 DMEM	 vs.		
SN	MSCs	#215:	*).	*	P	<	0.05;	**	P	<	0.01.	
3.4.2. Transgenic AAT secreted from MSCs is as potent as natural AAT isolated from 
human plasma 
After	confirming	that	AAT	expressed	from	MSCs	was	functional,	we	then	analyzed	whether	there	are	
differences	in	the	potency	of	MSC-AAT	as	compared	to	natural	AAT	from	human	plasma.	To	this	end,	
five	dilutions	of	the	MSC	supernatant	samples	tested	in	3.4.1	were	generated	and	analyzed	using	the	
neutrophil	 elastase	 inhibitor	 screening	 assay.	 AAT	 contents	 in	 these	 samples	 as	 well	 as	 in	 natural	
human	AAT	dilution	samples	were	determined	by	ELISA,	and	neutrophil	elastase	activity	was	plotted	
against	 AAT	 concentration.	 Figure	 22	 shows	 a	 graphic	 representation	 of	 the	 results.	 There	was	 no	
difference	seen	in	the	log(inhibitor)	vs.	response	curve	fit	between	AAT	derived	from	human	plasma	
and	AAT	secreted	from	MSCs	(P	=	0.80),	confirming	that	transgenic	AAT	expressed	from	human	MSCs	
is	equally	potent	as	a	serine	protease	inhibitor	as	natural	AAT	isolated	from	human	plasma.		
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Figure	22:	Transgenic	AAT	secreted	from	transduced	primary	human	MSCs	is	as	potent	as	natural	
AAT	 isolated	 from	human	plasma.	Dilutions	of	 supernatants	collected	 from	MSCs	 transduced	with	
vector	 #194	 and	 #215	 were	 generated,	 and	 inhibition	 of	 neutrophil	 elastase	 was	 assessed.	 AAT	
protein	 content	 in	 diluted	MSC	 supernatant	 samples	 and	 natural	 AAT	 samples	 was	 quantified	 by	
ELISA.	 Only	 samples	 were	 included	 in	 which	 neutrophil	 elastase	 inhibition	 values	 and	 AAT	
concentration	were	measurable	 for	 all	 5	 dilutions	 (MSC-AAT:	 n	 =	 25;	 human	plasma	AAT:	 n	 =	 20).	
Neutrophil	 elastase	 activity	 [%]	was	plotted	against	 log10	 of	AAT	 concentration.	 Curves	were	 fitted	
using	 the	 log(inhibitor)	vs.	 response	model	 (R²	 =	 0.95	 for	AAT	 from	MSCs;	 R²	 =	 0.93	 for	AAT	 from	
human	 plasma).	 There	 was	 no	 statistical	 difference	 between	 both	 groups	 as	 determined	 by	
comparison	of	fits	using	the	Extra	sum-of-squares	F	test	(P	=	0.80).	
3.5. Scale-up, batch generation and characterization 
The	 next	 step	was	 to	 assess	 if	 the	 transduction	 and	 cell	 expansion	 processes	 used	 in	 all	 previous	
experiments	 were	 scalable	 since	 the	 execution	 of	 in	 vivo	 studies	 requires	 large	 quantities	 of	 cells	
from	the	same	batch.	Thus,	we	next	 set	out	 to	produce	 large	batches	of	native	as	well	as	gamma-
retrovirally	 and	 lentivirally	 transduced	 MSCs	 from	 two	 donors	 to	 generate	 a	 supply	 of	 cells	 for	
subsequent	 animal	 studies.	 We	 also	 assessed	 if	 the	 MSCs	 at	 the	 end	 of	 the	 production	 process	
fulfilled	specifications	of	MSC	quality	parameters	(expression	of	typical	surface	markers,	adipogenic	
and	osteogenic	differentiation,	 sterility,	 testing	 for	Mollicutes).	We	also	determined	whether	 there	
was	 a	 difference	 between	 non-modified	 and	 gene-modified	 MSCs,	 and	 if	 the	 cell	 donor	 had	 an	
impact	on	the	outcome	of	the	aforementioned	parameters.		
3.5.1. Surface marker expression 
Flow	 cytometric	 analyses	 of	 surface	 antigen	 expression	 revealed	 that	 values	 were	 comparable	
between	 the	 two	 donors,	 AP00158	 and	 AP00208,	 as	 well	 as	 between	 non-modified	 and	 gene-
modified	MSCs,	and	that	all	four	batches	fulfilled	surface	marker	specifications	(Table	13).	In	all	four	
batches,	 MSC	 content	 was	 well	 above	 90%	 as	 measured	 by	 the	 expression	 of	 CD73,	 CD90,	 and	
CD105,	and	there	were	only	traces	of	contaminating	hematopoietic	cells	such	as	HSCs,	lymphocytes,	
erythrocytes	 or	 thrombocytes	 as	 confirmed	 by	 the	 lack	 of	 cells	 expressing	 CD45,	 CD34,	 CD235a,	
CD41,	CD3,	CD19,	and	CD14.		
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Table	13:	Expression	of	MSC	and	hematopoietic	 surface	markers	on	 four	MSC	batches	generated	
from	 2	 donors.	 Native	 and	 transduced	 MSC	 batches	 from	 two	 donors	 (AP00158	 and	 AP00208)	
consisted	 of	 >90%	 MSCs,	 and	 levels	 of	 contaminating	 hematopoietic	 cells	 were	 below	 3%	 in	 all	
samples	as	analyzed	by	flow	cytometry.		
Parameter	 Specification	 AP00158	native	
AP00158	
TD	#194	
AP00208	
native	
AP00208	
TD	#215	
Vital	cells	(7AAD-)	[%]	 >80	 95.43	 94.69	 98.61	 91.68	
MSCs	(CD73+/CD90+,	CD34-/CD45-)	[%]	 >90	 92.22	 96.94	 97.66	 92.78	
MSCs	(CD105+,	CD34-/CD45-)	[%]	 >90	 95.77	 95.57	 98.42	 95.71	
HSCs	(CD45+/CD34+)	[%]	 <10	 0.05	 0.07	 0.00	 0.00	
Erythrocytes	(CD235a+)	[%]	 <10	 0.11	 0.07	 0.00	 0.02	
Thrombocytes	(CD41+)	[%]	 <10	 1.63	 2.78	 0.44	 0.89	
T-Lymphocytes	(CD45+/CD3+)	[%]	 <10	 0.00	 0.03	 0.00	 0.00	
B-Lymphocytes	(CD45+/CD19+)	[%]	 <10	 0.00	 0.04	 0.00	 0.00	
Monocytes	(CD45+/CD14+)	[%]	 <10	 0.00	 0.01	 0.00	 0.00	
	
Figure	 23	 depicts	 representative	 flow	 cytometry	 plots	 of	 native	 as	 well	 as	 gamma-retrovirally	
transduced	 MSCs	 from	 one	 donor	 stained	 with	 the	 different	 fluorescently	 labeled	 antibodies	
detecting	MSC	and	hematopoietic	surface	antigens.		
3.5.2. Adipogenic and osteogenic differentiation capability 
After	confirming	that	there	were	no	differences	in	the	MSC	phenotype	between	the	two	donors	and	
between	non-modified	and	modified	cells,	adipogenic	and	osteogenic	differentiation	capabilities	of	
the	MSCs	were	analyzed	as	an	additional	measure	of	quality.	Cells	from	all	four	batches	were	able	to	
differentiate	 into	 adipocytes	 as	 determined	 by	 Oil	 Red	 O	 staining	 as	 well	 as	 into	 osteoblasts	 as	
assessed	by	Alizarin	Red	staining.	These	results	suggest	that	the	genetic	modifications	performed	did	
not	 alter	 adipogenic	 and	 osteogenic	 differentiation	 capabilities	 of	 the	 engineered	MSCs,	 and	 that	
donors	 AP00158	 and	 AP00208	 are	 comparable	 in	 that	 regard.	 Figure	 24	 shows	 representative	
pictures	 of	 native	 and	 gamma-retrovirally	 transduced	MSCs	 from	 donor	 AP00158	 after	 adipogenic	
and	osteogenic	differentiation.		
3.5.3. Additional parameters 
In	 a	next	 step,	we	characterized	 the	 cell	 yields	 in	 the	 four	batches	produced.	 It	was	possible	 in	all	
cases	to	produce	quantities	>1.5x108	MSCs	(Table	14	and	Table	15),	sufficient	for	the	execution	of	a	
series	 of	 in	 vivo	 studies,	 and	 to	 cryopreserve	 the	 cells	 in	 passage	 five.	 The	 batch	 of	 lentivirally	
transduced	 cells	derived	 from	donor	AP00208	was	expanded	on	 six	5-layer	 cell	 stack	 systems;	 this	
explains	 the	high	cell	yield	of	4.63x108,	about	 twice	 the	amount	of	cells	harvested	 for	 the	gamma-
retrovirally	transduced	batch	(donor	AP00158),	which	was	expanded	on	three	5-layer	cell	stacks.	The	
batches	were	 tested	 for	 sterility	 and	 for	 the	presence	of	Mollicutes	 as	part	of	a	 standard	panel	of	
quality	 control	 assays	 for	 MSCs,	 and	 these	 specifications	 were	 also	 met.	 Batches	 of	 gamma-
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retrovirally	 and	 lentivirally	 modified	 MSCs	 were	 additionally	 characterized	 regarding	 transduction	
efficacy,	outcome	of	the	antibiotic	selection	procedure,	VCN	in	the	bulk	population	of	selected	cells,	
AAT	 protein	 yield	 per	 1x105	 cells	 in	 48	 hours	 normalized	 to	 VCN,	 and	 the	 capacity	 to	 inhibit	
neutrophil	elastase	in	comparison	to	natural	AAT	purified	from	human	plasma.		
	
	
Figure	23:	Representative	flow	cytometry	plots	of	native	and	gamma-retrovirally	transduced	MSCs	
from	 donor	 AP00158	 stained	 for	 MSC	 and	 hematopoietic	 surface	 markers.	 Native	 and	 gamma-
retrovirally	 transduced	cells	were	negative	 for	hematopoietic	markers	 (CD45,	CD34,	CD235a,	CD41,	
CD3,	CD19,	and	CD14),	but	positive	for	MSC	markers	(CD73,	CD90,	CD105).	Histogram	plots	show	an	
overlay	of	results	generated	by	staining	the	cells	with	an	isotype	control	antibody	(white	peak)	and	
with	an	antibody	specific	to	the	antigen	denominated	in	the	graph	above	the	histogram	plot	(colored	
peak).	 Colors	 represent	 the	 fluorochromes	 the	 respective	 antibodies	 are	 labeled	 with:	 green	 =	
fluorescein	isothiocyanate	(FITC),	yellow	=	R-phycoerythrin	(PE),	orange	=	energy	coupled	dye	(ECD),	
purple	=	phycoerythrin-cyanin-7	(PC7).		
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Figure	 24:	 Differentiation	 capabilities	 of	 native	 and	 gamma-retrovirally	 transduced	 MSCs	 are	
comparable.	No	difference	in	the	differentiation	potential	of	native	and	transduced	MSCs	was	seen	
after	adipogenic	and	osteogenic	differentiation	and	subsequent	staining.	Shown	are	 representative	
pictures	of	cells	derived	from	donor	AP00158.		
For	 the	 AAT-expressing	 MSCs	 there	 are	 at	 present	 no	 standard	 specifications	 regarding	 these	
parameters,	thus	specifications	were	chosen	based	on	empirical	“good”	values	generated	in	various	
previous	experiments.	As	these	genetically	modified	cells	were	to	be	used	for	 in	vivo	studies	at	our	
collaborators’	 non-biosafety	 level	 (BSL)	 2	 facilities,	 transduced	MSC	 batches	 were	 assayed	 for	 the	
presence	 of	 replication-competent	 retrovirus	 (RCR)	 and	 replication-competent	 lentivirus	 (RCL),	
respectively;	both	tested	negative.	The	results	of	all	tests	performed	are	summarized	in	Table	14	and	
Table	15.	
Table	14:	Characteristics	of	native	MSC	batches	derived	from	donors	AP00158	and	AP00208.	MSCs	
fulfilled	 standard	 specifications	 regarding	 sterility,	 expression	 of	 surface	 markers,	 differentiation	
potential,	and	testing	for	Mollicutes;	inter-donor	variability	was	negligible	for	the	parameters	tested.		
Native	MSC	batches	 	 	 	
Parameter	 Specification	 AP00158	native	 AP00208	native	
Donor	 	 AP00158	 AP00208	
Number	of	cryopreserved	cells	
[x106]	 N.a.	 245	 164	
Sterility	 No	growth	of	bacteria	or	fungi	
No	growth	of	
bacteria	and	fungi	
No	growth	of	
bacteria	and	fungi	
Surface	marker	expression	 All	surface	makers	within	specification	(cf.	Table	13)	 Yes	 Yes	
Adipogenic	differentiation	 Several	adipocytes	visible	 Yes	 Yes	
Osteogenic	differentiation	 Osteogenic	mineralization	visible	 Yes	 Yes	
Testing	for	Mollicutes	 Negative	 Negative	 Negative	
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Table	 15:	 Specifications	 of	 genetically	modified	MSC	 batches	 derived	 from	 donors	 AP00158	 and	
AP00208.	 MSCs	 fulfilled	 standard	 specifications	 regarding	 sterility,	 expression	 of	 surface	 markers,	
differentiation	 potential,	 and	 testing	 for	 Mollicutes;	 inter-donor	 variability	 was	 negligible	 for	 the	
parameters	tested.	Transduced	MSCs	also	fulfilled	self-chosen	specifications	for	the	values	of	%AAT-
positive	 cells	 before	 and	 after	 antibiotic	 treatment,	 VCN,	 AAT	 protein	 yield,	 and	 the	 potential	 to	
inhibit	neutrophil	elastase.		
Gene-modified	MSC	batches	 	 	 	
Parameter	 Specification	 AP00158	TD	#194	 AP00208	TD	#215	
Donor	 	 AP00158	 AP00208	
Number	of	cryopreserved	cells	
[x106]	 N.a.	 230	 463	
Sterility	 No	growth	of	bacteria	or	fungi	
No	growth	of	
bacteria	and	fungi	
No	growth	of	
bacteria	and	fungi	
Surface	marker	expression	 All	surface	makers	within	specification	(cf.	Table	13)	 Yes	 Yes	
Adipogenic	differentiation	 Several	adipocytes	visible	 Yes	 Yes	
Osteogenic	differentiation	 Osteogenic	mineralization	visible	 Yes	 Yes	
Testing	for	Mollicutes	 Negative	 Negative	 Negative	
%	AAT	positive	pre-selection	 >25%	 72,9	 54,0	
%	AAT	positive	post-selection	 >90%	 96,2	 93,9	
VCN	 1.0-5.0	 1,7	 2,4	
AAT	protein	expression		
[ng/105	cells/48h/VCN]	 >250	 595	 369	
Neutrophil	elastase	inhibition	
assay	
Neutrophil	elastase	
inhibition	comparable	to	
AAT	from	human	plasma	
Yes	 Yes	
Testing	for	RCR/RCL	 Negative	 Negative	 Negative	
	
In	 summary,	 all	 batches	 fulfilled	 the	 specifications	 of	 the	 standard	 quality	 parameters.	 Values	 for	
native	 and	 genetically	 modified	MSCs	 were	 comparable,	 and	 also	 inter-donor	 variability	 between	
AP00158	and	AP00208	was	limited	for	the	parameters	tested.		
These	results	suggest	that	the	development	of	a	large	scale	procedure	of	transduction	and	expansion	
of	 AAT-modified	 MSCs	 was	 successful,	 and	 that	 genetic	 modification	 with	 gamma-retroviral	 or	
lentiviral	vectors	for	expression	of	human	AAT	does	not	alter	the	established	quality	parameters	from	
the	 panel	 of	 standard	 assays.	 Moreover,	 both	 gene-modified	 batches	 fulfilled	 all	 self-chosen	
specifications	believed	to	be	a	 reflection	of	“good”	AAT-expressing	MSCs,	and	differences	between	
the	 batches	were	minor.	 Transduction	 efficacies	were	 high	 for	 each	 batch;	 VCNs	were	well	 in	 the	
range	 of	 what	 has	 been	 considered	 safe	 in	 previous	 gene	 therapy	 clinical	 trial	 protocols	 192.	 AAT	
protein	expression	from	both	batches	was	above	the	threshold	chosen	to	characterize	“good”	levels	
of	AAT	expression.	Assaying	of	MSCs	 from	both	batches	 in	 the	neutrophil	 elastase	 assay	 led	 to	 an	
inhibition	of	 the	 elastase	 comparable	 to	 that	 yielded	with	 natural	 AAT	 from	human	plasma	 at	 the	
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same	 concentration.	 Taken	 together,	we	 can	 conclude	 that	 the	 scale-up	 of	 the	 processes	 and	 the	
production	of	comparable	batches	of	native	and	AAT-expressing	MSCs	for	use	in	in	vivo	experiments	
were	successful.		
3.6. In vivo proof of concept study 
3.6.1. Elastase-induced lung emphysema – experimental design 
The	 in	 vivo	 experiments	 described	 in	 this	 work	 were	 conducted	 in	 collaboration	 with	 Ali	 Önder	
Yildirim’s	group	at	the	Comprehensive	Pneumology	Center	at	the	Helmholtz	Zentrum	München.	
To	assess	if	native	and	AAT-MSCs	were	able	to	generate	a	therapeutical	benefit	 in	an	inflammatory	
lung	 disease	 in	 vivo,	 the	 well-established	 model	 of	 elastase-induced	 lung	 emphysema	 331,341	 was	
applied	 in	 order	 to	 represent	 the	 emphysema	 observed	 in	 human	 COPD.	 Female	 C57BL/6N	mice	
were	 divided	 into	 four	 groups	 consisting	 of	 six	 mice	 each	 (Table	 12):	 Mice	 in	 group	 1	 served	 as	
negative	 controls	 and	 received	 PBS,	 while	 mice	 in	 all	 other	 groups	 were	 treated	 with	 a	 single	
intratracheal	 instillation	 of	 porcine	 pancreatic	 elastase	 on	 day	 0.	Mice	 in	 positive	 control	 group	 2	
additionally	 received	an	oropharyngeal	application	of	 saline	on	day	7,	while	mice	 in	group	3	and	4	
were	 oropharyngeally	 instilled	with	 5x105	 native	MSCs,	 and	 5x105	MSCs	modified	 to	 express	 AAT,	
respectively.	On	day	14,	native	and	AAT-MSC	application	in	groups	3	and	4	was	repeated.	Before	the	
mice	 were	 sacrificed	 on	 day	 21	 for	 histological	 and	 BALF	 analysis,	 they	 were	 anesthetized,	
tracheostomized,	and	 lung	 function	measurements	performed	using	 the	Buxco	pulmonary	 function	
testing	system.	One	mouse	in	the	PBS-treated	group	had	to	be	excluded	from	the	analysis	due	to	the	
development	 of	 spontaneous	 emphysema	 (probably	 resulting	 from	 a	 confusion	 of	 this	mouse	 and	
subsequent	inadvertent	elastase	instillation;	A.	Ö.	Yildirim,	personal	communication),	and	one	mouse	
died	in	each	of	the	groups	receiving	elastase	only,	and	elastase	plus	native	MSCs.	The	mouse	in	the	
group	 receiving	 elastase	 only	 died	 shortly	 before	 completion	 of	 the	 pulmonary	 function	 analyses;	
however,	 it	 was	 possible	 to	 perform	 histological	 analyses.	 For	 that	 reason,	 pulmonary	 function	
measurements	generated	from	five	mice	could	be	analyzed	in	the	groups	treated	with	PBS,	elastase,	
and	 elastase	 plus	 native	MSCs,	 and	 from	 six	mice	 in	 the	 group	 receiving	 elastase	 plus	 AAT-MSCs;	
BALF	 and	 histology	 could	 be	 analyzed	 from	 five	 mice	 in	 the	 PBS	 and	 elastase	 plus	 native	 MSCs	
groups,	and	from	six	mice	in	the	elastase	only	and	elastase	plus	AAT-MSCs	groups.		
3.6.2. Amelioration of pulmonary function after treatment with AAT-MSCs 
Instillation	of	 porcine	pancreatic	 elastase	 in	mouse	 lungs	 is	 known	 to	 induce	 a	 breakdown	of	 lung	
tissue	 and	 a	 severe	 destruction	 of	 small	 airways	 that	 is	 comparable	 to	 emphysema	 in	 COPD	
patients	342.	The	model	leads	to	the	formation	of	large	air	pockets	that	replace	lung	tissue	resulting	in	
a	 dramatic	 increase	 of	 lung	 function	 parameters	 343.	 We	 observed	 this	 increase	 in	 pulmonary	
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measures	 in	mice	 receiving	 a	 single	 application	of	 elastase	 compared	 to	PBS-treated	animals	 in	 all	
parameters	analyzed;	however,	all	statistical	analyses	(Figure	25)	were	performed	by	comparing	the	
results	measured	in	groups	3	and	4	(“treatment	groups”	receiving	native	and	AAT-MSCs,	respectively)	
to	 the	 values	 measured	 in	 the	 elastase	 group	 (“disease	 group”)	 in	 order	 to	 assess	 a	 potential	
therapeutic	 effect	 of	 MSC	 treatment	 –	 the	 main	 focus	 of	 the	 current	 work.	 We	 observed	 a	
statistically	 significant	 improvement	 in	 lung	 function	 as	 expressed	 by	 parameters	 measuring	
expiratory	airflow	(forced	expiratory	volume	in	100ms	(FEV100ms):	P	<	0.05,	forced	vital	capacity	(FVC):	
P	 <	 0.01;	 Figure	 25A	 and	 Table	 16),	 chord	 compliance	 (Cchord),	 a	measure	 of	 the	 lung’s	 ability	 to	
stretch	and	expand	(Cchord:	P	<	0.001;	Figure	25B	and	Table	16),	as	well	as	inspiratory	capacity	(IC:		
P	<	0.01)	and	vital	capacity	(VC:	P	<	0.05,	Figure	25C	and	Table	16)	in	the	group	in	which	mice	were	
treated	with	AAT-MSCs	in	comparison	to	the	elastase	group.	The	most	striking	amelioration	was	seen	
in	Cchord,	from	an	average	of	0.0929mL/cmH2O	in	the	elastase-treated	group	to	0.0718	in	the	AAT-
MSC	group	(average	in	the	PBS	group	=	0.0431),	amounting	to	an	improvement	of	this	parameter	by	
42.3%	assuming	that	values	in	the	PBS	group	are	equal	to	100%	improvement.	FEV100ms	and	FVC,	the	
two	 parameters	 the	 diagnosis	 of	 human	 COPD	 is	 based	 on,	 were	 improved	 by	 31.0%	 and	 25.7%,	
respectively.	The	P-value	 for	dynamic	 compliance	 (Cdyn)	was	not	 statistically	 significant	 (P	 =	0.18);	
however,	 the	 same	 trend	 towards	 an	 amelioration	 was	 visible	 as	 for	 the	 other	 parameters	
determined.	 In	 some	of	 the	parameters	analyzed	 (e.g.	 FEV100ms,	 IC)	we	could	observe	an	 indication	
that	treatment	with	native	MSCs	might	as	well	be	beneficial,	however,	comparison	of	these	results	
with	 the	 values	 measured	 in	 the	 elastase-treated	 group	 never	 reached	 statistical	 significance,	
indicating	that	AAT	overexpression	is	required	to	achieve	a	clear	therapeutic	benefit	in	this	model.		
3.6.3. Amelioration of emphysema after treatment with AAT-MSCs 
Next,	 it	 was	 assessed	 whether	 MSC	 treatment	 had	 an	 effect	 on	 the	 emphysema	 present	 in	 this	
model.	To	that	end,	airspace	enlargement	was	quantified	in	H&E	stained	sections	(Figure	26A)	of	lung	
tissue	using	an	emphysema	score	from	0-5	(Figure	26B	and	Table	17).	A	noticeable	amelioration	of	
pulmonary	 tissue	 destruction	 was	 observed	 after	 treatment	 with	 native	 MSCs,	 as	 indicated	 by	 a	
decrease	in	the	average	emphysema	score	from	4.25	±	0.61	in	the	elastase	group	to	3.50	±	0.50	in	
the	mouse	group	receiving	native	MSCs	(equal	to	an	amelioration	of	17.6%	assuming	that	the	score	
of	 elastase-treated	 mice	 corresponds	 to	 100%),	 suggesting	 that	 treatment	 with	 MSCs	 led	 to	
regeneration	 or	 repair	 of	 the	 injured	 lung	 tissue.	 However,	 a	 much	 more	 dramatic	 decrease	 in	
emphysema	was	noticed	when	mice	were	treated	with	AAT-MSCs	(from	4.25	±	0.61	in	the	elastase	
group	to	2.17	±	0.75;	P	<	0.001,	equal	to	an	amelioration	of	49.0%),	indicating	that	the	combination	
of	 AAT	 and	 MSCs	 resulted	 in	 a	 more	 than	 additive	 beneficial	 effect	 that	 led	 to	 an	 enhanced	
amelioration	of	pulmonary	tissue	injury.		
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Figure	25:	Treatment	with	AAT-MSCs	leads	to	improved	pulmonary	function	in	a	model	of	elastase-
induced	 emphysema	 (collaboration	 with	 A.Ö.	 Yildirim/CPC).	 Lung	 function	 parameters	 were	
measured	using	the	Buxco	forced	pulmonary	maneuver	system.	A:	Expiratory	airflow.	A	statistically	
significant	 beneficial	 effect	 of	 treatment	 with	 AAT-MSCs	 was	 observed	 for	 both	 parameters	
describing	expiratory	airflow	 (FEV100ms:	P	 <	0.05,	 FVC:	P	 <	0.01),	equaling	an	amelioration	of	31.0%	
and	 25.7%,	 respectively.	 B:	 Lung	 compliance.	 While	 application	 of	 AAT-MSCs	 led	 to	 a	 highly	
statistically	 significant	 decrease	 in	 Cchord	 (P	 <	 0.001;	 42.3%	 improvement),	 a	 trend	 towards	
amelioration	 of	 Cdyn	 (P	 =	 0.18)	was	 observed	 after	 treatment	with	 AAT-MSCs.	C:	 Inspiratory	 and	
vital	capacity.	For	IC	as	well	as	VC,	a	statistically	significant	improvement	after	treatment	with	AAT-
MSCs	was	measured	 (IC:	P	 <	 0.01,	VC:	P	 <	 0.05),	 equal	 to	 an	amelioration	of	 these	parameters	by	
30.9%	and	21.7%,	respectively.	MSC-	and	AAT-MSC-treated	groups	were	compared	to	mice	receiving	
elastase	 only	 for	 all	 parameters.	 Each	 symbol	 represents	 one	 mouse;	 the	 horizontal	 lines	 denote	
means.	Statistical	significance	of	differences	between	the	elastase	group	and	the	groups	treated	with	
native	 MSCs	 and	 AAT-MSCs,	 respectively,	 was	 calculated	 applying	 ordinary	 one-way	 ANOVA,	
followed	 by	 Dunnett's	 multiple	 comparisons	 test.	 Normality	 of	 the	 data	 was	 confirmed	 by	 the	
Kolmogorov-Smirnov	normality	test.	*	P	<	0.05;	**	P	<	0.01;	***	P	<	0.001.	Only	the	clinically	most	
significant	parameters	 are	presented	 in	 this	 figure;	 results	 for	 resistance	 (RI),	 peak	expiratory	 flow	
(PEF),	and	expiratory	reserve	volume	(ERV)	are	depicted	in	Supplemental	figure	19.		
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Table	 16:	 Pulmonary	 function	 measurements	 (collaboration	 with	 A.Ö.	 Yildirim/CPC).	 Shown	 are	
average	 values	 measured	 for	 FEV100ms,	 FVC,	 Cdyn,	 Cchord,	 IC,	 and	 VC	 ±	 SD.	 n	 =	 5	 for	 the	 groups	
receiving	PBS,	elastase,	and	elastase	+	MSCs,	and	n	=	6	for	the	group	receiving	elastase	+	AAT-MSCs.	
	
PBS	 Elastase	 Elastase	+	MSCs	 Elastase	+	AAT-MSCs	
	
Average	 SD	 Average	 SD	 Average	 SD	 Average	 SD	
FEV100ms	 0,6982	 0,0534	 1,1305	 0,0616	 1,0751	 0,0927	 0,9964	 0,0591	
FVC	 0,7075	 0,0538	 1,5133	 0,0797	 1,4853	 0,1044	 1,3062	 0,0672	
Cdyn	 0,0245	 0,0028	 0,0519	 0,0061	 0,0574	 0,0084	 0,0440	 0,0079	
Cchord	 0,0431	 0,0048	 0,0929	 0,0068	 0,0921	 0,0068	 0,0718	 0,0060	
IC	 0,5833	 0,0414	 1,2372	 0,0828	 1,2021	 0,0789	 1,0558	 0,0462	
VC	 0,7702	 0,0756	 1,6131	 0,0758	 1,6139	 0,1380	 1,4299	 0,0795	
	
	
Figure	 26:	 Treatment	 with	 AAT-MSCs	 leads	 to	 significant	 lung	 tissue	 repair/regeneration	
(collaboration	with	A.Ö.	 Yildirim/CPC).	A:	 Representative	 photomicrographs	 of	H&E-stained	 lung	
sections.	 Treatment	 with	 MSCs	 and	 AAT-MSCS	 led	 to	 repair	 and	 regeneration	 of	 lung	 tissue,	 as	
indicated	 by	 a	 decrease	 in	 airspace	 enlargement	 noticeable	 in	 the	 respective	 slides.	 Shown	 are	
representative	slides	from	one	mouse	each	treated	with	PBS,	elastase,	elastase	plus	native	MSCs,	and	
elastase	plus	AAT-MSCs.	B:	Marked	amelioration	of	emphysema	in	AAT-MSC-treated	mice.	Airspace	
enlargement	was	assessed	by	using	an	emphysema	scoring	 system	 ranging	 from	0–5.	Each	 symbol	
represents	 one	 mouse;	 the	 horizontal	 lines	 denote	 means.	 Gaussian	 distribution	 of	 the	 data	 was	
analyzed	by	 the	Kolmogorov-Smirnov	normality	 test.	 Statistical	 significance	of	differences	between	
the	 elastase	 group	 and	 the	 groups	 treated	 with	 native	 MSCs	 and	 AAT-MSCs,	 respectively,	 was	
calculated	applying	ordinary	one-way	ANOVA,	followed	by	Dunnett's	multiple	comparisons	test.	***	
P	<	0.001.	
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Table	 17:	 Emphysema	 scoring	 results	 (collaboration	 with	 A.Ö.	 Yildirim/CPC).	 Shown	 are	 the	
emphysema	scoring	results	for	mice	in	all	groups.	
Mouse	No.	 PBS	 Elastase	 Elastase		+	MSCs	
Elastase		
+	AAT-MSCs	
1	 0,0	 4,0	 3,0	 2,0	
2	 0,0	 5,0	 4,0	 2,0	
3	 excluded	 4,0	 3,0	 3,0	
4	 0,0	 3,5	 3,5	 3,0	
5	 0,0	 5,0	 4,0	 1,0	
6	 1,0	 4,0	 died	 2,0	
	
3.6.4. Increased inflammation scoring after treatment with MSCs 
When	designing	this	in	vivo	study,	we	were	aware	of	the	possibility	that	the	administration	of	human	
cells	 expressing	 a	 human	 protein	 to	 immunocompetent	 mice	 might	 cause	 an	 immune	 response	
against	the	foreign	antigens.	Moreover,	during	the	histopathologic	examination	of	the	H&E	sections	
in	 the	 context	 of	 the	 assessment	 of	 the	 emphysema	 scoring	 an	 increase	 of	 inflammatory	 cell	
recruitment	to	the	lungs	of	mice	treated	with	MSCs	and	AAT-MSCs	was	observed	(Figure	27A).	Thus,	
in	a	next	step	an	analysis	of	the	 inflammation	score	was	performed	using	a	scoring	system	ranging	
from	 0–3	 (Table	 18).	 As	 graphically	 represented	 in	 Figure	 27B,	 there	 was	 a	 marked	 increase	 in	
inflammation	 score	 from	 0	 ±	 0	 in	 the	 elastase	 group	 to	 1.50	 ±	 1.0	 in	 the	 group	 receiving	 MSCs		
(P	<	0.01)	and	to	1.83	±	0.75	in	the	group	treated	with	AAT-MSCs	(P<	0.001).	 It	 is	possible	that	this	
inflammatory	 response	 results	 from	 the	 application	 of	 human	MSCs	 and	 human	MSCs	 expressing	
human	AAT	in	immunocompetent	mice,	fostering	an	immune	response	against	the	foreign	cells	and	
protein.		
3.6.5. Analysis of total and differential cell counts in the BALF 
To	further	analyze	the	inflammation	in	the	lungs	of	the	mice,	and	to	further	assess	if	treatment	with	
MSCs	and	AAT-MSCs	had	a	beneficial	effect	on	the	inflammation	caused	by	the	elastase	treatment,	
bronchoalveolar	lavage	(BAL)	was	performed	by	instilling	the	lungs	of	the	mice	with	PBS.	Total	and	
differential	cell	counts	analyzing	the	recruitment	of	inflammatory	cells	such	as	neutrophils,	
macrophages,	and	lymphocytes	were	measured.	A	graphical	representation	of	the	results	is	shown	in		
Figure	 28	 and	 a	 summary	 of	 the	 data	 presented	 in	 Table	 19.	 As	 for	 the	 pulmonary	 function	
parameters	described	 in	3.6.2,	we	were	mainly	 interested	 in	 the	possible	effect	of	our	 “treatment	
groups”	in	comparison	to	the	“disease	group”.	Thus,	analyses	of	statistical	significance	were	carried	
out	 by	 comparing	 values	measured	 for	 the	MSC-treated	 groups	vs.	 the	 elastase	 only	 group.	 There	
was	 no	 significant	 difference	 in	 total	 cell	 numbers	 in	 these	 three	 groups;	 however,	 a	 statistically	
significant	 increase	 in	 absolute	 average	 lymphocyte	 and	 eosinophil	 counts	 in	 the	 mouse	 group	
Results   
	
76 
receiving	AAT-MSCs	as	compared	to	the	elastase	only	group	(lymphocytes:	from	4076	±	2638	in	the	
elastase	group	 to	19240	±	 3499	 in	 the	AAT-MSC	group;	P	<	0.001;	 eosinophils:	 from	0	 to	19775	±	
11171;	P	 <	0.01)	was	noted;	 a	marked	 rise	 in	 these	 cell	 numbers	was	 also	observed	 in	 the	 groups	
treated	 with	 native	 MSCs,	 however,	 statistical	 significance	 was	 only	 reached	 for	 lymphocytes		
(P	 <	 0.01).	 Concomitant	 with	 these	 results	 was	 a	 tendency	 towards	 decreased	 numbers	 of	
macrophages	in	both	groups	treated	with	MSCs	(from	100778	±	22579	in	the	elastase	group	to	75453	
±	 39084	 in	 the	 MSC-treated	 group,	 and	 to	 78631	 ±	 23263	 in	 the	 AAT-MSC	 group),	 as	 well	 as	
neutrophils	 in	 the	AAT-MSC	group	(from	730	±	390	 in	 the	elastase	group	to	450	±	722	 in	 the	AAT-
MSC	 group).	 Taken	 together,	 these	 results	 indicate	 that	 an	 immune	 reaction	 to	 the	 instilled	 cells	
might	be	happening	 in	the	mice	that	received	MSCs,	while	at	 the	same	time	a	tendency	towards	a	
decrease	of	the	cell	types	involved	in	emphysema	development	is	noticeable.		
Next,	the	relative	proportions	of	each	cell	type	were	analyzed	(Figure	29).	As	expected,	percentages	
of	 lymphocytes	and	eosinophils	were	markedly	 increased	 in	both	mouse	groups	treated	with	MSCs	
compared	 to	 the	 group	 receiving	 elastase	 only	 (lymphocytes:	 MSCs:		
P	 <	 0.0001,	 AAT-MSCs:	 P	 <	 0.0001;	 eosinophils:	 MSCs:	 P	 <	 0.05,	 AAT-MSCs:	 P	 <	 0.001),	 and	
percentages	of	macrophages	were	significantly	decreased	(MSCs:	P	<	0.0001,	AAT-MSCs:	P	<	0.0001).		
	
Figure	 27:	 Treatment	 with	 AAT-MSCs	 leads	 to	 significant	 increase	 in	 inflammation	 scoring	
(collaboration	with	A.Ö.	 Yildirim/CPC).	 A:	 Representative	 photomicrographs	 of	H&E-stained	 lung	
sections.	 Instillation	 of	MSCs	 and	 AAT-MSCs	 leads	 to	 inflammatory	 cell	 recruitment	 to	 the	mouse	
lungs.	Shown	are	representative	slides	from	one	mouse	each	treated	with	PBS,	elastase,	elastase	plus	
native	MSCs,	 and	 elastase	 plus	AAT-MSCs.	B:	 Significant	 increase	 of	 inflammation	 score	 in	 native	
and	 AAT-MSC-treated	 mice.	 Inflammation	 score	 was	 assessed	 by	 using	 a	 scoring	 system	 ranging	
from	 0–3.	 Each	 symbol	 represents	 one	 mouse;	 the	 horizontal	 lines	 denote	 means.	 Gaussian	
distribution	 of	 the	 data	 was	 analyzed	 by	 the	 Kolmogorov-Smirnov	 normality	 test.	 Statistical	
significance	of	differences	between	the	elastase	group	and	the	groups	treated	with	native	MSCs	and	
AAT-MSCs,	 respectively,	 was	 calculated	 applying	 ordinary	 one-way	 ANOVA,	 followed	 by	 Dunnett's	
multiple	comparisons	test.	**	P	<	0.01;	***	P	<	0.001.	
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Table	 18:	 Inflammation	 scoring	 results	 (collaboration	 with	 A.Ö.	 Yildirim/CPC).	 Shown	 are	 the	
inflammation	scoring	results	for	mice	in	all	groups.		
Mouse	No.	 PBS	 Elastase	 Elastase		+	MSCs	
Elastase		
+	AAT-MSCs	
1	 0,0	 0,0	 0,0	 1,0	
2	 0,0	 0,0	 2,0	 2,0	
3	 excluded	 0,0	 1,0	 2,0	
4	 0,0	 0,0	 2,0	 3,0	
5	 0,0	 0,0	 2,5	 1,0	
6	 0,0	 0,0	 died	 2,0	
	
	
Figure	28:	Increase	in	absolute	numbers	of	lymphocytes	and	eosinophils	after	treatment	with	AAT-
MSCs	 (collaboration	 with	 A.Ö.	 Yildirim/CPC).	No	 significant	 difference	 in	 total	 cell	 numbers	 was	
noted.	A	statistically	 significant	 increase	 in	 the	absolute	number	of	 lymphocytes	and	eosinophils	 in	
mice	 receiving	 AAT-MSCs	 in	 comparison	 to	 mice	 treated	 with	 elastase	 only	 was	 observed	
(lymphocytes:	P	<	0.001,	eosinophils:	P	<	0.01).	The	same	effect	was	noted	for	native	MSCs;	however,	
statistical	 significance	was	 only	 reached	 for	 lymphocytes	 (P	 <	 0.01).	 Accompanied	 by	 these	 results	
was	 a	 trend	 towards	 lower	macrophage	 counts	 in	 both	 groups	 treated	with	MSCs,	 and	 neutrophil	
counts	in	the	AAT-MSC	groups.	Mouse	lungs	were	lavaged	3	times	with	PBS,	cells	were	pelleted,	and	
the	 pellet	 resuspended	 in	medium	 for	 the	 total	 cell	 count.	 Cytospins	 of	 the	 cell	 suspension	 were	
prepared	 for	 differential	 cell	 counting.	 MSC-treated	 groups	 were	 compared	 to	 mice	 receiving	
elastase	 only	 for	 all	 cell	 types.	 Each	 symbol	 represents	 one	 mouse;	 the	 horizontal	 lines	 denote	
means.	Gaussian	distribution	of	 the	data	was	analyzed	by	 the	Kolmogorov-Smirnov	normality	 test.	
Statistical	significance	of	differences	between	the	elastase	group	and	the	groups	treated	with	native	
MSCs	 and	 AAT-MSCs,	 respectively,	was	 calculated	 applying	 ordinary	 one-way	 ANOVA,	 followed	 by	
Dunnett's	multiple	comparisons	test	for	total	cells,	macrophages,	lymphocytes,	and	eosinophils,	and	
Kruskal-Wallis	 test,	 followed	 by	 Dunn’s	 multiple	 comparisons	 test	 for	 neutrophils.	 **	 P	 <	 0.01;		
***	P	<	0.001.	
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Figure	29:	Relative	proportions	of	lymphocytes	and	eosinophils	are	increased,	and	percentages	of	
macrophages	are	decreased	after	 treatment	with	MSCs	 (collaboration	with	A.Ö.	Yildirim/CPC).	A	
statistically	 significant	 increase	 in	 the	 relative	 proportions	 of	 lymphocytes	 and	 eosinophils	 in	mice	
receiving	 either	 native	MSCs	 or	 AAT-MSCs	 in	 comparison	 to	 mice	 treated	 with	 elastase	 only	 was	
observed	(lymphocytes:	MSCs:	P	<	0.0001,	AAT-MSCs:	P	<	0.0001;	eosinophils:	MSCs:	P	<	0.05,	AAT-
MSCs:	P	<	0.001),	while	macrophage	percentages	were	markedly	decreased	(MSCs:	P	<	0.0001,	AAT-
MSCs:	P	<	0.0001).	Mouse	 lungs	were	 lavaged	3	 times	with	PBS,	cells	were	pelleted	and	 the	pellet	
resuspended	in	medium	for	the	total	cell	count.	Cytospins	of	the	cell	suspension	were	prepared	for	
differential	cell	counting.	MSC-treated	groups	were	compared	to	mice	receiving	elastase	only	for	all	
cell	 types.	 Each	 symbol	 represents	 one	 mouse;	 the	 horizontal	 lines	 denote	 means.	 Gaussian	
distribution	 of	 the	 data	 was	 analyzed	 by	 the	 Kolmogorov-Smirnov	 normality	 test.	 Statistical	
significance	of	differences	between	the	elastase	group	and	the	groups	treated	with	native	MSCs	and	
AAT-MSCs,	 respectively,	 was	 calculated	 applying	 ordinary	 one-way	 ANOVA,	 followed	 by	 Dunnett's	
multiple	 comparisons	 test	 for	 total	 cells,	macrophages,	 lymphocytes,	 and	eosinophils,	 and	Kruskal-
Wallis	test,	followed	by	Dunn’s	multiple	comparisons	test	for	neutrophils.	*	P	<	0.05;	***	P	<	0.001;	
****	P	<	0.0001.	
Table	 19:	Cell	 counts	 in	 the	 BALF	 (collaboration	with	 A.Ö.	 Yildirim/CPC).	 Shown	 are	 average	 cell	
numbers	counted	in	the	BALF	of	the	mice	for	total	cells,	macrophages,	neutrophils,	lymphocytes,	and	
eosinophils	±	SD.	n	=	5	 for	 the	groups	receiving	PBS,	and	elastase	+	MSCs,	and	n	=	6	 for	 the	group	
receiving	elastase	and	elastase	+	AAT-MSCs.	
	
PBS	 Elastase	 Elastase	+	MSCs	 Elastase	+	AAT-MSCs	
	
Average	 SD	 Average	 SD	 Average	 SD	 Average	 SD	
Total	cells	 46500	 14748	 105583	 23570	 104500	 58986	 117083	 29087	
Macrophages	 45308	 14421	 100778	 22579	 75453	 39084	 78631	 23263	
Neutrophils	 0	 0	 730	 390	 768	 753	 450	 722	
Lymphocytes	 1193	 331	 4076	 2638	 15628	 9164	 19240	 3499	
Eosinophils	 0	 0	 0	 0	 12260	 12336	 19775	 11171	
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3.6.6. Summary 
In	summary,	application	of	AAT-MSCs	 led	to	significantly	 improved	respiratory	 function	parameters	
and	 enhanced	 regeneration	 and	 repair	 of	 lung	 tissue	 as	 indicated	 by	 a	 dramatic	 decrease	 in	
emphysema	 scoring	 in	 a	 model	 of	 elastase-induced	 lung	 emphysema.	 However,	 treatment	 with	
native	 and	 AAT-MSCs	 also	 induced	 an	 inflammatory	 response	 in	 the	 mouse	 lungs	 as	 well	 as	
significant	accumulation	of	 lymphocytes	and	eosinophils	 in	 the	BALF,	which	will	need	to	be	 further	
investigated.		
Taken	 together,	 this	 is,	 to	 the	 author’s	 knowledge,	 the	 first	 proof	 of	 concept	 for	 the	 treatment	of	
lung	emphysema	with	MSCs	virally	modified	to	stably	express	the	serine	protease	inhibitor	AAT.	
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4. Discussion 
4.1. Targeting construct 
One	 major	 aim	 of	 the	 present	 work	 was	 to	 design	 an	 optimized	 transfer	 vector	 for	 the	 genetic	
modification	 of	 human	MSCs	 to	 express	 the	 serine	 protease	 inhibitor	 AAT.	 Several	 considerations	
were	 taken	 into	 account	 for	 the	 design	 of	 this	 targeting	 construct.	 First,	 for	 construction	 of	 the	
SERPINA1	expression	cassette,	 transcript	variant	1	out	of	11	transcript	variants	published	at	NCBI’s	
Nucleotide	comprising	the	same	coding	sequence	of	1254	bases	was	chosen.	Variant	1	differs	from	
the	other	10	transcript	variants	only	by	the	portion	of	the	5’UTR	included	in	the	published	sequence,	
ranging	from	240	(transcript	variant	3,	accession	number	NM_001002235.2)	to	573	bases	(transcript	
variant	 5,	 accession	 number	NM_001127701.1).	 The	 5’	UTR	 of	 transcript	 variant	 1	 has	 a	 relatively	
small	 size	 of	 261	 bases,	 as	 do	 the	majority	 of	 the	 transcript	 variants.	 Therefore,	 it	 could	 easily	 be	
included	 in	 the	 expression	 construct	 without	 having	 to	 fear	 a	 major	 drop	 in	 viral	 titers.	 Our	
hypothesis	was	that	the	5’	UTR	might	contain	sequences	inducing	cap-independent	translation	344,345,	
serve	as	a	natural	site	for	the	potential	binding	of	regulatory	factors	such	as	miRNAs	346,	or	comprise	
other	 sequences	 possibly	 leading	 to	 enhanced	 protein	 expression	 347,348.	 The	 SERPINA1	 3’	 UTR	
published	at	Nucleotide	is	the	same	for	all	11	transcript	variants	and	contains	1702	bases.	Although	
there	are	papers	describing	that	inclusion	of	the	3’	UTR	can	lead	to	enhanced	gene	expression	349,	it	
was	not	incorporated	into	the	expression	cassette	due	to	size	restrictions	in	the	retroviral	backbone.	
During	 the	 ordering	 process	 of	 the	 SERPINA1	 expression	 cassette	 from	GeneArt,	 a	modified	 Kozak	
consensus	sequence	327	was	inserted	5’	of	the	SERPINA1	start	codon	to	ensure	efficient	initiation	of	
translation,	 and	 the	 CDS	 was	 codon	 optimized	 350,351	 for	 homo	 sapiens.	 Although	 it	 might	 seem	
unnecessary	and	counterintuitive	to	codon	optimize	a	human	cDNA	for	homo	sapiens,	we	performed	
this	step	as	it	has	been	shown	that	homo	sapiens	codon	optimization	of	human	genes	could	increase	
protein	expression	up	to	200%	in	a	gene	therapy	setting	for	hemophilia	A	352.	
The	next	important	point	to	consider	was	the	choice	of	promoters	to	be	tested	for	the	expression	of	
SERPINA1.	AAT	is	a	protein	that	 is	highly	expressed	in	the	human	body	with	an	average	production	
rate	 of	 34mg/kg	 body	 weight	 per	 day	 353.	 Thus,	 the	 endogenous	 human	 AAT	 promoter	 would	
theoretically	be	well-suited	to	drive	high-level	expression	of	AAT	in	a	gene	therapy	setting,	as	it	has	
been	described	for	the	expression	of	transgenes	in	hepatocytes	354,355.	However,	as	 it	has	also	been	
published	that	the	human	AAT	promoter	is	not	active	in	bone	marrow-derived	MSCs	243,	we	refrained	
from	 including	 it	 in	 our	 list	 of	 promoters	 to	 be	 tested.	 Instead,	 we	 focused	 on	 the	 following	
constitutive	 promoters	 in	 order	 to	 assess	 the	 impact	 of	 different	 promoters	 on	 gene	 expression	
levels:	 The	 PGK	 and	 EF1a	 promoters	 are	 human	 physiological	 promoters	 normally	 driving	 the	
expression	of	ubiquitous	proteins	crucial	for	glycolysis	356,357	and	protein	translation	358,	respectively,	
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processes	that	are	essential	for	all	living	organisms.	Thus,	these	proteins	are	constantly	produced	in	
all	 nucleated	 human	 cells	 at	 high	 levels,	 indicating	 that	 these	 promoters	 are	 capable	 of	 driving	
constant	high	gene	expression.	Furthermore,	it	has	been	described	that	pPGK	and	pEF1a	when	used	
in	retroviral	vectors	are	able	to	govern	high-level	gene	expression	also	in	stem	cells	such	as	HSCs	359,	
ESCs	360,	and	MSCs	361,362,	and	that	expression	of	the	transgene	from	physiological	promoters	such	as	
pPGK	 and	 pEF1a	 is	 detectable	 over	 several	 weeks,	 while	 viral	 promoters	 are	 more	 prone	 to	
silencing		363,364.	Another	reason	to	favor	physiological	promoters	over	strong	viral	promoters	despite	
their	high-level	gene	expression	is	safety:	In	all	documented	cases	of	insertional	transformation	that	
have	 occurred	 in	 gene	 therapy	 clinical	 trials	 to	 date,	 conventional	 LTR-driven	 gamma-retroviral	
vectors	had	been	used	to	genetically	modify	the	cells	185–187.	Physiological	promoters	in	contrast	have	
been	shown	to	markedly	reduce	the	risk	of	genotoxicity	365.	Based	on	these	considerations,	pPGK	and	
pEF1a	were	chosen	as	test	candidates	to	drive	SERPINA1	expression	 in	our	transfer	constructs.	The	
third	 promoter	 analyzed	 was	 pEFS	 (pEF1a	 short),	 the	 intron-less	 form	 of	 pEF1a	 described	 by	
Schambach	and	colleagues	329.	Comprising	only	233	bases,	it	is	almost	six	times	shorter	than	the	full	
length	EF1a	promoter,	which	 is	expected	 to	be	beneficial	with	 regards	 to	 resulting	viral	 titers,	 and	
expression	 from	 pEFS	 has	 been	 described	 to	 be	 approximately	 half	 of	 pEF1a	 in	 HSCs	 329.	 These	
features	make	pEFS	a	 very	 attractive	 candidate	promoter,	 and	 indeed	 is	 it	 presently	being	used	 in	
several	gene	therapy	clinical	trials	worldwide	189,366,367.	The	CAG	promoter	consists	of	the	CMV	early	
enhancer	 in	combination	with	 the	chicken	beta	actin	promoter	and	usually	yields	higher	 transgene	
expression	as	 compared	 to	 the	promoters	described	above	 335.	 Thus,	 it	was	 included	 to	 serve	as	 a	
positive	control	for	high	expression	in	early	experiments.	As	expected,	MFI	values	of	AAT	expressed	
from	 pCAG	 measured	 by	 flow	 cytometry	 for	 intracellular	 AAT	 were	 twice	 as	 high	 as	 e.g.	 MFIs	
measured	 for	 AAT	 driven	 from	 pEF1a.	 Transduction	 efficacies	 of	 primary	 MSCs,	 however,	 were	
unacceptably	 low	 using	 pCAG,	 probably	 due	 to	 very	 low	 viral	 titers,	 with	 the	 large	 size	 of	 the	
promoter	of	~1600	bases	most	likely	being	the	reason	for	these.	Thus,	pCAG	was	not	included	in	any	
further	 experiments,	 and	 the	 three	 promoters	 tested	 for	 SERPINA1	 expression	were	 pPGK,	 pEF1a,	
and	pEFS.		
In	addition	to	SERPINA1,	the	pac	gene	was	needed	to	be	expressed	in	the	targeting	construct	to	allow	
for	 antibiotic	 selection	 of	 transduced	 cells.	 Thus,	 the	 next	 point	 to	 consider	 when	 designing	 our	
expression	vector	was	how	the	pac	gene	should	be	co-expressed.	Common	strategies	used	to	drive	
the	expression	of	more	 than	one	gene	per	 targeting	construct	make	use	of	multiple	promoters	 368,	
IRES	 sequences	 369,	 fusion	 proteins	 370	 or	 insertion	 of	 cleavage	 signals	 such	 as	 2A	 peptides	 371,372.	
Among	 these	 strategies,	 multiple	 promoters	 and	 the	 utilization	 of	 IRES	 sequences	 are	 the	 most	
frequently	employed	337.	Thus,	we	decided	to	assess	both	approaches	and	drive	pac	expression	from	
either	a	 second	promoter	or	use	 the	well	described	EMCV	 IRES	sequence	332,333	 to	 link	both	genes.	
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Due	 to	 pEF1a	 being	 the	 largest	 promoter	 under	 evaluation,	 and	 because	 we	wanted	 to	 keep	 the	
construct	sizes	as	small	as	possible,	the	choice	was	narrowed	down	to	pPGK	and	pEFS	promoters	for	
pac	expression	in	evaluation	of	the	two	promoter	approach.		
Another	point	of	 consideration	 regarding	 the	use	of	 two	promoters	was	 their	 configuration	within	
the	expression	cassettes.	 It	has	been	described	 that	 two	active	 transcription	units	 linked	 in	cis	 can	
influence	 each	 other,	 usually	 in	 a	 suppressive	 manner,	 a	 phenomenon	 called	 promoter	 or	
transcriptional	interference	336,337,373–376.	This	suppressive	effect	can	happen	upstream	or	downstream	
of	the	nearby	active	gene	and	is	dependent	on	the	position	and	strength	of	the	promoters	involved,	
and	among	other	things,	the	state	of	the	chromatin	surrounding	the	expression	cassette	336,374,377,378.	
The	mechanisms	 leading	 to	 this	 perturbation	 of	 one	 transcription	 unit	 by	 another	 are	 diverse	 and	
include	e.g.	 read-through	 from	 the	upstream	 transcription	unit	 into	 the	downstream	unit,	 thereby	
disrupting	the	binding	of	transcription	factors	and	other	DNA-binding	proteins,	competition	between	
promoters	for	transcription	factors,	enhancers	or	their	binding	proteins	or	topological	changes	in	the	
DNA	induced	by	transcription	such	as	supercoiling	337,373,374,379,380.	However,	the	interplay	between	all	
the	cis-acting	transcriptional	elements	is	 intricate,	and	a	clear	mechanism	for	this	phenomenon	has	
yet	to	be	described.	Because	of	this,	 it	was	hard	to	predict	which	promoter–gene	combination	and	
arrangement	 in	 the	 retroviral	 vector	would	 lead	 to	 highest	SERPINA1	 expression.	 Thus,	 a	 series	 of	
combinations	 were	 evaluated:	 SERPINA1	 driven	 from	 pPGK,	 pEF1a,	 and	 pEFS,	 and	 the	 expression	
cassette	placed	5’	of	the	pac	cassette	in	some	constructs,	and	3’	in	others,	resulting	in	a	total	of	six	
gamma-retroviral	transfer	plasmids.	As	our	focus	was	optimizing	SERPINA1	expression,	permutations	
of	 different	 promoters	 were	 omitted	 for	 the	 pac	 gene.	 Instead,	 expression	 of	 the	 pac	 gene	 was	
driven	by	pEFS	when	SERPINA1	was	expressed	from	pPGK,	and	by	pPGK	when	pEFS	or	pEF1a	were	
used	for	SERPINA1	expression.	It	was	avoided	to	use	the	same	promoter	twice	in	the	same	construct	
to	obviate	possible	unwanted	recombination	events.		
As	detailed	above,	the	second	strategy	was	to	test	the	efficiency	of	bicistronic	expression	using	the	
established	EMCV	IRES	sequence	to	co-express	pac.	This	strategy	has	been	shown	to	function	more	
efficiently	in	some	cases	than	using	a	second	internal	promoter	333.	A	second	advantage	of	utilizing	an	
IRES	sequence	is	that	all	cells	will	express	pac	as	well	as	SERPINA1	after	antibiotic	selection	because	
one	 long	mRNA	containing	both	genes	 is	produced	during	 transcription	of	 the	expression	cassette.	
This	is	not	necessarily	the	case	when	two	promoters	are	used	as	only	one	of	the	transgenes	may	be	
expressed	while	 the	promoter	of	 the	second	gene	becomes	silenced.	However,	concerns	 regarding	
the	IRES	approach	were	raised	by	the	fact	that	oftentimes	the	gene	downstream	the	IRES	sequence	is	
expressed	 at	markedly	 lower	 levels	 compared	 to	 the	 upstream	 gene	 381.	 Thus,	 as	maximizing	 AAT	
yield	 was	 our	 main	 focus,	 SERPINA1	 was	 only	 tested	 in	 a	 position	 5’	 of	 the	 IRES	 sequence,	 and	
expression	from	pPGK	and	pEFS	were	compared	in	two	constructs.	The	EF1a	promoter	was	not	used	
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in	an	IRES	construct	due	to	its	 large	size	and	the	fact	that	the	IRES	sequence	by	itself	 is	 larger	than	
pPGK	 and	 pEFS	 combined.	 Thus,	 for	 this	 construct	 a	massive	 drop	 in	 viral	 titers	would	 have	 been	
expected,	 prompting	 us	 to	 refrain	 from	 cloning	 and	 testing	 this	 vector.	 Taken	 together,	 all	 these	
considerations	led	us	to	the	construction	of	the	eight	gamma-retroviral	transfer	vectors	depicted	in	
Figure	6.	Although	making	predictions	regarding	the	expected	performance	of	these	constructs	was	
almost	impossible	due	to	all	the	aforementioned	factors	influencing	expression,	from	a	hypothetical	
point	 of	 view,	 our	 best	 guess	 regarding	 the	 construct	 becoming	 the	 lead	 candidate	 among	 all	 the	
vectors	 designed	 was	 construct	 #194	 due	 to	 several	 reasons:	 First,	 with	 a	 size	 of	 the	 expression	
cassette	 of	 ~4500	 base	 pairs,	 it	 was	 one	 of	 the	 smallest	 constructs	 suggesting	 that	 resulting	 viral	
titers	would	most	 likely	 be	 higher	 than	 those	 of	 larger	 cassettes	 338.	 Second,	 as	 detailed	 above,	 it	
contains	 an	 IRES	 sequence	 instead	 of	 a	 second	 internal	 promoter,	 thus	 minimizing	 the	 risk	 of	
transcriptional	 interference	 on	 one	 hand,	 and	 guaranteeing	 expression	 of	 both	 transgenes	 after	
antibiotic	 selection	on	 the	other.	And	 third,	 it	 has	been	described	 that	pEF1a	yields	~4-fold	higher	
transgene	expression	than	pPGK	in	primary	MSCs	as	well	as	different	cell	 lines	362,364;	assuming	that	
expression	 from	 pEFS	 is	 about	 half	 of	 what	 can	 be	 achieved	 which	 full	 length	 EF1a	 329,	 we	 were	
expecting	that	pEFS	would	still	be	more	potent	than	pPGK,	thus	making	construct	#194	preferable	to	
construct	#193	in	theory.	Indeed,	all	these	predictions	proved	to	be	accurate,	which	will	be	described	
in	the	following	chapters	in	greater	detail.		
4.2. Viral titers 
With	 regard	 to	 the	 viral	 titers	 obtained	with	 the	 SERPINA1	 constructs,	 the	 highest	 value	 reached,	
[3x105	 TU/mL],	 appears	 relatively	 low	 at	 first	 glance.	 However,	 the	 procedure	 of	 transduction	
included	the	use	of	adherent	cells	without	the	addition	of	compounds	neutralizing	negative	charges,	
such	 as	 the	 cationic	 PLL.	 These	 chemicals	 are	 oftentimes	 added	 to	 improve	 transduction	 by	
minimizing	repulsion	between	cells	and	viral	particles	382–384.	Such	being	the	case,	the	conditions	we	
chose	were	suboptimal	for	transduction.	However,	we	were	interested	in	comparing	the	titers	of	the	
constructs	 in	 order	 to	 transduce	 our	 cells,	 primary	 human	MSCs,	 with	 the	 same	 amount	 of	 viral	
particles	in	subsequent	experiments.	Thus,	we	chose	the	fastest	and	easiest	way	of	transducing	the	
cells,	 resulting	 in	 the	 lower	absolute	 titers	observed.	A	 second	 issue	 regarding	SERPINA1	 construct	
titers	is	the	negative	impact	of	a	larger	genetic	payload	on	viral	titers.	This	effect	has	been	described	
for	lentiviral	vectors,	with	the	reason	for	decreased	titers	linked	to	inefficient	incapsidation	of	larger	
viral	 RNA	 genomes	 into	 infectious	 particles	 338,339,385.	 In	 these	 publications	 the	 addition	 of	 ~1000	
bases	 to	 the	provirus	 led	 to	 a	 ~10-fold	decrease	of	 lentiviral	 titers.	 For	 the	 retroviral	 vectors	 used	
here	 the	 effect	 was	 much	 more	 pronounced:	 In	 our	 hands,	 the	 addition	 of	 ~1000	 bases	 to	 the	
expression	cassette	in	constructs	in	which	SERPINA1	is	driven	from	pEF1a	results	in	a	massive	drop	in	
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titers	 of	 close	 to	 two	 log	 units.	 This	 discrepancy	 may	 result	 from	 the	 different	 transduction	
characteristics	 of	 VSV.G-pseudotyped	 lentiviral	 vectors,	 and	 GaLV-pseudotyped	 retroviral	 vectors.	
Alternatively	the	suboptimal	conditions	used	for	transduction	in	the	titration	experiments	may	have	
a	larger	impact	on	viral	supernatants	which	have	low	titers,	leading	to	disproportionally	low	results.	
However,	apart	from	the	constructs	containing	pEF1a,	all	viral	constructs	yielded	comparable	titers.	
4.3. Transduction of primary MSCs and expression of transgenic AAT 
The	 transduction	efficacy	and	 transgenic	AAT	protein	expression	were	assessed	 in	 two	ways:	 First,	
the	percentage	of	cells	intracellularly	staining	positive	for	AAT	as	well	as	the	MFI	of	these	cells	used	
as	an	indicator	of	expression	strength	were	measured	shortly	after	transduction	by	flow	cytometry.	
Second,	 after	 pure	 populations	 of	 transduced	 cells	 were	 generated	 by	 antibiotic	 selection	 with	
puromycin	and	expanded	in	a	long-term	culture,	the	average	number	of	viral	integrations	per	cell	in	
the	bulk	population	was	analyzed	by	qPCR,	and	AAT	secretion	from	a	defined	number	of	plated	cells	
in	a	distinct	volume	over	a	specified	time	period	was	measured	by	ELISA.	This	gave	us	an	opportunity	
to	 compare	 the	 expression	 constructs	 at	 a	 time	when	 the	MSCs	were	 in	 early	 passages	 following	
transduction,	and	at	a	point	when	the	cells	were	 in	higher	passages	after	culture	for	several	weeks	
and	subjected	to	ex	vivo	procedures	such	as	cell	expansion	or	antibiotic	selection.	This	 is	important	
for	 the	potential	 application	of	 these	 cells	 in	 a	 gene	 therapy	 setting.	 The	MSCs	at	higher	passages	
having	undergone	these	ex	vivo	manipulation	steps	more	closely	 resemble	the	 final	cell	product	as	
compared	to	the	cells	analyzed	shortly	after	transduction.	The	relative	performance	of	the	constructs	
tested	 stayed	 the	 same	 at	 different	 times,	 i.e.	 the	 same	 constructs	 yielded	 good	 results	 in	 all	
experiments,	 and	 the	 “bad”	 vectors	 were	 inferior	 in	 all	 analyses.	 It	 was	 thus	 possible	 for	 us	 to	
conclude	that	the	results	observed	were	constant	over	time	and	not	influenced	by	MSC	expansion	or	
treatments	 such	 as	 antibiotic	 selection,	mirroring	 the	properties	of	 the	expression	 constructs.	 This	
was	reassuring	regarding	our	choice	of	lead	construct:	Since	our	transduction	and	expression	results	
did	not	appear	to	be	affected	by	outside	influences	such	as	selection	or	expansion	processes,	it	was	
fair	to	assume	that	the	vector	in	which	SERPINA1	is	driven	by	the	EFS	promoter	and	pac	linked	via	an	
IRES	sequence	would	probably	yield	good	results	under	all	circumstances.	
Culturing	cells	 for	extended	culture	 time	as	described	above	would	most	 likely	have	enabled	us	 to	
observe	any	potential	unwanted	effects	such	as	silencing	of	gene	expression	386	or	cytotoxicity	of	AAT	
overexpression.	We	could	not	detect	 these	phenomena	 in	any	of	 the	experiments	performed,	thus	
we	could	assume	that	genetic	modification	of	primary	human	MSCs	with	our	retroviral	vectors	leads	
to	non-cytotoxic,	 long-term	 transgenic	AAT	expression.	This	 is	of	 great	 importance	 for	a	 cell-based	
gene	therapy	approach,	since	the	therapeutic	benefit	relies	on	stable	expression	of	the	therapeutic	
transgene	over	 a	 prolonged	period	of	 time.	As	 of	 yet,	 it	 is	 not	 clear	 how	 long	MSCs	persist	 in	 the	
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human	body	after	administration,	but	data	generated	 in	animal	models	 indicate	 that	human	MSCs	
can	live	in	rat	lungs	for	several	weeks	387.	Thus,	it	was	crucial	to	confirm	stable	AAT	expression	from	
our	transduced	cells	over	a	longer	period	of	time.	This	result	was	also	supported	by	data	generated	
later	in	this	project	during	the	production	process	of	large	MSC	batches	for	in	vivo	experiments:	AAT	
levels	were	constant	even	after	cryopreservation	of	 transduced	and	selected	MSCs,	 thawing	of	 the	
cells	 and	 expansion,	 indicating	 that	 transgene	 silencing	 is	 not	 a	 problem	 in	 our	 approach.	 As	
mentioned	above,	 it	 is	also	critical	 that	 long-term	transgene	expression	 is	not	 toxic	 for	 the	cells.	 In	
some	preclinical	gene	therapy	studies,	significant	toxicity	of	the	therapeutic	transgene	necessitated	
the	use	of	complex	expression	systems	388;	AAT	however,	 is	used	in	extremely	high	doses	 in	clinical	
studies	for	AAT	deficiency	without	any	signs	of	toxicity	of	the	protein	321,389.	Also	 in	our	case,	when	
AAT	 is	 permanently	 overexpressed	 from	 constitutive	 promoters	 in	MSCs,	we	 did	 not	 perceive	 any	
signs	of	toxicity,	even	during	prolonged	culture	periods:	During	the	generation	of	large	MSC	batches,	
AAT-MSCs	fulfilled	all	quality	specifications	for	MSCs,	viability	was	constantly	>90%,	and	results	were	
comparable	to	the	ones	generated	from	non-transduced	MSCs,	thus	making	AAT-MSCs	a	well-suited	
candidate	for	the	use	in	a	gene	therapy	approach.	
Another	 important	 point	 is	 that	 when	 transducing	 primary	 MSCs	 with	 our	 eight	 retroviral	
supernatants,	it	was	striking	that	although	the	cells	had	been	treated	with	the	same	amount	of	viral	
particles	 for	 each	 construct,	 transduction	 efficacies	were	not	 similar	 as	might	 have	been	expected	
(Figure	 8):	 MSCs	 transduced	 with	 supernatants	 #161	 and	 #164	 (in	 which	 SERPINA1	 expression	 is	
driven	from	pEF1a)	only	reached	transduction	efficacies	of	about	10–30%	of	the	ones	measured	with	
#160,	 #163,	 #194	 (all	 three	 constructs	 which	 contain	 pEFS	 to	 express	 SERPINA1)	 or	 #193	
(pPGK_SERPINA1_IRES_pac),	while	#159	and	#162	(constructs	in	which	SERPINA1	expression	is	driven	
by	pPGK)	yielded	 intermediate	results.	As	the	constructs	producing	these	 low	results	were	also	the	
ones	 having	 the	 lowest	 titers,	 we	 speculate	 that	 there	might	 be	 a	 correlation	 between	 titers	 and	
transduction	efficacies.	In	order	to	treat	MSCs	with	the	same	amount	of	viral	particles	per	construct,	
very	different	volumes	of	viral	supernatant	were	used	 in	these	experiments:	For	supernatants	with	
high	viral	titers	such	as	#160,	#163,	#193	or	#194,	only	a	few	microliters	were	pipetted	onto	the	cells,	
whereas	almost	pure	viral	supernatant	was	needed	for	constructs	#161	and	#164	to	reach	the	same	
MOI.	Viral	supernatant	is	basically	DMEM	containing	10%	FBS	that	has	been	incubated	on	a	confluent	
layer	of	293T	cells	for	24–36	hours.	Thus,	 it	 is	depleted	of	nutrients	but	full	of	byproducts	secreted	
from	the	cells	that	might	be	inhibitory	to	transduction	as	it	has	been	described	for	empty	envelope	
proteins	 shed	 from	 packaging	 cells	 or	 non-transducing	 viral	 particles	 390.	 Adding	 pure	 viral	
supernatant	 to	 the	 MSCs	 might	 create	 an	 unhealthy	 environment	 for	 the	 cells,	 and	 the	 waste	
products	 present	 in	 the	 supernatant	 might	 impede	 transduction,	 both	 factors	 together	 possibly	
giving	 an	 explanation	 why	 transduction	 efficacies	 of	 constructs	 #161	 and	 #164	 were	 that	 low.	
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Another	issue	was	that	although	the	titers	of	the	remaining	supernatants	were	similar,	transduction	
efficacies	were	 not;	 there	 appeared	 to	 be	 a	 dependence	 of	 the	 results	 on	 the	 promoter	 used:	 All	
constructs	containing	pEFS	reached	similar	high	values,	while	the	results	achieved	with	pPGK	vectors	
tended	 to	 be	 lower.	 Furthermore,	we	 showed	 that	 AAT	 expression	 from	pPGK-based	 constructs	 is	
also	 lower	 in	MSCs	 than	 that	seen	 from	pEFS-based	vectors	 (Figure	9).	This	might	have	 led	 to	cells	
expressing	low	levels	of	AAT	ending	up	in	the	negative	gate	during	flow	cytometry	analysis.	If	this	was	
the	 case,	 the	 transduction	 efficacies	 of	 pPGK	 constructs	 would	 have	 been	 underestimated,	
potentially	explaining	the	results	observed.	The	AAT	expression	seen	from	vector	#193,	a	construct	
containing	the	PGK	promoter	and	an	IRES	sequence	instead	of	a	second	promoter,	was	higher,	and	
transduction	 efficacies	 obtained	 with	 this	 construct	 were	 more	 similar	 to	 that	 seen	 with	 pEFS	
constructs,	which	would	support	the	abovementioned	hypothesis.	VCN	data	from	bulk	populations	of	
transduced	 and	 selected	 MSCs,	 however,	 contradict	 this	 idea.	 Also	 in	 these	 analyses,	 which	 are	
independent	 of	 the	 strength	 of	 AAT	 expression,	 pPGK-based	 constructs,	 especially	 the	 ones	
containing	a	second	promoter,	fared	poorly	(Figure	11),	thus	confirming	the	flow	cytometry	data	and	
indicating	that	these	constructs	indeed	lead	to	lower	transduction	efficacies.		
Due	 to	 high	 donor-to-donor	 variability,	 in	 order	 to	 compare	 transduction	 efficacies	 as	 described	
above,	it	was	necessary	to	normalize	the	values	determined	in	each	experiment	to	the	highest	result	
measured	 in	 the	 same	 run.	 The	 fact	 that	 MSCs	 derived	 from	 different	 donors	 yield	 very	 diverse	
results	 when	 the	 same	 experiment	 is	 performed,	 is	 a	 common	 problem	 in	MSC	 research	 391,392.	 A	
representative	example	of	the	impact	of	the	cell	donor	on	transduction	efficacies	is	shown	in	Figure	
30.	A	5-fold	difference	was	seen	in	transduction	efficacies	when	using	the	same	viral	supernatant	on	
cells	derived	 from	different	donors.	 It	 is	worth	mentioning,	however,	 that	despite	 the	variability	 in	
absolute	numbers,	the	relative	pattern	of	the	results	was	the	same,	no	matter	which	donor	was	used.		
	
	
Figure	 30:	 Impact	 of	 cell	 donor	 on	 transduction	 efficacies	 achieved	 with	 constructs	 #159,	 #160,	
#162,	and	#163.	Normalized	transduction	efficacies	differed	by	the	factor	5	between	2	cell	donors.	
Primary	human	MSCs	derived	from	2	healthy	donors	(AP00109	and	AP00158)	were	transduced	with	
viral	 supernatants	 #159,	 #160,	 #162,	 and	 #163	 at	 MOI	 0.25,	 and	 transduction	 efficacies	 were	
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assessed	 by	 intracellular	 staining	 for	 AAT	 and	 subsequent	 flow	 cytometric	measurement	 72	 hours	
after	transduction.	Bars	represent	average	values	of	2	independent	transduction	experiments	±	SD.		
In	 the	 present	 study	 we	 also	 compared	 the	 various	 constructs	 by	 values	 not	 impaired	 by	 donor	
variability,	 but	 depending	 solely	 on	 the	 expression	 construct:	 As	 all	 flow	 cytometry	 experiments	
performed	 to	 compare	 the	 eight	 gamma-retroviral	 constructs	 were	 measured	 using	 the	 same	
settings,	 absolute	MFI	 values	 of	 AAT-positive	 cells	 could	 be	 compared	 as	 a	measure	 of	 expression	
strength.	The	same	is	true	for	VCN	determination	which	was	performed	after	antibiotic	selection	of	
the	bulk	cell	population;	as	such,	the	selection	and	subsequent	expansion	processes	compensate	for	
the	 different	 transduction	 efficacies.	 Moreover,	 for	 determination	 of	 AAT	 content	 in	 cell	 culture	
supernatants	 by	 ELISA,	 the	 same	 experimental	 scheme	 was	 applied	 in	 all	 experiments:	 The	 same	
numbers	of	cells	per	cm2	were	plated,	the	same	volume	of	medium	was	added	and	incubated	for	the	
same	time	on	the	cells	before	AAT	protein	content	was	determined.	Thus,	the	(absolute	and	relative)	
transduction	 and	 expression	 results	 generated	 provided	 a	 good	 platform	 for	 characterizing	 the	
system.		
Subsequent	experiments	led	us	to	exclude	pEF1a-driven	constructs.	As	described	above,	transduction	
efficacies	achieved	on	primary	MSCs	with	these	supernatants	were	extremely	 low,	probably	due	to	
very	low	viral	titers	resulting	from	larger	genetic	payload	sizes	as	compared	to	the	other	constructs.	
The	 low	 transduction	 efficacies	 suggest	 that	 a	 high	 percentage	 of	 cells	 harvested	 from	 a	 healthy	
donor	will	not	get	gene-modified	and	thus	be	eliminated	during	antibiotic	selection.	This	 is	bad	not	
only	from	an	economic	point	of	view,	but	also	implies	that	the	remaining	transduced	cells	will	have	
to	undergo	more	population	doublings	 to	 reach	 cell	 numbers	 sufficient	 for	 treating	 a	patient.	 This	
should	be	avoided	as	cells	in	lower	passages	are	thought	to	produce	better	outcomes	in	clinical	trials	
for	 inflammatory	 diseases	 including	 GvHD	 393.	 To	 accept	 all	 these	 disadvantages	 and	 still	 use	 the	
pEF1a-driven	constructs	would	only	have	made	sense	 if	AAT	expression	would	have	been	markedly	
higher	in	comparison	to	the	other	constructs.	Although	it	has	been	described	that	the	first	intron	of	
pEF1a	is	required	for	high	gene	expression	394,395,	and	the	intron-less	EFS	promoter	has	been	shown	
to	yield	expression	approximately	half	of	what	is	achievable	with	the	full-length	promoter	in	HSCs	329,	
in	our	hands	both	promoters	were	performing	equally	regarding	AAT	expression,	suggesting	that	the	
lack	of	the	first	intron	has	no	influence	on	transgene	expression	in	human	bone-marrow	MSCs.	Viral	
titers	 and	 transduction	 efficacies	 were	 highest	 in	 pEFS	 constructs.	 Thus,	 there	 was	 no	 reason	 to	
further	evaluate	constructs	comprising	pEF1a.	While	performing	these	experiments,	 it	also	became	
clear	 that	 expression	 vectors	 using	 pPGK	 were	 not	 as	 efficient	 as	 pEFS-based	 constructs,	 at	 least	
when	two	promoters	were	used:	Transduction	efficacies	and	AAT	expression	were	lower	than	those	
achieved	with	pEFS	constructs	 in	all	cases.	Only	the	pPGK	construct	that	used	an	IRES	sequence	for	
bicistronic	pac	gene	expression	yielded	transduction	efficacies	comparable	to	pEFS	vectors,	thus	this	
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construct	 was	 further	 characterized	 to	 include	 at	 least	 one	 construct	 in	 which	 SERPINA1	 was	 not	
driven	 from	 pEFS.	 The	 remaining	 four	 constructs	 (#160,	 #163,	 #193,	 and	 #194)	 achieved	 similar	
results	 with	 respect	 to	 transduction	 and	 AAT	 expression,	 thus	 it	 was	 difficult	 to	 select	 a	 lead	
candidate	based	only	on	these	parameters.	However,	the	cell	numbers	after	transduction	with	these	
supernatants	and	antibiotic	selection	varied	greatly.	Despite	transduction	efficacies	being	similar	for	
all	constructs,	both	IRES	vectors	yielded	similar	cell	numbers	after	selection,	while	MSC	content	was	
markedly	decreased	for	the	supernatants	in	which	the	two	genes	were	expressed	from	two	different	
promoters	(Figure	13).	This	suggested	that	in	these	constructs	pac	gene	expression	was	too	low	for	
the	 cells	 to	 survive	 antibiotic	 selection	 with	 puromycin	 at	 the	 used	 concentration.	 Another	 fact	
supporting	this	idea	was	that	for	the	IRES	constructs	cell	numbers	also	agreed	well	with	transduction	
efficacies	 determined,	 i.e.	 50%	 transduction	 efficacy	 would	 result	 in	 approximately	 50%	 of	 the	
transduced	 cells	 surviving	 the	 selection	 process	 during	 the	 first	 days	 of	 selection,	 while	 the	
percentage	of	surviving	cells	was	much	lower	for	the	two	promoter	constructs.	These	results	suggest	
that	 the	 two	 transcription	 units	 present	 in	 these	 vectors	 perturbed	 one	 another,	 a	 phenomenon	
fairly	common	in	gene	therapy	settings	called	transcriptional	or	promoter	interference	373,374,379,380.	It	
has	e.g.	been	described	that	during	the	development	of	a	polycistronic	vector	for	liver-directed	gene	
therapy,	a	pronounced	decrease	in	expression	of	the	transgenes	was	observed,	and	that	this	drop	in	
expression	 was	 found	 to	 be	 due	 to	 promoter	 interference	 between	 the	 CMV	 and	 the	 EF1a	
promoter	337.	 While	 in	 this	 publication	 the	 effect	 was	 bidirectional,	 i.e.	 the	 upstream	 promoter	
impaired	transgene	expression	from	the	downstream	promoter	and	vice	versa,	in	our	case	the	effect	
was	unidirectional.	SERPINA1	expression	was	the	same	for	all	three	pEFS	constructs,	 indicating	that	
the	 pPGK_pac	 transcription	 unit	 did	 not	 have	 an	 impact	 on	 the	 pEFS_SERPINA1	 unit.	 Thus,	 the	
differences	 in	pac	expression	seen	may	 result	 from	pEFS,	which	 is	very	 strongly	activated	 in	MSCs,	
competing	with	the	weaker	PGK	promoter	for	the	binding	of	transcription	factors,	enhancers	or	other	
DNA-binding	 proteins,	 resulting	 in	 a	 decrease	 in	 pac	 expression	 in	 the	 constructs	 comprising	 two	
promoters.	 The	 fact	 that	 the	 IRES	 constructs	 were	 not	 affected	 by	 this	 phenomenon	 of	
transcriptional	 interference	 in	 our	 setting	would	 support	 this	 hypothesis.	 Although	pac	 expression	
might	 be	 lower	 than	 SERPINA1	 expression	 in	 the	 IRES-based	 constructs	 as	 described	 for	 gene	
expression	downstream	of	an	IRES	sequence	381,	it	was	sufficient	for	the	selection	process.		
Another	aspect	we	analyzed	was	 if	different	configurations	of	the	expression	units	 (5’	vs.	3’)	 in	the	
expression	 cassette	 could	 have	 an	 influence	 on	 AAT	 expression.	 Swapping	 the	 position	 of	 the	
SERPINA1	 unit	 in	 the	expression	 cassette	did	not	 seem	 to	have	an	 impact	on	AAT	expression.	This	
may	 be	 because	 pEFS	 is	 considerably	 strong	 in	MSCs,	 so	 that	 possible	 effects	 on	 AAT	 expression	
caused	by	the	position	of	the	transcription	units	are	too	minor	to	be	noticed.	Cell	numbers	obtained	
after	antibiotic	selection	 (Figure	13),	however,	suggest	a	position	effect.	Transduction	efficacies	 for	
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cells	 transduced	with	constructs	#160	and	#163	were	similar.	Average	cell	numbers	after	antibiotic	
selection	were	different	for	these	two	constructs	by	more	than	factor	2,	suggesting	that	the	position	
of	 the	 pac	 unit	 in	 relation	 to	 the	 SERPINA1	 unit	 might	 play	 a	 role	 in	 how	 strong	 transcriptional	
interference	impairs	pac	gene	expression.	
Based	 on	 these	 results,	 construct	 #194	 (pEFS_SERPINA1_IRES_pac)	 was	 selected	 as	 our	 lead	
candidate	for	preclinical	evaluation.		
4.4. Comparison of gamma-retroviral with lentiviral vector 
Another	 aim	 of	 this	 study	 was	 to	 further	 optimize	 AAT	 expression	 by	 evaluating	 a	 second	 viral	
backbone.	 In	 addition	 to	 gamma-retroviral	 vectors,	 lentiviral	 vectors	 are	 the	 only	 viral	 vectors	
currently	used	 for	 clinical	 applications	 leading	 to	 stable	 integration	of	 genetic	 information	 into	 the	
host	genome	and	a	permanent	modification	of	 the	host	cell	and	 its	progeny	 396,397.	Since	MSCs	are	
dividing	relatively	rapidly,	transient	cell	modification	would	result	in	a	dilution	effect	fairly	quickly,	so	
that	only	by	applying	permanent	modification	techniques	a	 long-lasting	therapeutical	effect	can	be	
achieved.	Lentiviruses	such	as	HIV-1	belong	to	the	same	family	of	Retroviridae	as	gamma-retroviruses	
and	 are	 also	 single	 stranded,	 positive-sense	 RNA	 viruses.	 Both	 viral	 vectors	 can	 transfer	 genetic	
payloads	of	approximately	7–10kb	398,399.	The	production	of	gamma-retro-	and	lentiviral	supernatants	
is	 similar,	as	are	 the	 transduction	procedures.	All	 these	 factors	enable	a	direct	comparison	of	both	
vector	 systems.	 Our	 lead	 expression	 cassette	 was	 subcloned	 into	 the	 pCCL	 backbone,	 and	 viral	
supernatants	were	generated.	Although	the	genetic	payload	of	the	lentiviral	vector	is	approximately	
1kb	 larger	 due	 to	 more	 regulatory	 viral	 sequences	 being	 included	 between	 the	 LTRs,	 the	 titers	
achieved	 on	 HT1080	 cells	 were	 higher	 than	 those	 seen	 for	 the	 retroviral	 supernatants.	 The	main	
difference	between	these	two	viral	vectors	is	that	while	gamma-retroviruses	need	dissolution	of	the	
nuclear	 membrane	 of	 the	 host	 cell	 for	 successful	 insertion	 of	 their	 genome	 into	 the	 host	 DNA,	
lentiviruses	 transfer	 their	 pre-integration	 complex	 into	 the	 nucleus	 through	 the	 intact	 nuclear	
envelope.	Because	of	 this,	 retroviral	 transduction	 is	 limited	 to	mitotic	 cells,	while	 lentiviral	 vectors	
can	also	transduce	growth-arrested	and	terminally	differentiated	cells	400–402.	This	phenomenon	was	
observed	 in	 the	 transduction	experiments	performed	using	MOIs	 ranging	 from	0.25–5.0:	While	 for	
the	gamma-retroviral	supernatant,	there	was	only	a	very	slight	 increase	 in	normalized	transduction	
efficacy	when	the	MOI	was	increased	10-fold	(from	~50%	of	the	maximum	transduction	achieved	in	
each	 experiment	 at	 MOI	 0.25	 to	 ~53%	 at	 MOI	 2.5),	 lentiviral	 transduction	 went	 from	 ~20%	 of	
maximum	at	MOI	0.25	to	~90%	at	MOI	2.5,	indicating	that	at	MOI	0.25	almost	all	dividing	cells	were	
transduced	with	the	retroviral	supernatant,	so	that	the	maximum	transduction	possible	was	reached.	
With	 the	 lentiviral	 supernatant,	 transduction	 efficacies	 were	 less	 than	 half	 of	 that	 seen	 with	 the	
retroviral	vector	at	the	lowest	MOI,	but	rose	in	a	dose-dependent	manner	when	more	viral	particles	
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were	added	to	the	cells,	until	at	the	highest	MOI	tested	more	than	80%	of	MSCs	were	gene-modified.	
It	is	possible	that	100%	of	the	MSCs	could	be	transduced	using	the	lentiviral	vector	when	using	higher	
MOIs.		
Analyses	of	VCNs	in	the	bulk	population	of	cells	after	selection,	of	MFIs	in	non-selected	cells,	and	of	
AAT	 expression	 in	 pure	 populations	 of	 selected	 MSCs	 revealed	 the	 same	 pattern	 as	 seen	 for	
transduction	efficacies:	a	plateau	of	values	generated	with	the	gamma-retroviral	vector	and	a	dose-
dependent	 increase	measured	after	transduction	with	the	 lentiviral	supernatant.	This	suggests	that	
transduction	and	transgene	expression	follow	the	same	pattern	and	that	the	retroviral	vector	has	a	
different	 transduction	 behavior	 from	 the	 lentiviral	 vector.	 No	 increase	 in	 VCNs	 or	 AAT	 expression	
after	 transduction	with	 the	 gamma-retroviral	 supernatant	 at	 higher	MOIs	was	 seen,	 although	 this	
would	have	been	expected,	since	in	theory	the	mitotic	cells	should	have	acquired	more	copies	of	the	
transgene	per	cell	with	increasing	MOIs.	As	this	plateau	effect	was	observed	for	cells	derived	from	all	
three	donors	tested	and	therefore	did	not	appear	to	be	influenced	by	the	MSCs	or	their	source,	we	
hypothesized	that	 it	was	 linked	to	 the	gamma-retroviral	 supernatant.	 Indeed	 it	has	been	described	
that	molecules	present	 in	retroviral	supernatants	such	as	free	envelope	glycoproteins	or	negatively	
charged	molecules	secreted	from	the	producer	cell	line	such	as	glycosaminoglycans	or	proteoglycans	
can	 interfere	 with	 transduction	 at	 high	 MOIs	 384,390,403–405.	 For	 transductions	 at	 lower	 MOIs,	 the	
volume	 of	 viral	 supernatant	 used	 was	 low,	 suggesting	 that	 potential	 repressive	 effects	 on	
transduction	would	have	been	 lower;	at	high	MOIs,	however,	when	 larger	volumes	of	 supernatant	
were	used,	a	higher	amount	of	 inhibitory	 factors	could	be	present	potentially	 resulting	 in	 the	non-
linear	transduction	observed	with	the	gamma-retroviral	supernatant.		
Considering	the	results	generated	in	comparing	the	gamma-retroviral	and	lentiviral	vectors,	it	still	is	
not	clear	which	vector	system	is	optimal	in	this	setting.	If	maximum	transduction	efficacy	and	highest	
AAT	 expression	were	 desired,	 and	 scalable	 transduction	was	 an	 aim,	 the	 lentiviral	 vector	 appears	
preferable	 to	 the	 gamma-retroviral.	However,	 if	 the	 goal	was	 not	 to	 reach	maximum	 transduction	
levels,	but	if	a	well-balanced	ratio	between	AAT	expression	and	number	of	integrations	per	cell	was	
required,	 the	 gamma-retroviral	 system	 appears	 to	 be	 superior,	 since	 much	 less	 viral	 supernatant	
would	be	needed	employing	the	gamma-retroviral	system	to	yield	this	result.		
Importantly,	regulatory	agencies	are	less	likely	to	approve	a	cell	therapy	product	having	high	levels	of	
vector	 integrations	due	 to	safety	concerns:	The	more	viral	 integrations,	 the	higher	 the	chance	 that	
regulatory	elements	such	as	promoters	or	enhancers	included	in	the	provirus	may	interfere	with	the	
surrounding	chromatin	of	 the	host	cell,	which	could	 lead	to	deregulation	of	nearby	oncogenes	and	
insertional	 transformation	 185–187.	 The	 lentiviral	 integration	 pattern	 is	 thought	 to	 be	 safer	 than	 the	
retroviral	406–411.	However,	to	the	author’s	knowledge,	no	case	of	genotoxicity	has	been	described	for	
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human	 MSCs,	 for	 either	 vector	 types	 used	 in	 the	 present	 study,	 SIN	 gamma-retroviral	 and	 SIN	
lentiviral	vectors.	
With	regards	to	economic	factors:	If	the	desired	outcome	was	maximum	transduction,	the	lentiviral	
supernatant	at	an	MOI	of	5.0	was	most	sufficient.	However,	much	more	viral	supernatant	would	be	
needed	 in	 this	 approach	 as	 compared	 to	 aiming	 for	 transduction	 efficacies	 of	 about	 half	 and	
expression	 levels	of	~2/3	of	the	maximum,	which	required	20-fold	 less	volume	of	gamma-retroviral	
supernatant	 in	our	preclinical	experiments.	The	first	approach	would	therefore	be	more	expensive,	
while	 it	 is	unknown	 if	maximum	transduction	and	expression	are	required	to	achieve	a	therapeutic	
benefit.	Also,	in	a	clinical	gene	therapy	setting,	it	is	preferable	to	treat	as	many	patients	as	possible	
with	 the	 same	 batch	 of	 viral	 supernatant	 to	 ensure	 optimal	 comparability	 of	 the	 results.	 Using	
producer	 cell	 lines	 expressing	 the	MLV	 gagpol	 and	 the	 GaLV	 env,	 as	 it	 is	 commonly	 done	 for	 the	
generation	 of	 gamma-retroviral	 supernatants,	 it	 is	 possible	 to	 produce	 batches	 of	 high-titer	
supernatants	in	liter	volumes	for	clinical	trials	412–414.	To	establish	such	scale-up	production	processes	
is	more	 difficult	 for	 lentiviral	 vectors,	 since	 due	 to	 the	 toxicity	 of	 the	 VSV.G	 protein	 there	 are	 no	
GMP-compliant	 packaging	 cell	 lines	 for	 VSV.G-pseudotyped	 lentiviral	 vectors	 available	 to	 date	 415.	
Taken	 together,	 both	 viral	 vectors	 have	 advantages	 and	 disadvantages,	 and	 further	 experiments,	
especially	assessing	the	amount	of	MSCs	and	AAT	needed	to	achieve	a	therapeutic	benefit,	need	to	
be	performed	to	be	able	to	select	the	viral	vector	that	is	better	suited	for	the	present	application.		
4.5. Functionality of transgenic AAT 
The	 next	 aim	 was	 to	 confirm	 the	 functionality	 of	 transgenically	 expressed	 AAT.	 AAT	 is	 normally	
primarily	 expressed	 in	 hepatocytes	 (70–80%),	 but	 neutrophils,	mononuclear	 phagocytes,	 intestinal	
epithelial	and	lung	alveolar	cells	are	also	able	to	synthesize	small	amounts	of	the	protein	217,257.	Bone	
marrow	derived	MSCs,	however,	are	not	thought	to	produce	AAT	naturally	243.	AAT	is	a	glycoprotein	
with	 a	 highly	 ordered	 tertiary	 structure	 that	 is	 co-	 and	 posttranslationally	 modified,	 and	 whose	
function	 depends	 on	 a	 conformational	 transition	 from	 “stressed”	 to	 “relaxed”	 during	 binding	 to	
proteases	231,251,416,417.	Because	it	is	a	secreted	protein,	it	contains	a	targeting	signal	that	is	cleaved	by	
signal	 peptidase,	 allowing	 secretion.	 To	 confirm	 that	AAT	expression	 in	MSCs	 results	 in	 a	 correctly	
cleaved,	N-glycosylated	and	folded	protein,	thereby	preserving	AAT	functionality,	a	functional	assay	
of	 neutrophil	 elastase	 inhibition	 by	 AAT	 was	 used.	 The	 assay	 confirmed	 that	 concentrated	
supernatants	 from	serum	free	cultures	efficiently	 inhibited	neutrophil	elastase,	demonstrating	 that	
AAT	 secreted	 from	 transduced	 MSCs	 is	 functional.	 MSC-derived	 AAT	 was	 also	 found	 to	 inhibit	
neutrophil	 elastase	 with	 approximately	 the	 same	 efficiency	 as	 natural	 AAT	 isolated	 from	 human	
plasma,	currently	used	in	clinical	trials	of	AAT	augmentation	for	AAT	deficiency	321.	
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4.6. In vivo mouse model of elastase-induced lung emphysema 
We	next	set	out	to	demonstrate	a	proof	of	principle	for	AAT-MSC-based	treatment	of	inflammatory	
lung	diseases	using	an	in	vivo	model.	
COPD	is	an	extremely	heterogeneous	disease	with	many	different	pathophysiological	aspects	such	as	
a	 chronic	 inflammatory	 response	 to	 inhaled	 irritants,	emphysema,	 small	 airway	 fibrosis	and	mucus	
hypersecretion,	 leading	 to	 an	 irreversible,	 progressive	 airflow	 limitation	 and	 loss	 of	 lung	 function	
over	 time	 8,11.	 It	 is	 extremely	 difficult	 to	mimic	 all	 these	 symptoms	 in	 one	 animal	model	 at	 once,	
especially	because	the	pathology	of	the	small	airways	is	hard	to	reproduce	in	mouse	models	due	to	
the	limited	airway	branching	seen	in	small	animals	418.	The	standard	in	vivo	model	used	for	COPD	is	a	
cigarette	smoke-induced	model,	since	the	injury	is	caused	by	the	same	insult	as	in	humans,	and	many	
symptoms	 that	are	comparable	 to	 the	human	disease	such	as	chronic	 lung	 inflammation,	 impaired	
lung	function,	emphysema,	mucus	hypersecretion,	and	small	airway	wall	thickening	and	remodeling	
are	 induced	8.	However,	this	model	requires	several	months	of	exposure	to	cigarette	smoke	before	
emphysematous	changes	and	alterations	 in	 lung	 function	occur,	 thus	making	 it	very	expensive	and	
also	not	suitable.	More	importantly,	it	cannot	fully	reproduce	the	severity	of	the	human	disease,	but	
resembles	 a	 fairly	 mild	 COPD	 instead	 (comparable	 to	 GOLD	 stage	 1	 or	 2),	 while	 in	 humans	 the	
morbidity	and	mortality	occurs	in	higher	GOLD	stage	diseases	418.	For	example,	pulmonary	lesions	do	
not	appear	to	progress	after	discontinuation	of	smoke	exposure	in	the	murine	model,	but	this	is	the	
case	in	human	disease	418.		
A	 second	 commonly	 applied	 in	 vivo	 COPD	model	 is	 the	 elastase-induced	 emphysema	model.	 This	
model	was	developed	based	on	two	observations:	First,	 it	was	described	in	the	1960s	that	patients	
suffering	 from	AAT	deficiency	develop	early	emphysema	and	COPD	 200,419.	And	 second,	 around	 the	
same	 time,	 the	 induction	 of	 emphysema	 in	 rats	 by	 installation	 of	 the	 protease	 papain	 was	
reported	201.	 It	 is	 generally	 accepted	 that	 a	 protease-antiprotease	 imbalance	 is	 one	 of	 the	 major	
pathogenetic	 factors	 for	 the	 development	 of	 smoke-induced	 emphysema	 in	 COPD	 patients.	 The	
underlying	hypothesis	is	that	proteases,	which	are	released	from	inflammatory	cells	recruited	to	the	
small	 airways	 by	 cigarette	 smoke,	 destroy	 the	 parenchymal	 matrix	 of	 the	 lung,	 leading	 to	
emphysema	3,418,420.	On	these	grounds,	the	elastase-induced	model	was	thought	to	be	appropriate	as	
a	 proof	 of	 concept	 study	 of	 AAT-MSCs.	Moreover,	 the	 elastase	model	 is	 a	 rapidly	 inducible	 short-
term	model,	 thus	allowing	a	quick	assessment	of	 the	potential	 therapeutic	benefit	of	a	 treatment;	
mice	 can	 be	 analyzed	 after	 21	 days	 in	 this	 model.	 In	 addition,	 the	 elastase	 model	 generates	
emphysema	 from	 a	 single	 application	 of	 elastase,	while	 in	 the	 smoke-induced	model	mice	 usually	
have	 to	 be	 subjected	 to	 cigarette	 smoke	 twice	 daily	 421,422.	 The	 elastase	model	 is	 preferable	when	
therapeutic	agents	 for	alveolar	 repair	and	 regeneration	are	evaluated:	 In	 contrast	 to	 lesions	 in	 the	
smoke-induced	 model,	 emphysema	 in	 the	 elastase	 model	 is	 permanent	 and	 additionally	 more	
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severe,	 and	 has	 been	 described	 to	 even	 continue	 progressing	 for	 more	 than	 five	 months	 after	
instillation	 of	 elastase	 341,342,	 making	 it	 possible	 to	 assess	 a	 potential	 therapeutic	 benefit	 more	
easily	418,420.		
MSCs	have	been	described	to	contribute	to	lung	regeneration	in	various	diseases	142.	Thus,	we	tested	
the	 therapeutic	 effect	 of	 two	 applications	 of	 AAT-MSCs	 in	 the	 porcine	 pancreatic	 elastase	 (PPE)-
induced	emphysema	model	 in	comparison	to	non-modified	MSCs	133.	Our	hypothesis	was	that	AAT-
MSCs	will	have	an	improved	therapeutic	effect	based	on	an	additive,	or	more	than	additive	action	of	
AAT	and	MSCs	in	comparison	to	non-modified	MSCs.	
It	 is	surprising	that	even	though	the	diagnosis	of	COPD	in	humans	as	defined	by	GOLD	guidelines	 is	
based	 on	 pulmonary	 function	 measurements,	 specifically	 FEV	 and	 FVC,	 these	 parameters	 are	
oftentimes	not	analyzed	when	performing	in	vivo	COPD	models	343.	Non-invasive	methods	to	analyze	
lung	function	parameters	like	whole	body	plethysmography	have	been	criticized	by	some	researchers	
as	being	flawed	for	the	analysis	of	airway	mechanics	423.	In	contrast,	invasive	methods	are	believed	to	
produce	 more	 sensitive	 and	 specific	 results	 343.	 Through	 collaboration	 with	 the	 Comprehensive	
Pneumology	Center,	we	were	able	to	employ	invasive	lung	measurements	using	the	Buxco	system	to	
determine	 parameters	 such	 as	 FEV100ms	 (which	 is	 the	murine	 equivalent	 to	 FEV1	 in	 humans),	 FVC,	
Cdyn	and	Cchord	(both	measures	for	lung	compliance),	as	well	as	IC	and	VC	in	order	to	analyze	the	
outcome	of	the	treatment	in	our	in	vivo	model	343.		
The	experimental	group	of	mice	that	received	only	PBS	served	as	the	negative	control	in	our	study,	
and	 thus	was	 excluded	 from	 statistical	 analysis	 since	 comparing	 the	 other	 groups	with	 this	 group	
would	 yield	 statistically	 significant	 results	 without	 contributing	 additional	 information	 regarding	 a	
therapeutic	 potential	 of	 the	 treatment	 vs.	 the	 disease	 groups,	 which	 was	 the	 main	 focus	 of	 our	
analyses.		
We	did	observe	a	statistically	significant	amelioration	of	five	out	of	six	important	pulmonary	function	
parameters	analyzed	when	mice	were	treated	with	elastase	plus	AAT-MSCs	as	compared	to	elastase	
only.	These	parameters	included	FEV	and	FVC,	on	which	the	diagnosis	of	human	COPD	is	based,	thus	
providing	an	 indication	 that	 these	 results	might	be	highly	 relevant	 for	 the	human	disease.	We	also	
saw	 a	 dramatic	 improvement	 in	 the	 two	 factors	 describing	 lung	 volumes,	 IC	 and	 VC,	 as	 well	 as	
Cchord,	 which	 is	 a	 measure	 for	 compliance,	 representing	 the	 ability	 of	 the	 lung	 to	 stretch	 and	
expand.	Due	to	the	breakdown	of	lung	tissue	and	the	resulting	airspace	enlargement	in	emphysema,	
this	 parameter	 is	 drastically	 increased	 in	 the	model	 we	 employed,	 and	 treatment	 with	 AAT-MSCs	
reversed	this	increase	by	>40%	(mean	Cchord:	PBS:	0.0431;	elastase:	0.09291;	elastase	+	AAT-MSCs:	
0.07182).	 The	 only	 pulmonary	 function	 parameter	 that	 did	 not	 reach	 statistical	 significance	 is	 the	
second	 measure	 for	 compliance,	 Cdyn;	 however,	 the	 same	 trend	 towards	 an	 amelioration	 after	
treatment	with	AAT-MSCs	was	clearly	visible.	Treatment	with	non-modified	MSCs	did	not	result	in	a	
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statistically	significant	improvement	of	any	of	the	lung	function	parameters	analyzed,	confirming	that	
the	genetic	modification	of	MSCs	with	AAT	created	an	additional	beneficial	effect	and	improved	the	
efficacy	of	MSC	treatment.	
As	 for	 pulmonary	 functions,	 application	 of	 AAT-MSCs	 resulted	 in	 a	 clear	 improvement	 of	 the	
emphysema	 score	of	 ~50%	 that	was	 also	 statistically	 significant	 (P	 <	 0.001).	Again,	 the	effect	 seen	
with	 non-modified	 MSCs	 was	 substantially	 smaller,	 and	 did	 not	 reach	 statistical	 significance.	 This	
indicates	that	AAT	has	not	only	an	additional	beneficial	effect	on	lung	function	when	combined	with	
MSCs,	but	also	on	repair	and	regeneration	of	pulmonary	tissue.	This	finding	could	shed	light	onto	the	
mode	 of	 action	 of	 AAT	 in	 this	 model.	 It	 has	 been	 described	 that	 the	 elastase	 used	 to	 induce	
emphysema	is	cleared	from	the	mouse	lungs	within	24	hours	424,	but	that	the	airspace	enlargement	
continues	even	when	the	elastase	is	long	gone	331,425.	Together,	this	suggests	that	the	beneficial	effect	
of	 AAT	 in	 this	 model	 is	 not	 solely	 due	 to	 protease	 inhibition,	 but	 has	 an	 additional	
immunomodulatory	 component	 as	 well,	 a	 very	 well	 recognized	 phenomenon	 in	 protease	
biology		216,257,426.	
During	analysis	of	the	lung	sections	it	was	seen	that	apart	from	the	amelioration	of	lung	destruction	
in	 mice	 treated	 with	 AAT-MSCs,	 there	 was	 also	 a	 profound	 increase	 in	 inflammatory	 cells	 in	 the	
tissue,	 reflected	 by	 a	 significantly	 higher	 inflammation	 score	 when	 compared	 to	 mice	 receiving	
elastase	 alone.	 This	 was	 true	 for	 both	mouse	 groups	 receiving	MSCs	 (MSCs:	 P	 <	 0.01;	 AAT-MSCs:		
P	<	0.001).	This	finding	was	corroborated	by	analysis	of	total	and	differential	cell	counts	in	the	BALF	
of	 the	mice,	which	 revealed	 a	 drastic	 increase	 in	 absolute	 and	 relative	 lymphocyte	 and	 eosinophil	
counts	in	all	mice	receiving	either	MSCs	or	AAT-MSCs.	The	inflammatory	response	was	more	distinct	
in	the	group	receiving	AAT-MSCs,	suggesting	that	the	murine	immune	cells	may	be	reacting	against	
the	 human	 MSCs,	 and	 potentially	 against	 the	 human	 AAT	 protein	 being	 secreted	 from	 the	 cells.	
Indeed,	it	has	been	described	that	the	repeated	administration	of	human	AAT	and	human	albumin	is	
immunogenic	 in	 immunocompetent	 mice	 427.	 However,	 since	 MSCs	 have	 been	 described	 to	 be	
immune-evasive	in	many	studies	99,428–430,	an	alternative	hypothesis	would	be	that	the	inflammatory	
infiltrate	 is	needed	to	effect	tissue	repair	and	regeneration	431.	Thus,	further	studies	to	analyze	this	
inflammatory	 response	 are	 underway,	 e.g.	 a	 repetition	 of	 the	 same	 model	 with	 murine	 MSCs	
expressing	murine	AAT.		
Interestingly,	despite	the	increase	in	lymphocytes	and	eosinophils,	total	cell	numbers	in	the	BALF	of	
mice	receiving	MSCs	did	not	change	significantly	as	compared	to	the	mice	treated	with	elastase	only.	
When	 analyzing	 absolute	 differential	 cell	 numbers,	 there	 was	 a	 trend	 towards	 lower	macrophage	
counts	 in	 both	MSC	 groups;	 however,	 these	 differences	 did	 not	 reach	 statistical	 significance.	 Still,	
when	 calculating	 relative	 proportions	 of	 the	 cells	 in	 the	 BALF,	 there	was	 a	 significant	 decrease	 in	
macrophages,	which	are	one	of	the	major	cell	 types	 involved	 in	the	pathogenesis	of	COPD,	 in	both	
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mouse	groups	receiving	MSCs	compared	to	the	elastase	group.	The	second	effector	cell	type	in	COPD	
is	neutrophilic	granulocytes.	In	this	model	of	emphysema	these	cells	were	drastically	increased	after	
elastase	 instillation.	 Remarkably,	 four	 out	 of	 six	 mice	 had	 no	 neutrophils	 in	 their	 BALF	 after	
treatment	 with	 AAT-MSCs.	 These	 observations	 suggest	 that	 human	MSCs,	 and	 even	more	 human	
MSCs	 expressing	 human	 AAT,	 appear	 to	 exert	 immunomodulatory	 effects	 on	 the	major	 cell	 types	
involved	in	the	pathogenesis	of	the	lung	disease.		
Native	MSCs	showed	only	a	mild	improvement	of	emphysema,	and	had	a	very	minor	effect	on	lung	
function	 parameters.	 This	 is	 in	 contrast	 to	 published	 studies	 133,164,432,433,	 which	 describe	 a	 clear	
beneficial	effect	of	MSC	treatment	 in	elastase-induced	emphysema	in	mice.	This	discrepancy	might	
be	due	to	different	experimental	 setups	 133,164,	diverging	MSC	numbers	used	 433,	and	different	MSC	
sources	 analyzed	 164.	 Also,	 pulmonary	 function	 measurements	 were	 not	 always	 performed,	 the	
assessment	of	an	amelioration	of	the	disease	was	based	on	histological	findings,	where	the	effect	of	
MSCs	seems	to	be	more	pronounced	(also	in	our	case).		
The	model	employed	here	 is	very	stringent,	since	 it	 is	a	model	of	treatment	and	not	prevention.	 In	
our	case,	 the	 first	application	of	 the	cells	was	made	seven	days	after	elastase	 instillation	when	the	
animals	 had	 full-blown	disease	 as	 compared	e.g.	 to	 Tibboel	 and	 colleagues,	who	 injected	 the	 cells	
either	24	hours	before	or	after	elastase	treatment	as	a	preventive	measure	at	a	time	when	the	mice	
had	not	developed	emphysema	yet	432.	These	factors	may	help	explain	the	diverging	results	observed	
with	non-modified	MSCs	in	models	of	elastase-induced	emphysema.	
A	 question	 raised	 by	 the	 positive	 results	 obtained	with	 AAT-MSCs	 is	 why	 the	 relatively	moderate	
additional	 human	 AAT	 expressed	 from	 the	 MSCs	 led	 to	 such	 a	 dramatic	 improvement	 of	 lung	
function,	as	well	as	emphysema,	as	compared	to	the	treatment	with	non-modified	MSCs,	when	these	
mice	were	not	AAT-deficient	and	had	physiological	AAT	levels	in	their	plasma.	Average	physiological	
AAT	concentrations	in	the	blood	of	female	C57BL/6	mice	have	been	described	to	be	[~3mg/mL]	434.	
The	average	amount	of	AAT	produced	in	vitro	by	cells	from	the	very	batch	of	AAT-MSCs	used	in	this	
in	vivo	 study	 is	~1000ng/1x105	cells/48h	as	determined	by	ELISA.	Considering	that	5x105	cells	were	
instilled	 into	 the	 mice	 twice,	 one	 time	 on	 day	 7,	 a	 second	 time	 on	 day	 14,	 and	 the	 mice	 were	
sacrificed	on	day	21,	the	total	amount	of	secreted	AAT	would	be	~50µg,	not	considering	half-life	of	
the	 protein	 or	 cell	 death.	 The	 blood	 volume	 of	 mice	 is	 in	 the	 range	 of	 1.5–2.5mL	 435,	 thus	 the	
maximum	 systemic	 human	 AAT	 concentration	without	 calculating	 any	 losses	would	 be	 ~25µg/mL,	
which	 is	 still	 ~100-fold	 lower	 than	 physiological	 murine	 AAT	 concentrations,	 thus	 making	 it	 very	
unlikely	that	the	results	seen	are	due	to	actions	of	additional	systemic	AAT.	Instead,	our	hypothesis	is	
that	the	therapeutic	effect	observed	in	our	work	results	from	the	 locally	 increased	levels	of	human	
AAT	expressed	from	MSCs	in	the	lungs	of	the	mice,	working	its	effects	at	the	site	of	inflammation	and	
injury.	 It	 has	 been	 suggested	 that	 AAT	 serum	 concentrations	 reaching	 20%	 of	 physiological	 serum	
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levels	 are	 sufficient	 to	 protect	 the	 alveoli	 in	 humans	 436.	Moreover,	 it	 has	 been	 also	 found	 that	 in	
humans,	the	distribution	of	AAT	is	fairly	heterogeneous,	and	that	e.g.	 in	the	epithelial	lining	fluid	of	
the	 lower	 respiratory	 tract,	 AAT	 levels	 are	 only	 10%	 of	 serum	 levels	 under	 physiological	
conditions	217,	 indicating	 that	 the	 addition	 of	 even	 small	 amounts	 of	 extra	 AAT	 might	 have	 even	
stronger	effects	 in	 this	 tissue.	Thus,	we	hypothesize	 that	due	to	 the	 instillation	of	 the	cells	directly	
into	the	lung,	the	homing	of	the	MSCs	to	the	most	damaged	and	inflamed	sites,	and	the	cumulative	
expression	of	AAT	there,	levels	high	enough	to	exceed	the	threshold	for	a	beneficial	effect	could	be	
achieved	locally	in	the	present	study,	leading	to	the	therapeutic	effects	we	observed.	Another	factor	
to	consider	is	that	physiological	AAT	levels	in	the	mouse	are	twofold	higher	than	the	average	levels	in	
humans,	which	range	between	0.9–1.75mg/mL	216.	Since	we	saw	such	impressive	therapeutic	results	
in	the	mouse,	the	therapeutic	benefits	in	humans	might	be	even	stronger.		
The	efficacy	of	AAT-MSCs	for	the	treatment	of	inflammatory	lung	diseases	needs	to	be	confirmed	in	
additional	 in	vivo	models	such	as	bleomycin-induced	 lung	fibrosis	or	smoke-induced	COPD,	and	the	
mechanisms	by	which	AAT-MSCs	are	able	 to	ameliorate	 lung	 function	and	effect	pulmonary	 tissue	
repair	and	regeneration	better	understood.	The	 inflammatory	response	elicited	 in	the	mouse	 lungs	
after	treatment	with	MSCs	should	be	studied	in	detail,	e.g.	by	conducting	a	study	with	murine	MSCs	
expressing	murine	AAT.		
An	 interesting	 question	 that	 also	 needs	 clarification	 is	 how	 strong	 the	 additive	 effect	 of	 AAT	 and	
MSCs	 is	 in	 comparison	 to	 AAT	 protein	 isolated	 from	 human	 plasma	 alone	 in	 an	 efficacy	 model.	
Moreover,	crucial	questions	regarding	biodistribution	and	tumorigenicity	of	the	cells	after	application	
as	well	as	dosing	and	treatment	regime	have	to	be	clarified	in	further	studies.		
It	would	also	be	interesting	to	assess	the	therapeutic	potential	of	extracellular	vesicles	derived	from	
AAT-MSCs.	 These	microvesicles	or	 exosomes,	 as	 already	mentioned	briefly	 in	 the	 introduction,	 are	
circular	 membrane	 fragments	 released	 from	 MSCs,	 that	 are	 involved	 in	 the	 transfer	 of	 cellular	
material	 and	 in	 cell-cell	 communication,	 and	 have	 recently	 emerged	 as	 a	 mechanism	 of	 MSC-
mediated	 functions	 437,438.	 Since	 microvesicles	 have	 been	 described	 to	 maintain	 the	 functional	
phenotype	 of	 the	 parent	 cell	 438,	 it	 is	 likely	 that	 they	 also	 exert	 beneficial	 functions	 in	 regard	 to	
inflammation	and	tissue	damage.	Indeed,	MSC-derived	microvesicles	have	been	recently	described	to	
ameliorate	acute	lung	injury	and	hypoxic	pulmonary	arterial	hypertension	in	mice	167,439.	Thus,	testing	
this	approach	might	be	worthwhile	in	the	future.	
In	 summary,	 this	 study	provides	 the	 first	 proof	of	 concept	 for	 the	 treatment	of	 inflammatory	 lung	
diseases	 with	 MSCs	 transduced	 to	 express	 AAT.	 Application	 of	 these	 cells	 in	 a	 murine	 model	 of	
elastase-induced	emphysema	resulted	not	only	in	impressive	repair	and	regeneration	of	lung	tissue,	
but	moreover	also	in	significantly	improved	pulmonary	function	parameters,	giving	a	first	indication	
that	this	gene-modified	MSC	cell	product	might	be	well-suited	for	the	treatment	of	COPD.	 	
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6. Supplemental material  
6.1. Sequences 
SERPINA1	 CDS:	 Bases	 262	 to	 1518	 of	 the	 full	 reference	 sequence	 published	 at	
http://www.ncbi.nlm.nih.gov/nuccore/NM_000295.4.	
                             262 atgccgtct tctgtctcgt ggggcatcct cctgctggca 
      301 ggcctgtgct gcctggtccc tgtctccctg gctgaggatc cccagggaga tgctgcccag 
      361 aagacagata catcccacca tgatcaggat cacccaacct tcaacaagat cacccccaac 
      421 ctggctgagt tcgccttcag cctataccgc cagctggcac accagtccaa cagcaccaat 
      481 atcttcttct ccccagtgag catcgctaca gcctttgcaa tgctctccct ggggaccaag 
      541 gctgacactc acgatgaaat cctggagggc ctgaatttca acctcacgga gattccggag 
      601 gctcagatcc atgaaggctt ccaggaactc ctccgtaccc tcaaccagcc agacagccag 
      661 ctccagctga ccaccggcaa tggcctgttc ctcagcgagg gcctgaagct agtggataag 
      721 tttttggagg atgttaaaaa gttgtaccac tcagaagcct tcactgtcaa cttcggggac 
      781 accgaagagg ccaagaaaca gatcaacgat tacgtggaga agggtactca agggaaaatt 
      841 gtggatttgg tcaaggagct tgacagagac acagtttttg ctctggtgaa ttacatcttc 
      901 tttaaaggca aatgggagag accctttgaa gtcaaggaca ccgaggaaga ggacttccac 
      961 gtggaccagg tgaccaccgt gaaggtgcct atgatgaagc gtttaggcat gtttaacatc 
     1021 cagcactgta agaagctgtc cagctgggtg ctgctgatga aatacctggg caatgccacc 
     1081 gccatcttct tcctgcctga tgaggggaaa ctacagcacc tggaaaatga actcacccac 
     1141 gatatcatca ccaagttcct ggaaaatgaa gacagaaggt ctgccagctt acatttaccc 
     1201 aaactgtcca ttactggaac ctatgatctg aagagcgtcc tgggtcaact gggcatcact 
     1261 aaggtcttca gcaatggggc tgacctctcc ggggtcacag aggaggcacc cctgaagctc 
     1321 tccaaggccg tgcataaggc tgtgctgacc atcgacgaga aagggactga agctgctggg 
     1381 gccatgtttt tagaggccat acccatgtct atcccccccg aggtcaagtt caacaaaccc 
     1441 tttgtcttct taatgattga acaaaatacc aagtctcccc tcttcatggg aaaagtggtg 
     1501 aatcccaccc aaaaataa 
	
The	SERPINA1	CDS	was	codon	optimized	for	homo	sapiens	to	increase	protein	production.	The	CDS	
after	codon	optimization	reads	as	follows:	
	
ATGCCCAGCAGCGTGTCCTGGGGAATTCTGCTGCTGGCCGGCCTGTGTTGTCTGGTGCCTGTGTCTCT
GGCCGAGGACCCTCAGGGGGATGCCGCCCAGAAAACCGATACCAGCCACCACGACCAGGACCACCCCA
CCTTCAACAAGATCACCCCCAACCTGGCCGAGTTCGCCTTCAGCCTGTACAGACAGCTGGCCCACCAG
AGCAACAGCACCAACATCTTTTTCAGCCCCGTGTCTATCGCCACCGCCTTCGCCATGCTGAGCCTGGG
CACAAAGGCCGACACCCACGACGAGATCCTGGAAGGCCTGAACTTCAACCTGACCGAGATCCCCGAGG
CCCAGATCCACGAGGGCTTCCAGGAACTGCTGCGGACCCTGAACCAGCCCGATAGCCAGCTGCAGCTG
ACAACCGGCAACGGCCTGTTTCTGAGCGAGGGACTGAAGCTGGTGGACAAGTTTCTGGAAGATGTGAA
GAAGCTGTATCACAGCGAGGCCTTCACCGTGAACTTCGGCGACACCGAGGAAGCCAAGAAGCAGATCA
ACGACTACGTGGAAAAGGGCACCCAGGGCAAGATCGTGGACCTCGTGAAAGAGCTGGACCGGGACACC
GTGTTCGCCCTCGTGAACTACATCTTCTTCAAGGGCAAGTGGGAGCGGCCCTTCGAAGTGAAGGACAC
AGAGGAAGAGGACTTTCACGTGGACCAAGTGACCACCGTGAAGGTGCCCATGATGAAGAGACTGGGCA
TGTTCAACATCCAGCACTGCAAGAAACTGAGCAGCTGGGTGCTGCTGATGAAGTACCTGGGCAACGCT
ACCGCCATATTCTTTCTGCCCGACGAGGGCAAGCTGCAGCACCTGGAAAACGAGCTGACCCACGACAT
CATCACCAAATTTCTGGAAAATGAGGACCGGCGGAGCGCCAGCCTGCATCTGCCTAAGCTGTCTATCA
CCGGCACCTACGACCTGAAGTCCGTGCTGGGACAGCTGGGCATCACCAAGGTGTTCAGCAACGGCGCC
GATCTGAGCGGCGTGACAGAAGAGGCCCCTCTGAAGCTGTCCAAGGCCGTGCACAAAGCCGTGCTGAC
CATCGACGAGAAGGGCACCGAAGCCGCTGGCGCCATGTTTCTGGAAGCCATCCCCATGAGCATCCCCC
CTGAAGTGAAGTTCAACAAGCCCTTCGTGTTCCTGATGATCGAGCAGAACACCAAGAGCCCCCTGTTC
ATGGGCAAGGTCGTGAACCCCACCCAGAAA 
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6.2. Plasmid maps – intermediate constructs 
	
Supplemental	figure	1:	Plasmid	map	of	plasmid	#110	pSERS11_pPGK_IFNb_fw_IRES_pac	
	
Supplemental	figure	2:	Plasmid	mag	of	plasmid	#112	pSERS11_pEF1a_IFNb_fw_IRES_pac	
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Supplemental	figure	3:	Plasmid	map	of	plasmid	#139	pSERS11_Leader_MCS_oPRE	
	
	
Supplemental	figure	4:	Plasmid	map	of	plasmid	#168	pSERS11_pEFS_luc2_P2A_eGPF_IRES_pac	
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Supplemental	figure	5:	Plasmid	map	of	plasmid	#172	pCCL-c-EFS-hADA_WPRE	
6.3. Plasmid maps – helper plasmids 
6.3.1. Gamma-retroviral helper plasmids 
	
Supplemental	figure	6:	Plasmid	map	of	plasmid	#70	pcDNA3-MLV-gagpol	
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Supplemental	figure	7:	Plasmid	map	of	plasmid	#39	pALF-PERV	A_GaLV	
6.3.2. Lentiviral helper plasmids 
	
	
Supplemental	figure	8:	Plasmid	map	of	plasmid	#170	pCMV-dR8.91	
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Supplemental	figure	9:	Plasmid	map	of	plasmid	#171	pCAGGS-VSVG	
6.4. Plasmid maps – gamma-retroviral AAT expression constructs 
	
Supplemental	figure	10:	Plasmid	map	of	plasmid	#159	pSERS11_pPGK_SERPINA1_pEFS_pac	
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Supplemental	figure	11:	Plasmid	map	of	plasmid	#160	pSERS11_pEFS_SERPINA1_pPGK_pac	
	
Supplemental	figure	12:	Plasmid	map	of	plasmid	#161	pSERS11_pEF1a_SERPINA1_pPGK_pac	
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Supplemental	figure	13:	Plasmid	map	of	plasmid	#162	pSERS11_pEFS_pac_pPGK_SERPINA1	
	
	
Supplemental	figure	14:	Plasmid	map	of	plasmid	#163	pSERS11_pPGK_pac_pEFS_SERPINA1	
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Supplemental	figure	15:	Plasmid	map	of	plasmid	#164	pSERS11_pPGK_pac_pEF1a_SERPINA1	
	
	
	
Supplemental	figure	16:	Plasmid	map	of	plasmid	#193	pSERS11_pPGK_SERPINA1_IRES_pac	
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Supplemental	figure	17:	Plasmid	map	of	plasmid	#194	pSERS11_pEFS_SERPINA1_IRES_pac	
6.5. Plasmid maps – lentiviral AAT expression construct 
	
Supplemental	figure	18:	Plasmid	map	of	plasmid	#215	pCCL_pEFS_SERPINA1_IRES_pac	
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6.6. Additional pulmonary function parameters 
	
	
Supplemental	 figure	19:	 Invasive	 lung	 function	measurements	using	 the	Buxco	 forced	pulmonary	
maneuver	system.	Lung	function	parameters	were	measured	applying	the	Fast	Flow	Volume	(FV)	and	
the	Quasistatic	Pressure	Volume	(PV)	tests.	 Invasive	pulmonary	function	analyses	of	resistance	(RI),	
peak	expiratory	flow	(PEF),	and	expiratory	reserve	volume	(ERV).		
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